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ABSTRACT 
 
RNA editing is a posttranscriptional modification mechanism that changes 
gene-specified codons. One of the main forms of RNA editing is the conversion 
of adenosine to inosine by the enzyme adenosine deaminase (ADAR) acting 
on the RNA of the GluA2 subunit of AMPA receptors. AMPA receptors 
(AMPARs) are a subset of ionotropic glutamate receptor composed of one or 
more of four subunits (GluA1-4). Incorporation of the GluA2 subunit and 
expression of the edited Q/R site is required to reduce calcium permeability. 
Deficient RNA editing has been shown to trigger significant neuron cell death 
in patients with motor neuron disease. Adenosine deaminase (ADAR2) exists 
as multiple splice variants. In one variant, the inclusion of a 120 bp AluJ 
cassette has been shown to reduce the catalytic activity of ADAR2. We sought 
to investigate the effects of specifically targeted PMOs that manipulate the 
alternative splicing of ADAR2 in SH-SY5Y cells and increase the expression 
of the more catalytically active ADAR2-AluJ exon 5a-absent isoform.  
Subsequently, we examined the gene expression of Pin1 and WWP2 in cells 
following PMO transfection, as these two proteins are known to regulate 
ADAR2 activity.  
 
Our results show that the PMOs were able to induce alternative splicing events 
in SH-SY5Y cells, where increase in both exon skipping of the AluJ cassette 
and RNA editing levels was observed compared to baseline levels. Hence, the 
PMOs are able to manipulate RNA editing in cell lines endogenously 
expressing GluA2. Additionally, increased expression of the ADAR2a-AluJ 
exon 5a-absent isoform upregulated Pin1 gene expression, whereas WWP2 
gene expression was downregulated. Hence, the ADAR2a-AluJ exon 5a-
absent isoform can regulate gene expression of both Pin1 and WWP2, 
suggesting significant implications for their roles in neurodegenerative 
disorders. Taken together, our findings suggest PMO-induced changes in 
RNA editing can influence the gene expression of proteins regulating ADAR2-
activity.  
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ABBREVIATIONS 
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GWAS genome-wide association studies 
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mRNA messenger RNA 
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PCR polymerase chain reaction 
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RIPA radio immunoprecipitation assay 
RNA ribonucleic acid 
RT-PCR reverse transcriptase PCR 
sALS sporadic amyotrophic lateral sclerosis 
SMA spinal muscular atrophy 
SNP single nucleotide polymorphism 
SOD1 superoxide dismutase 1 
TAE tris-acetate-EDTA buffer 
TARDBP TAR DNA-binding protein 
TARP transmembrane AMPA receptor regulatory proteins 
TBS tris buffered saline 
TEMED tetramethylethyldiamine 
TM transmembrane 
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CHAPTER 1 INTRODUCTION 
1.1 a-AMINO-3-HYDROXY-5-METHYL-4-
ISOXAZOLEPROPRIONIC ACID (AMPA) RECEPTORS 
1.1.1 INTRODUCTION 
 
Synaptic plasticity can be regulated at the presynaptic side by 
modifying the efficacy of neurotransmitter release, or on the postsynaptic side 
by changing the density, types, and properties of neurotransmitter receptors. 
AMPA receptors (AMPARs) are the primary ionotropic glutamate receptors 
that mediate fast excitatory synaptic transmission in mammalian brain. 
AMPARs are tetrameric assemblies of highly homologous subunits encoded 
by four different genes, GluA1-4 (Wisden & Seeburg, 1993). The trafficking of 
AMPARs into and out of synapses is highly dynamic and undergoes regulation 
by various post-translational modifications that occur on their C-terminal 
domains. The regulated trafficking of AMPARs is a key mechanism underlying 
activity-induced changes in synaptic transmission (Shepherd & Huganir, 
2007). 
 
1.1.2 AMPA RECEPTOR STRUCTURE 
 
AMPARs are mainly impermeable to Ca2+, exhibit remarkably fast kinetics, 
and mediate fast synaptic transmission. These functional properties rely on 
the subunit composition and alterations induced by alternative splicing events. 
The subunits GluA1-GluA4 can exist as homomeric or heteromeric tetramers 
in distinctive stoichiochemistries, determining channel function and synaptic 
trafficking. Each subunit is made up of roughly 900 amino acids and weigh 
approximately 105 kDa. Subunits GluA1-GluA4 share 68-74% amino acid 
sequence identity and comprise of four hydrophobic domains; M1, M3 and M4 
transverse the domain, while M2 enters the lipid bilayer as a re-entrant loop 
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which makes up part of the channel pore (Santos, Carvalho, Caldeira, & 
Duarte, 2009) (Figure 1.1).  
 The ligand-binding domain (LBD) is divided into S1 and S2 segments 
by the transmembrane (TM) segments (Figure 1.1). Ligand binding to this 
domain initiates conformational modifications that are transduced to the TM 
segments and activate the channel gates opening. The N-terminus, the LBD, 
and ion-channel domain are involved in separate and interdependent subunit-
subunit interactions. The C-terminal of the S2 does not play a direct role in 
agonist binding. The C-terminal is expressed in two isoforms – flip and flop – 
due to alternative RNA splicing. The alternative splice cassette is located at 
the C-terminal end of the loop between M3 and M4. Even though these 
isoforms only differ by a few amino acids, this results in AMPA receptors with 
distinctive desensitisation and endoplasmic reticulum (ER) export kinetics 
(Santos et al., 2009). 
RNA editing, a process that involves enzymatic deamination of 
ribonucleotides in pre-spliced mRNA, is a regulator of AMPA receptor 
permeability (Bass, 2002). Glutamine to arginine (Q/R) editing in the M2 region 
regulates calcium permeability and channel rectification in the ion channel 
pore region of the GluA2 subunit. This editing process also affects the 
endoplasmic reticulum retention of the subunit (Shepherd & Huganir, 2007). 
Editing of an arginine (R) codon to a glycine (G) codon, which occurs in the 
S2 loop of GluA4, modifies resensitisation kinetics, where edited G forms 
recover faster from desensitisation (Shepherd & Huganir, 2007). Little is 
known regarding the regulation of these splicing and editing events. In 
neurons, alternative splicing is regulated by neuronal activity, such as the 
GluN1 subunit splicing of the NMDA receptor (Mu, Otsuka, Horton, Scott, & 
Ehlers, 2003). However, it is still unclear whether neuronal activity regulates 
AMPAR subunit editing or splicing. 
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Figure 1.1 AMPA receptor structure. 
Structure of the GluA2 subunit. The subunit illustrates the structural properties of the AMPA 
receptor subunits. The N-terminus is extracellular while the C-terminus is intracellular. 
Splice variation occurs in the 'Flip/Flop' region, resulting in two variants for each gene 
sequence. The C-terminus contains binding regions for various intracellular proteins. Figure 
retrieved from: http://www.bristol.ac.uk/synaptic/receptors/ampar/. 
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1.1.3 THE GLUA2 SUBUNIT 
 
The ability of Ca2+ to enter the cell through the AMPARs is determined 
by the GluA2 subunit, which is preferentially incorporated into the receptor 
(Sans et al., 2003). AMPARs made up of subunits GluA1, GluA3 and GluA4 
are highly permeable to Ca2+, whilst GluA2-containing AMPARs have 
profoundly decreased permeability to Ca2+ (Burnashev et. al., 1992). Since 
most AMPARs are hetero-oligomers that consist of GluA1/GluA2 or 
GluA2/GluA3 subunits, they are thus Ca2+-impermeable (Wright & Vissel, 
2012). 
Most mature GluA2 protein contains an arginine residue (R) within the 
re-entrant M2 membrane loop region at amino acid residue position 607 in 
place of the genomically encoded glutamine (Q) (Sommer, Kohler, Sprengel, 
& Seeburg, 1991). This alteration is the outcome of hydrolytic editing of a 
single adenosine base in the pre-mRNA to an inosine by the adenosine 
deaminase enzyme ADAR2 (Higuchi et al., 1993) (Figure 1.2). This Q/R 
editing is specific to the GluA2 subunit; more than 95% of GluA2 mRNA 
transcripts are edited in postnatal brain (Isaac, Ashby, & McBain, 2007). This 
editing is vital for brain function as revealed by premature death and 
neurological dysfunctions as early-onset epilepsy of mice heterozygous for an 
editing-deficient GluA2 allele and ADAR2-/- mice as well (Bassani, Valnegri, 
Beretta, & Passafaro, 2009). Interactions between the GluA2 subunit and its 
intracellular and extracellular partners such as transmembrane AMPA 
receptor regulatory protein (TARP) and PDZ proteins (protein molecules that 
recognise short motifs at the C-terminus) have been shown to be critical in 
determining AMPAR functions at the synapse, including trafficking, some 
forms of synaptic plasticity, and the formation and maturation of dendritic 
spines (Bassani et al., 2009).
 21 
 
  
Figure 1.2 Schematic diagram of the GluA2 structure.  
AMPA receptors containing edited GluA2 are impermeable to Ca2+ (left). AMPA 
receptors containing unedited GluA2 and lacking GluA2 are Ca2+-permeable 
(right). 
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1.2 RNA EDITING 
1.2.1 OVERVIEW 
 
The term “RNA editing” was first conceived in 1986 to refer to the 
process of uridine residue insertion into mitochondrial mRNA in trypanosomes 
encoding cytochrome oxidase subunit II (Benne et al., 1986). The term is now 
used to describe insertion, deletion, as well as conversion of one base to 
another. Uridine to cytidine conversion through amination is rare and has only 
been discovered in the transcript encoding Wilms’ tumour susceptibility gene 
in mammals. The removal of an amine group, known as deamination, is most 
common and takes place on several bases within DNA or RNA; adenosine to 
inosine (A-to-I) and cytosine to uracil (C-to-U) (Hogg et. al., 2011). A-to-I 
editing modifies the information content of the RNA molecule, as inosine 
favourably base pairs with cytidine, causing the translational machinery to 
interpret inosine as guanosine (G). The three-dimensional structure of the 
dsRNA, which determines its RNA-binding protein interactions, is also altered 
due to the addition or removal of bulges formed by mismatched base pairs 
(Zinshteyn & Nishikura, 2010).  
 
 
N
N
N
N
NH2
H2O NH3
N
N
N
NH
O
Adenosine Inosine
ADAR
Figure 1.3 Adenosine deamination. 
ADAR enzymes catalyse A-to-I hydrolytic deamination, where an adenosine loses an 
amine group and is converted to inosine. 
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A-to-I conversion is catalysed by the enzyme family adenosine 
deaminase (ADAR) acting on RNA (Figure 1.3). In this process, ADARs were 
initially recognised to unwind dsRNA in Xenopus laevis embryo extracts, 
showing a different migration pattern when electrophoresised on a native 
polyacrylamide gel (Bass & Weintraub, 1987). The dsRNA was modified as 
such that up to half of the adenosine residues were deaminated to inosines 
(Bass & Weintraub, 1988).  
Three structurally related ADARs (ADAR1 to ADAR3) have been 
identified in mammals (Kwak & Kawahara, 2005). ADAR1 and ADAR2 are 
expressed in most tissues and recognise the adenosine residue to be edited 
through the duplex structure that is formed between the editing site and its 
editing site complementary sequence (ECS), which is located downstream of 
the pre-mRNA intron (Higuchi et al., 1993) (Figure 1.4). ADAR3 is thought to 
be catalytically inactive and is only expressed in the brain (Hogg et al., 2011). 
  
Figure 1.4 Formation of the double-stranded structure required for editing by 
ADAR. 
mRNAs form the double-stranded structure required for ADAR editing due to the 
incorporation of the editing-site complementary sequence (ECS) in the intronic 
region, allowing base-pairing with the exonic region. Stretches of imperfectly base-
paired dsRNA in precursor mRNA (pre-mRNA) are then formed, suitable for 
potential ADAR A-to-I editing. Figure adapted from Wulff and Nishikura (2010). 
 
 24 
1.2.2 STRUCTURAL FEATURES OF ADAR 
 
ADARs are modular proteins that share a common domain architecture 
comprising of several amino-terminal dsRNA binding domains (dsRBDs), 
which make direct contact with dsRNA substrates, and a carboxy-terminal 
catalytic deaminase domain (Figure 1.5a) (Mannion, Arieti, Gallo, Keegan, & 
O’Connell, 2015). Each dsRBD (three in ADAR1 and two in ADAR2 and 
ADAR3) contains an α-β-β-α topology made up of roughly 70 amino acids, 
where the two α helices are packed alongside a three-stranded anti-parallel β 
sheet. The dsRBDs are thought to synergistically act together, thus increasing 
the specificity and affinity for dsRNA targets (Tomaselli et al., 2013). 
The ADAR1 gene was mapped to the locus of c1q21.1-21.2 in humans at 
a size of ~30 Kbp (Weier, George, Greulich, & Samuel, 1995). ADAR1 is made 
up of two different isoforms: a 150 kDa protein (ADAR1 p150) which is induced 
by interferon (IFN) and a 110 kDa protein (ADAR1 p110) that is expressed 
constitutively (Figure 1.5b). ADAR1p150 initiates translation on exon 1A 
(AUG1) while ADAR1p110 starts from exon 2 (AUG296) (Patterson & Samuel, 
1995) (Figure 1.5b). The different isoforms are caused by alternative splicing 
in exon 1. Exon 1A contains an IFN-inducible promoter with a 12-bp IFN-
stimulated response element (ISRE), thus generating a transcript coding for 
the longer ADAR1p150 isoform. Transcripts that encode ADAR1p110 are 
generated from different promoters located within exon 1B, 1C, and exon 2 (C. 
X. George & Samuel, 1999). Since both exons 1B and 1C do not contain 
translation initiation sites, translation starts at codon AUG296 located in exon 
2. Other alternative splicing events identified within exon 7 generates variants 
that contain either exon 7a or 7b (Figure 1.6). Exon 7a contains 26 amino acids 
that are not found in exon 7b (Yong Liu, George, Patterson, & Samuel, 1997). 
(Figure 1.6) Additionally, exon 7a is present in ADAR1p110 transcripts whilst 
exon 7b is found in ADAR1p150 transcripts (Cyril X. George, Wagner, & 
Samuel, 2005). 
 A feature that is exclusive to ADAR1 is the presence of Z-DNA binding 
domains (ZBDs) at the N-terminus (Figures 1.5a and b). The Zα domain is 
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found only in ADAR1p150 while the Zβ domain can be found in both 
ADAR1p110 and ADAR1p150. Only the Zα domain has Z-DNA/RNA binding 
capacity. Even though the functional importance of the ZBDs in ADAR1 is 
unclear, Zα domain-containing proteins have been associated with the type I 
IFN response pathway. The Zα domain is also vital for ADAR1p150 
localisation to cytoplasmic stress granules resulting from the activation of type 
I IFN-induced stress (Mannion et al., 2015). 
 
 
 
Figure 1.5 Structure of ADAR1, ADAR2, and ADAR3. 
a) Indicated are the two Z-DNA binding domains (ADAR1), the dsRNA binding domains 
(dsRBDs). the arginine-rich, ssRNA binding domain (R domain), and the deaminase domain. 
The amino acid lengths and chromosomal location are shown. b) Two translation products of 
ADAR1. Exons E1A (IFN/ds-RNA inducible) and E1B AND E1C (constitutive) are spliced to 
exon 2 at approximately the same junction. Exon 1A incorporates the Met start codon for the 
1226-aa ORF that specifies the IFN/dsRNA inducible p150 protein, Exons 1B and 1C do not 
comprise of an AUG start codon. The second AUG start codon found in exon 2 initiates 
translation of the 931-aa encoding ADAR1 p110 protein. Figure adapted from Maas et. al. 
(2006). 
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Figure 1.6 Differential expression of ADAR1 exon splice variants.  
Schematic structure of the two ADAR1 exon 7 splice variants, designated as 7a and 7b, 
Exon 7a corresponds to the full-length 74-aa version of the mouse exon 7. Exon 7b lacks 
26 aa encoded by the 3’ end of exon 7a as a result of alternative splicing. Figure taken from 
George et al, 2005.  
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The human ADAR2 human gene spans a size of ~153 Kbp. While the 
promoter responsible for ADAR2 expression has not been functionally 
characterised, a putative promoter region upstream of a recently identified 
exon was described for both human ADAR2 and mouse Adar2 gene. This 
promoter contains a TATA box sequence and binding sites for nuclear factor 
kappa-light-chain-enhancer of activated B cells (Nf-κ B) and Specificity Protein 
1 (SP1). Subsequently, ADAR2 localisation into the cell nuclei is directed by 
importin α1, α4, and α5. ADAR2 can form homodimers and heterodimers with 
ADAR1. Dimerisation of ADAR2 appears to be vital for editing activity, 
although whether or not this interaction is mediated by dsRNA is still uncertain 
(Tomaselli et al., 2013).  
 Recombinant ADAR3 has been shown to bind to both dsRNA and 
ssRNA in vitro. Site-directed mutagenesis of ADAR3 revealed that it binds 
ssRNA through an arginine/lysine-rich domain (R-domain) positioned in the N-
terminus, similar to that of ADAR2 (Figure 1.5a). This domain is essential for 
determining the subcellular localisation of ADAR3 and acts as an NLS. The 
importin alpha-1 factor KPNA2 interacts with this R-domain to promote nuclear 
import of ADAR3. ADAR3 remains in its monomeric form, partly explaining its 
lack of editing function. Hence, its function is still unknown, although its ability 
to bind to ss- and dsRNAs suggests a regulatory function over ADAR1 and 
ADAR2. ADAR3 can in fact contest for dsRNA substrates, which inhibits 
binding of the other ADAR enzymes (Mannion et al., 2015).  
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1.2.3 ADAR2 
 
ADAR2 is an 80-kDa nuclear protein containing two ds-RNA binding 
domains (dsRBDs) in the amino-terminal region, and an adenosine deaminase 
domain near the carboxyl terminus, is responsible for most A-to-I editing 
modifications occurring in mammals (Feng et. al., 2006). It is a nuclear protein 
and has been shown to localise to the nucleolus in a dynamic manner (Dawson 
et. al., 2003). In cells transfected with plasmids that encode editable 
transcripts, ADAR2 was found to re-localise to the nucleoplasm where it 
carries out editing of the transcripts (Desterro et al., 2003). The nuclear 
localisation sequence (NLS) for ADAR2 has been recently discovered. Two 
NLS elements are positioned nearby each other in the amino terminus, 
adjacent to the first dsRBD (Behm, Wahlstedt, Widmark, Eriksson, & Öhman, 
2017). Nuclear localisation requires the interaction between importin-α and 
ADAR2. 
Whilst ADAR2 has been found to act as the primary editor of non-repetitive 
coding regions, the extent of variation of RNA editing caused by ADAR 
enzyme expression is not well-understood. Coding sites in over 8000 
Gentoype-Tissue Expression (GTEx) samples revealed that ADAR2 
expression in non-repetitive coding sites accounted for 25% of variation in 
RNA editing. This is in contrast to ADAR1 expression at the same sites, which 
accounted for only 6% of total variation (Tan et al., 2017). In vivo ADAR2 
targets were determined by examining multiple adult tissues from wild-type 
and Adar-/- Gria2R/R mice. The results showed that ADAR2-deficient mice had 
lower than average editing levels compared to wild type tissues. A total of 976 
sites were discovered to be edited by ADAR2 in mice (Tan et al., 2017).  
The reliance of ADAR1 and ADAR2 on each other varies from tissue to 
tissue. ADAR1 and ADAR2 performed comparable roles in the brain, whereas 
ADAR1 was the dominant editing enzyme in the liver, thymus and spleen, 
perhaps due to the lower expression levels of ADAR2 in non-brain tissues. 
Clustering analysis further revealed that the editing sites can be divided into 
five main regulatory groups that differ in their tissue-specific dependencies on 
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ADAR1 and ADAR2. Notably, the dependency of most of the sites on the 
editing enzymes varies from tissue to tissue (Tan et al., 2017). 
ADAR2 undergoes posttranslational modification. It can be phosphorylated 
at the N-terminus by an unknown kinase, before becoming a substrate for Pin1 
(peptidylprolyl cis/trans isomerase, NIMA-interacting 1) (Marcucci et al., 2011). 
Proline isomerisation of ADAR2 is essential for nuclear retention of ADAR2. In 
the absence of Pin1, ADAR2 is unstable and is present in the cytoplasm. 
Accumulation of ADAR2 in the cytoplasm allows it to interact with WWP2, a 
ligase that results in the subsequent degradation of ADAR2 (Marcucci et al., 
2011). Hence, Pin1 is a positive regulator for ADAR2 while WWP2 plays a 
negative role on ADAR2 regulation. Another protein that was found to be a 
negative regulator for ADAR2 is aminoacyl TRNA synthetase complex 
interacting multifunctional protein 2 (AIMP2) (Tan et al., 2017). AIMP2 
overexpression caused a significant decline in editing at over 1500 sites and 
a reduction in both ADAR1 and ADAR2 protein levels, signifying that AIMP2 
promotes ADAR1 and ADAR2 enzyme degradation (Tan et al., 2017).  
ADAR2 activity is also known to affect the expression of certain genes. For 
instance, knockdown of ADAR2 reduces RNA editing of glioma-associated 
oncogene 1 (GLI1), where decreased editing is found in cell lines from the 
cerebellar tumour medulloblastoma (Shimokawa et al., 2013). The introduction 
of edited GLI1 into medullablastoma cells confers a smaller increase in cellular 
growth compared to non-edited GLI1, indicating that RNA editing of GLI1 is a 
regulatory mechanism in tumourigenesis (Shimokawa et al., 2013). RNA 
editing can also effect protein stability of NOVA-1, a brain-specific regulator of 
alternative splicing (Irimia et al., 2012). Edited isoforms of NOVA-1 showed 
increased protein stability, increasing protein half-life and presumably 
increasing global NOVA-1 activity (Irimia et al., 2012).  
Recent reports have shown that incomplete nuclear localisation and lower 
ADAR2 levels are observed in the nucleus of immature neurons (Behm et al., 
2017). Editing levels of several sites were found to increase in vivo during 
mouse brain development (Wahlstedt et. al., 2009) and in vitro during rat 
neuron maturation (Orlandi et al., 2011). However, a parallel increase of ADAR 
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expression levels was not always found (Wahlstedt et al., 2009). The precise 
molecular regulation of ADAR2 activity and expression remains unclear.  
 
1.2.4 ALTERNATIVE SPLICING OF ADAR2 
 
Alternative splicing refers to a regulated process during gene expression 
which results in a single gene encoding multiple proteins. During this process, 
certain exons located in a gene may be included or excluded from the final, 
processed mRNA of that gene, resulting in protein isoforms with differing 
peptide sequences and thus chemical and biological functions (Black, 2003). 
Data from The International Genome Sequencing Consortium predicted that 
>50% of human genes are subjected to alternative splicing (Brett et. al., 2002). 
Various types of alternative splicing include exon skipping, intron retention, 
alternative 5’ or 3’ splice sites, mutually exclusive exons, mutually exclusive 5’ 
or 3’ untranslated regions (UTRs), and tandem UTRs (E. T. Wang et al., 2008).  
 Nine splice sites have been discovered in human ADAR2 pre-mRNA 
thus far (Table 1.1). Alternative splicing at these sites occurs independently, 
which results in dozens of ADAR2 spliced isoforms, making it challenging to 
analyse tissue-specific and developmental stage-dependent properties of 
these splice variants in vivo (Solomon et al., 2013). Five of these splicing 
events affect ADAR2 catalytic function (Li et al., 2015). The inclusion of exon 
1a between exon -1 and exon 1 results in an N-terminal extension of 28 amino 
acids, including seven arginine (R)/lysine (K) residues (Slavov & Gardiner, 
2002). The inclusion of exon 0, located between exon -1 and exon 1, results 
in the addition of 49 amino acids at the N-terminus (Maas & Gommans, 2009). 
The functional properties and relative protein abundance of these two ADAR2 
isoforms have yet to be determined.  
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Authors Alternative splice site Effect on ADAR2 transcript Effect on ADAR2 protein Effect on catalytic activity 
Gerber et. al., 1997 5-6 Inclusion of exon 5a Insertion of AluJ cassette in 
the catalytic domain 
Decreased 
Lai et. al., 1997 9 Truncates 3’ end of the 
coding region 
Replacement of 29 C-
terminal residues with 2 
amino acids 
None 
Rueter et. al., 1999 1-2 Addition of 47 nt to 5’ end of 
exon 2 
Generation of a 9 kDa protein Decreased 
Slavov and Gardiner, 2002 -1-1 Inclusion of exon 1a 28- amino acid N-terminal 
extension 
Unknown 
Kawahara et. al., 2005 1-3 Skipping of exon 2 Generation of a 12-amino 
acid protein 
None 
Kawahara et. al., 2005 9-10 Inclusion of intron 9 Unknown Unknown 
Kawahara et. al., 2005 9 Splices exon 9, 83 nt 
downstream from stop codon 
Unknown Unknown 
Maas and Gommans, 2009 -1-1 Inclusion of exon 0 49-amino acid N-terminal 
extension 
Unknown 
Agranat et. al., 2010 7-8 Inclusion of exon 7a Nonsense-mediated mRNA 
decay 
None 
Table 1.1 Alternative splicing sites in human ADAR2 reported in previous studies. Adapted from Fu et. al. (2018). 
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An A-to-I auto-editing event which creates a new 3’ splice acceptor site in 
the intron 1 sequence of ADAR2 results in the addition of 47 nt to the 5’ end 
of exon 2, causing a frameshift in the coding region. This is expected to 
generate a 9-kDa ADAR protein due to the insertion of a premature 
translational termination codon (Rueter et. al., 1999). Alternative splicing in 
exon 5, which causes the incusion of exon 5a, results in another ADAR2 
isoform. The alternatively-spliced exon 5a isoform encodes an in-frame AluJ 
cassette in the catalytic domain, resulting in protein with a twofold reduction in 
activity (Gerber et. al., 1997). Another splicing event in human ADAR2 mRNA 
results in the skipping of exon 2, causing a frameshift that inserts a stop codon 
in exon 3, producing a truncated protein of only 12 amino acids (Kawahara, 
Ito, Ito, Tsuji, & Kwak, 2005). The insertion of a 30-nt cassette in rats and mice 
(similar to a 120-nt cassette insertion in humans) results in the generation of 
two different ADAR isoforms (ADAR2a and ADAR2b). Although both isoforms 
are equally expressed during neuronal development, the ADAR2b variant is 
the less active isoform, due to the addition of a 10-aa loop which ultimately 
interferes with RNA binding, which could explain its lower editing efficiency 
compared to ADAR2a (Filippini et al., 2018a). 
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Figure 1.7 Exon-intron organisation of the human ADAR2 gene. 
The human ADAR2 gene spans ~150 kb of human chromosome 21q22. Exons are numbered 
from -2 to 10 and showed as filled boxes. Introns and 5’ and 3’ flanking regions are shown 
as solid lines. Shaded boxes denote alternatively utilized exons comprising alternative splice 
sites.  
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1.2.5 ADAR2 AND GLUA2 Q/R SITE EDITING 
 
ADAR2 edits specific adenosine residues found in RNA hairpins which are 
normally formed between a portion of an exon that flanks the edited adenosine 
and sequences in a nearby intron (Higuchi et al., 1993). The Q/R editing sites 
in mouse Gria2 and human GRIA2 transcripts are edited with over 99% 
efficiency (Sommer et al., 1991).  
 Adar2 homozygous mice with a targeted deletion of exon 6, which 
encodes the C-terminal deaminase domain, developed progressive seizures 
as pups and died by 21 days of age (Higuchi et al., 2000). Gria2 transcript 
mutations that prevent dsRNA structure formation required for editing also led 
to the death of mice, where increased calcium permeability and death of 
hippocampal neurons were found (Higuchi et al., 1993). Adar2 mutant pup 
death is avoided by combining the Adar2 mutation with a Gria2 mutant where 
the arginine residue of the Q/R editing site is introduced in the genomic 
sequence (Higuchi et al., 2000), thus showing that the Q/R site is the main 
physiological target of ADAR2 editing.  
 Glutamate excitotoxicity is an important factor in certain 
neurodegenerative diseases, such as spinal neurodegeneration in ALS (King 
et. al., 2016). The expression of ADAR2 is reduced in ALS patient motor 
neurons and editing downregulation at the Q/R site of GluA2 is seen in ALS 
patients’ motor neurons (Hideyama et al., 2012). The Adar2 mutant mice die 
too soon to present more widespread neurodegeneration; nonetheless, 
Adar2-targeted deletion in motor neurons of young mice leads to slow motor 
neuron degeneration (Hideyama et al., 2010). Vertebrate neuronal cells that 
are treated with excess glutamate to induce neurotoxicity led to the cleaving 
of ADAR2 protein by a calcium-activated protease, showing that glutamate 
excitotoxicity is mediated partly by suppressing GluA2 Q/R site editing 
(Mahajan et. al., 2011). 
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1.3 AMYOTROPHIC LATERAL SCLEROSIS 
1.3.1 INTRODUCTION 
 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s 
disease in the United States of America and motor neuron disease (MND) in 
the United Kingdom, is a neurodegenerative disease characterised by 
progressive muscular paralysis reflecting degeneration of motor neurons in 
the primary motor cortex, corticospinal tracts, brainstem, and spinal cord. The 
disease gradually starts off with focal weakness, before spreading to most 
muscles, including the diaphragm. Death normally occurs due to respiratory 
paralysis 3 to 5 years after disease onset (Brown & Al-Chalabi, 2017). The 
prevalence of ALS in European populations is projected to be at 2.6-3.0 cases 
per 100,000 people (van Es et al., 2017). Compared to Alzheimer’s disease, 
the risk of developing ALS peaks at 50-75 years of age and decreases 
afterwards (van Es et al., 2017). 
“Amyotrophy” signifies the atrophy of muscle fibres that are denervated 
due to degeneration of corresponding anterior horn cells, causing weakness 
and fasciculations. “Lateral sclerosis” refers to gliosis that replaces 
degenerated neurons that cause hardening of the corticospinal tract (Rowland 
& Shneider, 2001). Roughly two-thirds of patients with typical ALS have a 
spinal form of the disease and present with symptoms linked to focal muscle 
weakness and wasting. Gradually, spasticity may develop in the weakened 
atrophic limbs, thus affecting manual dexterity and gait. Most ALS cases are 
sporadic, whereas 5-10% of cases are familial. In roughly 60-80% of familial 
ALS patients, large mutation effects can be identified, of which C9ORF72 
(40%), SOD1 (40%), FUS (1-5%) and TARBDP (1-5%) are the most common 
(van Es et al., 2017). 
 A pathological hallmark of ALS is death of motor neurons in the motor 
cortex and spinal cord. Neuronal degeneration is more common in ALS with 
frontotemporal dementia, appearing throughout the frontal and temporal lobes 
(Brown & Al-Chalabi, 2017). Neuroinflammatory processes such as astroglia, 
microglia, and oligodendroglial cell proliferation occur alongside motor neuron 
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degeneration (Kang et al., 2013). One common feature seen in both familial 
and sporadic ALS is the aggregation of cytoplasmic proteins, notably in the 
motor neurons. TAR DNA-binding protein 43 (TDP-43) is cleaved, hyper-
phosphorylated, and mislocalised in the cytoplasm (Neumann et al., 2006). 
Ubiquitin 2 aggregates are also common, while superoxide dismutase 1 
(SOD1) are intracytoplasmically deposited in sporadic ALS (Brown & Al-
Chalabi, 2017). 
The management of ALS has been based on coordinated 
multidisciplinary care between specialist, community-based therapists and 
palliative care teams. Even though ALS is deemed incurable, symptoms that 
arise from the disease are treatable, thus efforts are made to improve life 
quality and help maintain the patient’s autonomy for as long as possible. The 
general recommendation for improving the quality of ALS patients is by 
discussing end of life care, respiratory, and nutritional management with 
patients and relatives at the earliest opportunity (Wijesekera & Leigh, 2009). 
There is a possibility that ALS patients and their relatives will suffer from 
depression, hopelessness, and anxiety resulting from the diagnosis or disease 
progression (Wicks et al., 2007). Hence, psychological support through 
counselling and palliative care should be offered to both the patients and 
relatives from early on (Leigh et al., 2003). Non-invasive ventilation increases 
survival and improves quality of life.  
Currently, no cure is available for ALS and only two compounds are 
available to treat this disease (riluzole and edaravone). Riluzole came to the 
market as the first FDA (Food and Drug Administration)-approved drug for 
ALS. It is still unknown what the mechanism of action of riluzole is, but is 
speculated to block voltage-gated sodium channels of presynaptic neurons, 
thus reducing glutamatergic neurotransmission (Hardiman et al., 2017). The 
drug is well-tolerated, but survival of patients was only prolonged by 2-3 
months compared to placebo (Lacomblez, Bensimon, Meininger, Leigh, & 
Guillet, 1996). Edaravone, a drug that can potentially reduce oxidative stress, 
is now approved by the FDA, but not by the European Medicines Agency 
(Hardiman et al., 2017). It has been shown to slow disease progression in 
highly selected patients with early-onset and rapidly-progressing disease (Abe 
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et al., 2017). However, further studies are necessary to establish whether 
edaravone would be safe and effective in advance stage ALS patients and to 
determine if the drug can prolong patient survival (Abe et al., 2017). 
 
1.3.2 MOLECULAR GENETICS 
 
ALS has traditionally been classified either as sporadic (sALS) or 
familial (fALS). fALS makes up 10-20% of ALS cases and is transmitted 
classically within families via Mendelian inheritance and is mainly autosomal 
dominant (Zarei et al., 2015). Most ALS cases (80-90%) are sporadic, which 
have no clear genetic linkage. Even though more than 30 genes are presented 
to be linked to ALS, evidence suggests that genetic pleiotropy (where one 
gene has many phenotypic manifestations) and oligogenic inheritance (where 
more than one gene determines a phenotypic trait) play a role in the disease 
(Hardiman et al., 2017). Population studies in those with European descent 
showed that up to 20% of ALS patients have a family member with either ALS 
or frontotemporal dementia (familial ALS). Among these, four genes are linked 
to 70% of all cases of fALS: C9ORF72, TARDBP (also known as TDP-43, 
encodes for TAR DNA binding protein), SOD1 (copper/zinc ion-binding 
superoxide dismutase), and FUS (encodes fusion in sarcoma) (Chiò et al., 
2014) (Table 1.2).
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Table 1.2 Summary of description of genes and loci associated with ALS. Adapted from Zufiria et. al. (2016). 
 
fALS Locus Inheritance
Mean 
age at 
onset
Gene Protein defective 
function/protein aggregates
Associated features References
ALS1/
SOD1
21q22.
11
Dominant/
Recessive
47
Superoxide 
dismutase 1 
(SOD1)
Protein aggregation, potential 
gain of redox function, 
weakened axonal transport, 
metabolic changes/cytoplasmic 
inclusions of SOD1, ubiquitin 
and p62
Lower (LMN) and 
upper motor neuron 
(UMN) involvement. 
Amyotrophy, 
autonomic and 
cognitive dysfunction, 
cerebellar ataxia
(Rosen et al., 
1993)
ALS6/
FUS
16p11.
2
Dominant/
Recessive
46
Fused in 
sarcoma 
(FUS)
Altered RNA processing, 
formation of inclusion 
bodies/FUS
LMN and UMN 
involvement, 
frontotemporal 
dementia (FTD)
(Vance et al., 
2009)
ALS9/
ANG
14q11.
1 Dominant 55
Angiogenin 
(ANG)
rRNA transcription, stress 
granule formation/TDP-43 
aggregates
LMN and UMN 
involvement, FTD, 
Parkinson’s disease
(Van Es et al., 
2011)
ALS10/
TARDBP
1p36.2
2
Dominant/
Recessive 
(rare)
55 TDP-43 (TARDBP)
RNA splicing, formation of 
protein inclusion bodies, 
metabolic changes, p62 and 
TDP-43-positive aggregates
LMN and UMN 
involvement, FTD
(Gitcho et al., 
2009)
ALS12/
OPTN
10p15-
p14
Dominant/
Recessive
51 Optineurin (OPTN)
Golgi maintenance, membrane 
trafficking and exocytosis, 
formation of inclusion bodies
LMN and UMN 
involvement, FTD
(Maruyama et 
al., 2010)
C9ORF72/
FTDALS1
9p21.2 Dominant 57 C9ORF72
Endosomal trafficking and 
autophagy, altered C9ORF72 
RNA splicing, formation of 
nuclear RNA foci/TDP-43-
positive and -negative 
aggregates localised in the 
hippocampus
LMN and UMN 
involvement, FTD
(DeJesus-
Hernandez et 
al., 2011; 
Renton et al., 
2011)
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SOD1 mutations, which make up 20% of fALS cases and 5% of sALS 
cases, cause cytotoxicity but its pathophysiology still remains unclear (Table 
1.2) (Kiernan et al., 2011). TARDBP and FUS, which account or 5% of fALS 
mutations, play a role in gene expression and regulation processes such as 
transcription, RNA splicing, transport, and translation (Table 1.2) (Kiernan et 
al., 2011). ANG, a gene responsible for 1% of fALS, codes for an angiogenic 
factor in response to hypoxia (Table 1.2) (Zarei et al., 2015). Mutations in 
OPTN, a gene involved in open-angle glaucoma, eliminates the inhibition of 
nuclear factor kappa-beta activation, modifying OPTN distribution in the 
cytoplasm (Table 1.2) (Kiernan et al., 2011). Although SOD1 and C9ORF72 
mutations most often cause fALS, their frequencies differ across populations 
(Zarei et al., 2015). 
 
Nearly up to half of fALS cases can be associated with specific genes, 
where most are apparently rare and highly penetrant de novo mutations within 
affected families. Common variables related to this disease have been 
identified by genome-wide association studies (He, Mangelsdorf, Fan, Bartlett, 
& Brown, 2015). Next-generation sequencing (NGS) has also provided a way 
to map mutations for single gene diseases (He et al., 2015). Both GWAS and 
NGS have identified genetic variables that are associated with higher risk of 
developing ALS. Establishing accurate clinical phenotypes of ALS is crucial in 
the success of GWAS and NGS to prevent false positive results (He et al., 
2015).  
 
The genetic mechanisms of sALS is poorly understood. Large and 
combined GWAS of seemingly sporadic ALS, which analysed disease 
heritability by allele frequency, insinuate that the genetic risk factors are mainly 
centred on rare variants (Van Rheenen et al., 2016). This contrasts with 
diseases associated with high numbers of common variants, such as 
schizophrenia, which are highly polygenic (Loh et al., 2015). The rare variants 
which confer risk that might be individual-, family-, and ancestral-specific 
makes GWAS studies for ALS complicated (Van Rheenen et al., 2016). 
Whole-genome sequencing comprising a high number of patients and controls 
will be necessary to completely unravel the genetics behind ALS considering 
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the disease’s genetic architecture. The Project MinE Consortium 
(www.projectmine.com), launched in 2012, aims to carry out whole-genome 
sequencing of more than 15,000 ALS patients and 7,500 controls. This is 
expected to provide better comprehension about the genetic architecture of 
ALS (Hardiman et al., 2017)
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1.3.3 PATHOPHYSIOLOGICAL MECHANISMS 
 
Pathogenic mechanisms that have been suggested for ALS comprise 
a plethora of changes to the motor neuron microenvironment. This includes 
the accumulation of protein aggregates, defective RNA processing, oxidative 
stress, glutamate excitotoxicity, glial dysfunction, neuroinflammation, 
apoptosis, mitochondrial dysfunction, and metal imbalances (Paez-Colasante, 
Figueroa-Romero, Sakowski, Goutman, & Feldman, 2015). The presence of 
intraneuronal aggregates of neurofilaments are apparent in ALS patients, 
particularly in spinal motor neurons (Paez-Colasante et al., 2015). Alterations 
in neurotransmitter release and synaptic function are also common to both 
ALS and FTD (reviewed in Paez-Colasante et. al., 2015). Furthermore, 
aberrations in RNA-processing protein networks in ALS and other 
neurodegenerative diseases prompt abnormal RNA regulation and exon 
splicing (Paez-Colasante et al., 2015). ALS pathogenesis is thus complex, with 
several causative factors. 
 
1.3.3.1 SOD1 
 
The discovery of dominant SOD1 mutations 20 years ago was the first 
to demonstrate how linkage analysis can determine the genetic cause of a rare 
neurodegenerative disease (Rosen et al., 1993). However, only a small 
number of reliable cases supporting the genetic evidence for the pathogenicity 
of SOD1 mutations exist (Andersen, 2006). Nonetheless, population-based 
studies demonstrate that this gene mutation accounts for ~12% of familial 
cases and ~1% of sporadic cases (Renton, Chiò, & Traynor, 2014). At least 
75 of SOD1’s 153 amino acids have been reported to be mutated in ALS and 
their positions are dispersed throughout the five exons of the gene (Saccon, 
Bunton-Stasyshyn, Fisher, & Fratta, 2013). 
SOD1 is highly conserved, ubiquitously expressed, and makes up 1-
2% of total soluble protein in the central nervous system. The gene is made 
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up of five exons that encode a 153-amino acid metalloenzyme, also known as 
Cu/Zn superoxide dismutase. The protein localises to the cytoplasm, 
lysosomes, nucleus, and the mitochondria intermembrane space (Saccon et 
al., 2013). It binds copper and zinc ions and forms a homodimer which mainly 
functions as a dismutase that removes dangerous superoxide radicals by 
metabolising them to molecular oxygen and hydrogen peroxide, thus providing 
a defence against oxygen toxicity (Saccon et al., 2013). SOD1 has recently 
been found to be vital in suppressing respiration and directing energy 
metabolism by integrating responses to oxygen, glucose and superoxide 
levels; this function is independent of its oxidative stress functions (Reddi & 
Culotta, 2013). SOD1 protein is produced in high quantities that have yet to 
be explained by known functions, thus, it may also play other neuron-specific 
and general roles (Reddi & Culotta, 2013). 
 Many lines of evidence have suggested that SOD1 mutations cause 
ALS by a yet unidentified gain of function, although some propose that loss-
of-function can also play a secondary role in disease, at least in some cases 
(Saccon et al., 2013). Many cellular mechanisms have been implicated to be 
potentially involved in SOD1-fALS pathogenesis. However, distinguishing 
cause from effect and identifying its critical processes remains a challenge 
(Redler & Dokholyan, 2013). 
No clear consensus has arisen to link SOD1 mutations to the premature 
death of motor neurons. Recent understanding has linked genetic mutations 
to a toxic gain of function of the SOD1 enzyme, with free radical generation 
that ultimately leads to cell injury and death (Bruijn, Miller, & Cleveland, 2004). 
Furthermore, mutations in SOD1 induce conformational instability and 
misfolding of the SOD1 protein, which results in formation of intracellular 
aggregates (Zetterström et al., 2007) that inhibit normal proteosomic function, 
disrupting axonal transport systems and vital cellular functions (Bruijn et al., 
2004). 
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1.3.3.2 TDP-43 
 
A breakthrough event in the understanding of ALS pathogenesis was 
the finding that TDP-43, a major component of ubiquitin-positive neuronal 
inclusions, is a pathological hallmark of ALS and frontemporal dementia (FTD) 
(Neumann et al., 2006). Although questions about whether such aggregates 
trigger neurodegeneration in ALS has arisen, mutations in TDP-43 were 
reported in 3% of familial ALS and 1.5% of sporadic ALS (Sreedharan et al., 
2008). TDP-43 is a ubiquitously expressed DNA-/RNA-binding protein, which 
is encoded by TARDBP (Ou, Wu, Harrich, Garcia-Martinez, & Gaynor, 1995). 
It is made up of two RNA recognition motifs, a nuclear localisation sequence 
(NLS), a nuclear export signal, and a glycine-rich C-terminus that mediates 
protein-protein interactions (Scotter et. al. 2015). TDP-43 is mainly found in 
the nucleus, but is also able to undergo nucleocytoplasmic shuttling (Winton 
et al., 2008). It plays an important role in regulation of RNA splicing and 
modulation of microRNA biogenesis in the nucleus (Scotter et al., 2015), which 
requires the glycine-rich C-terminal domain that is able to bind to several 
members of the heterogenous nuclear ribonucleoprotein (hnRNP) family 
(Mackenzie & Rademakers, 2008). TDP-43 is capable of regulating the 
stability of its own mRNA, which provides a mechanism for autoregulating 
TDP-43 protein levels (Ayala et al., 2010). Aside from TDP-43 RNA, it can also 
regulate splicing and stability of various other transcripts, thus influencing a 
large number of cellular processes (Scotter et al., 2015). TDP-43 is generally 
localised to nuclei of neuronal and some glial cells (Neumann et al., 2006). 
TDP-43 was recognised as a main component of ubiquitinated neuronal 
cytoplasmic inclusions deposited in FTD cortical neurons and ALS spinal 
motor neurons (Neumann et al., 2006). 97% of both sporadic and familial ALS 
cases have been shown to be positive for TDP-43 inclusions (Scotter et al., 
2015). A common theme seen in neurodegenerative disease is the presence 
of abnormally phosphorylated and ubiquitinated intracellular insoluble proteins 
(Lee, Lee, and Trojanowski 2012). Distinctive features of TDP-43 
proteinopathies include the mislocalisation of the cognate protein to the 
cytoplasm, and the loss of its normal nuclear localisation (Lee, Lee, and 
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Trojanowski 2012). It is still currently unknown which of these features are 
essential for development of ALS. Thus, all observed features of 
neurodegenerative diseases with TDP-43 proteinopathies need to be 
considered when conveying models of disease mechanisms (Lee, Lee, and 
Trojanowski 2012). 
 
1.3.3.3 C9ORF72 
 
An expanded non-coding GGGGCC repeat identified in C9ORF72 is 
the most common cause of familial ALS and is also one of the underlying 
causes to most sporadic ALS cases (DeJesus-Hernandez et al., 2011). This 
repeat expansion is not just limited to ALS; it also contributes to frontotemporal 
dementia (FTD) and ALS-FTD, and has been identified in other non-motor 
diseases such as Alzheimer’s disease and Lewy-body dementia (Cooper-
Knock, Shaw, & Kirby, 2014). 
Although the repeat size shows heterogeneity among patients as well 
as different tissues within the same individual, the correlation between the 
number of repeats and the severity of clinical phenotypes is unclear. It has 
been shown that C9ORF72 expansion carriers have a higher ALS prevalence, 
particularly bulbar onset ALS (reviewed by Zufiría et al. 2016). C9ORF72 is a 
gene that encodes an uncharacterised protein with no known domains or 
function, but is highly conserved across species (DeJesus-Hernandez et al., 
2011). Despite this, some evidence has shown that the C9ORF72 protein 
transcript is involved in endosomal trafficking (Farg et al., 2014). Farg et. al. 
depleted C9ORF72 expression in SH-SY5Y and Neuro2A cells using siRNA 
and found that this depletion results in impaired endocytosis and autophagy-
mediated trafficking, suggesting its downregulation as a putative pathogenic 
mechanism (Farg et al., 2014). Studies carried out by DeJesus-Hernandez 
et.al. (2011) suggest multiple potential disease mechanisms are associated 
with the GGGGCC repeat expansion, which includes a direct effect on 
C9ORF72 expression by affecting transcription through a loss-of-function 
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mechanism and an RNA-mediated gain-of-function mechanism through the 
generation of toxic RNA foci.  
One common characteristic seen in noncoding repeat expansion 
disorders that has recently gained increased scrutiny is the build-up of RNA 
fragments made up of the repeated nucleotides as RNA foci in the nucleus 
and cytoplasm of affected cells (Todd & Paulson, 2010). In some diseases, 
the RNA foci dysregulate alternative mRNA splicing by sequestering RNA-
binding proteins. The presence of such nuclear RNA foci in post-mortem 
cerebral cortex and spinal cord tissue of C9ORF72 expanded repeat carriers 
was confirmed using an oligonucleotide probe specific for the GGGGCC 
repeat (DeJesus-Hernandez et al., 2011). The hexanucleotide sequence motif 
predicts the possible binding of several RNA-binding proteins, such as the 
serine/arginine-rich splicing factor 1 (SRSF1) and the heterozygous nuclear 
ribonucleoprotein (hnRNP) A2/B1 (Smith et al. 2006; Sofola et al. 2007). 
Though further studies are required to illustrate whether these or other 
RNA-binding proteins are involved in disease pathogenesis, aberrant RNA 
splicing is a likely mechanism in chromosome 9p-linked FTD/ALS (Brown & 
Al-Chalabi, 2017). Cells which contain C9ORF72 repeats, including patient 
brain and spinal cord neurons, comprise of a prominent nuclear foci of the 
GGGGCC repeat RNA and the antisense GGCCCC RNA, causing 
sequestration of essential RNA-binding proteins, such as splicing factors, thus 
prompting pre-mRNA splicing defects by an RNA toxicity mechanism (Gitler & 
Tsuiji, 2016). Determining aberrantly spliced RNA targets that are integral in 
disorders could be pivotal to the discovery of future therapeutic strategies 
(DeJesus-Hernandez et al., 2011). 
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1.3.3.4 MICRORNA DYSREGULATION 
 
MicroRNAs (miRNA) are conserved noncoding RNAs that are 22 
nucleotides in length. They can individually regulate several hundred targets 
through RNA-dependent post-transcriptional silencing mechanisms 
(Schwanhäusser et al., 2008). Conversely, mRNA transcripts can be regulated 
by many miRNAs (Bartel, 2004). Primary miRNA transcripts (pri-miRNAs) are 
transcribed in the nucleus, and undergo processing by Drosha (also known as 
ribonuclease 3) to produce precursor miRNAs (pre-miRNAs) (Y. Lee et al., 
2004). Pre-miRNAs are then exported to the cytoplasm and processed by 
Dicer (an endoribonuclease) to become mature double-stranded miRNAs 
(Hutvágner et al., 2001). Precursor miRNAs in the human genome are able to 
modulate many physiological processes, such as neuronal homeostasis and 
cell differentiation, by elaborate fine-tuning of the transcriptome and proteome 
(Engels & Hutvagner, 2006; Lau, Lim, Weinstein, & Bartel, 2001; Ponomarev, 
Veremeyko, Barteneva, Krichevsky, & Weiner, 2011). miRNAs are temporally 
and differentially expressed among different tissues. miR-138 is confined 
within the CNS while its precursor is ubiquitously expressed, and miR-9 shows 
copious neuron-specific expression (Coolen, Katz, & Bally-Cuif, 2013; 
Mondanizadeh et al., 2015).  
In most diseases, differentially expressed miRNAs have been found 
between both diseased and normal tissue. They are typically subject to 
change amid the pathogenetic course (Engels & Hutvagner, 2006). Hence, 
biological pathways altered by miRNA could partially explain complex 
disorders such as ALS. The implications of miRNA dysregulation have not 
been entirely clarified in neurodegenerative diseases. It is thus imperative to 
determine whether dysregulation takes place via transcriptional or post-
transcriptional mechanisms, or both. Reduction in TDP-43 can affect RNA 
processing via interactions with Drosha-containing protein complexes (Honda 
et al., 2014). Drosha can also interact with other polypeptides, such as TDP-
43, AGO2, nuclear pri-miRNAs or cytoplasmic pre-miRNAs to establish an 
alternative complex with limited processing function (Kawahara & Mieda-Sato, 
2012). Reports have shown that TDP-43 mutations leads to differential 
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expression of mature and functional miRNAs such as miR-132, miR-143 and 
miR-558 that contribute to ALS pathology (Kye & Gonçalves, 2014). A 
reduction in TDP-43 led to a deficiency in neurite growth in Neuro2a cells, and 
this was only recovered by over-expressing miR-132 (Kawahara & Mieda-
Sato, 2012). The expression of miR-9 is shown to be reduced in iPSC-derived 
motor neurons in ALS patients containing TARDBP mutations (Zhang et al., 
2013). 
Recently, FUS/TLS (translocated in sarcoma) has been shown to 
encourage biogenesis of certain miRNAs by recruiting Drosha to pri-mRNAs. 
miR-9 regulates axon growth by regulating mRNA translation of microtubule-
associated protein 1b (MAP1B), while neuronal morphology and growth are 
regulated by miR-132 via targeting genes such as acetylcholinesterase and 
Tau. Neuronal activity triggers miR-134 response by regulating neuronal 
development and dendritogenesis (reviewed in Kye & Gonçalves, 2014). 
These results indicate that FUS/TLS mutations could lead to a disruption in 
miRNA biogenesis and function, thus contributing to pathological phenotypes 
observed in ALS patients.  
Sporadic ALS patients demonstrated a distinctive miRNA expression 
pattern in white blood cells throughout disease progression. An miRNA 
profiling data study revealed an increase in miR-338-3p expression, while the 
expression of seven other miRNAs is reduced in ALS patient leukocytes (De 
Felice et al., 2012). These findings suggested that disruption to miRNA 
pathways may be a likely cause or consequence that lead to ALS pathology, 
which include altered RNA and protein metabolism, cytotoxicity, and impaired 
structure and signalling at the neuromuscular junction (Figure 1.8) (Paez-
Colasante et al., 2015) (Paez-Colasante et al., 2015). Hence, profiling miRNA 
expression can potentially act as an ALS diagnostic tool (Kye & Gonçalves, 
2014). 
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Figure 1.8 Dysregulation of miRNA biogenesis and function. 
Dysregulation of miRNA biogenesis and function may be a cause and/or consequence of 
ALS pathogenesis, which can arise through dysregulation of several cellular pathways. 
RNA and protein metabolism may be altered by inclusion of cytoplasmic protein 
aggregates, signalling impairments at the neuromuscular junction, and cell death caused 
by cytotoxicity linked to excessive glutamate activation. 
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1.3.3.5 GLUTAMATE-INDUCED EXCITOTOXICITY 
 
Glutamate-induced excitotoxicity has been implicated in ALS 
pathogenesis. Glutamate is the major excitatory neurotransmitter in the central 
nervous system and binds to ionotropic N-methyl–D-aspartate (NMDA) 
receptors and AMPA receptors on the postsynaptic membrane (Heath & 
Shaw, 2002). Excessive activation of these postsynaptic receptors by 
glutamate can stimulate neurodegeneration by activating calcium-dependent 
enzymatic pathways (Regan & Choi, 1991).  
Glutamate released from the presynaptic neuron activates ionotropic 
glutamate receptors present on the postsynaptic neuron during glutamatergic 
neurotransmission (L. Van Den Bosch, Van Damme, Bogaert, & Robberecht, 
2006) (Figure 1.9a). Activation of these glutamate receptors results in Na+ and 
Ca2+ ion influx into the cell, which leads to depolarisation and ultimately 
generation of an action potential (Figure 1.9a). Excitotoxicity is neuronal 
degeneration caused by overstimulation of the glutamate receptors (L. Van 
Den Bosch et al., 2006) (Figure 1.9b). Olney (1978) first formulated this 
concept based on the observation that amino acids that induce neuronal death 
were those known to activate excitatory amino acid receptors. Since then, 
experimental evidence showed that excitotoxicity could contribute to neuronal 
damage in stoke, neurotrauma, epilepsy, and a number of neurodegenerative 
disorders including ALS (Doble, 1999).
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Figure 1.9 Glutamatergic neurotransmission and excitotoxicity. 
(A) During normal conditions, glutamate released from the presynaptic neuron activates NMDA 
and AMPA receptors. This leads to an influx of both Na+ and Ca2+ions, the depolarisation of 
the postsynaptic neuron and eventually the generation of an action potential. (B) Excitotoxicity 
is prompted by an elevation in extracellular glutamate concentration. This can be caused by 
an increased release of glutamate or defective re-uptake of glutamate into the astrocytes by 
the EAAT2/GLT-1 transporter. Excessive stimulation of the glutamate receptors causes in 
increased intracellular concentration of Na+ and Ca2+ions, resulting in neuronal death. 
Disintegration of neuronal cells induces a further increase of extracellular glutamate and 
amplifies the excitotoxic damage. Figure taken from Van Den Bosch et al, 2006. 
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RNA editing targets are plentiful in the CNS, where proteins involved in 
synaptic transmission are recoded (Rosenthal & Seeburg, 2012). Editing 
dysregulation can cause extensive modifications in neuronal signalling, thus 
inducing severe neurological disorders (Kawahara et al., 2004; Stefan Maas, 
Kawahara, Tamburro, & Nishikura, 2006). Since RNA editing recodes several 
glutamate receptor subunits, this process has acute effects on glutamate 
neurotransmission (Barbon & Barlati, 2011). Under normal physiological 
conditions, the Q/R site of GluA2 is fully edited, making the AMPA receptors 
Ca2+-impermeable. Loss of editing at the Q/R site produces an increased influx 
of Ca2+, leading to epileptic seizures and death in ADAR2-null mice (Miyoko 
Higuchi et al., 2000). Transient ischemia in humans lowered GluA2 subunit 
editing and reduced ADAR2 abundance, causing the death of pyramidal 
neurons (Peng et al., 2006). Moreover, spinal motor neurons of sALS patients 
showed severely reduced GluA2 Q/R site editing, possibly due to ADAR2 
downregulation, thus causing AMPA receptors to be highly permeable to Ca2+. 
This in turn facilitates the death of motor neurons, as reported in conditional 
ADAR2 knockout mice (T. Hideyama et al., 2010). Exposing cortical cells to 
excitotoxic levels of glutamate has also reported to promote ADAR2 cleavage 
and an ensuing loss of Q/R site editing, leading to excitotoxic cell death 
(Mahajan et al., 2011).  
The most imperative argument for the role of excitotoxicity in ALS is 
that riluzole, the only drug which is demonstrated to be effective against 
disease progression in patients, has anti-excitatory properties (Lacomblez et 
al., 1996). It is currently the only therapy proven in clinical trials to prolong 
survival of ALS patients (Traynor, Alexander, Corr, Frost, & Hardiman, 2003). 
Its neuroprotective effect is thought to benefit in many neurodegenerative 
diseases and amelioration of trauma and stroke (Albo, Pieri, & Zona, 2004). 
Riluzole slows disease progression and significantly increases survival by a 
few months. This drug has been shown to inhibit glutamate release due to 
inactivation of voltage-dependent Na+ channels on glutamatergic nerve 
terminals. Furthermore, evidence has shown that riluzole can also block some 
of the postsynaptic effects of glutamate by non-competitive inhibition of NMDA 
and AMPA receptors (Albo et al., 2004).  
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Motor neurons, both in vitro and in vivo, are particularly vulnerable to 
AMPA receptor-mediated excitotoxicity. Intrathecal or intraspinal 
administration of AMPA receptor agonists induced motor neuron degeneration 
in animals (Nakamura, Kamakura, & Kwak, 1994). Motor neurons are also 
proved to be particularly vulnerable to AMPA receptor-mediated excitotoxicity 
in organotypic rat spinal cord cultures (Saroff et. al., 2000). Direct application 
of AMPA receptor agonists lead to selective motor neuron loss, which could 
be prevented by AMPA receptor antagonists. 
Likewise, it was established that motor neurons in culture are 
susceptible to glutamate receptor agonists, particularly those that stimulate 
AMPA receptors (L. Van Den Bosch & Robberecht, 2000). Ca2+ influx through 
Ca2+-permeable AMPA receptors was shown to be essential for inducing 
motor neuron death when cultured on an astrocytic feeder layer whereas other 
neurons were resistant to AMPA receptor over-stimulation (L Van Den Bosch 
et al., 2002). Little or no effect of NMDA receptor agonists was apparent in 
these cultured motor neurons (L. Van Den Bosch et al., 2006). Additionally, 
depolarising these motor neurons by exposing them to a high extracellular K+ 
concentration was not sufficient to induce significant cell death (L Van Den 
Bosch et al., 2002). 
Since ADAR2 reduction may likely play a role in motor neuron survival 
in patients with sporadic ALS, one possible therapeutic strategy is restoring 
ADAR2 activity in neurons. This was carried out by delivering human ADAR2 
cDNA to motor neurons in conditional ADAR knockout (AR2) mice using an 
adeno-associated virus serotype 9 (AAV9) vector (Yamashita et al., 2013). 
The vector-based gene delivery prevented ALS phenotype progression, 
including progressive motor dysfunction. Moreover, the effect of ADAR2 gene 
delivery was observed even when delivered after the appearance of motor 
dysfunction (Yamashita et al., 2013). 
 Another study revealed that homozygous conditional ADAR2-knockout 
(AR2) mice displayed mislocalisation of TDP-43 from the nucleus to the 
cytoplasm, where TDP-43 aggregates. This resembles TDP-43 pathology in 
ADAR2-deficient motor neurons (Yamashita et al., 2012). An in vitro calpain 
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assay further demonstrated that TDP-43 was cleaved specifically by calpain, 
a Ca2+-dependent cysteine protease, suggesting that calpain-dependent 
cleavage of TDP-43 is possibly involved in the aetiology of TDP-43 pathology 
in ALS motor neurons (Yamashita et al., 2012). Oral administration of 
perampanel, an AMPA receptor antagonist, reduces motor neuron death and 
TDP-43 mislocalisation in AR2 mice (Akamatsu, Yamashita, Hirose, 
Teramoto, & Kwak, 2016). The robust effects of perampanel on ADAR2 on 
AR2 mice suggest that perampanel may have exerted its effects through a 
Ca2+-permeable AMPA receptor-mediated mechanism (Akamatsu et al., 
2016). 
 Reports have shown that inefficient GluA2 Q/R site editing does not 
seem to be an underlying mechanism behind ALS cases with C9ORF72 
mutations. Work carried out by (Selvaraj et al., 2018) discovered efficient RNA 
editing in mutant C9ORF72 motor neurons with increased Ca2+-permeability. 
This is consistent with findings in native neurons and familial ALS with SOD1 
mutations (Kawahara, Kwak, et al., 2003; Kawahara et al., 2006). Another 
explanation behind increased Ca2+-permeability include disease-related 
modifications in AMPA receptor subunit composition. The GluA1 subunit was 
found to be upregulated in C9ORF72 mutant motor neurons, which correlates 
with increased Ca2+-permeability in these cultures (Selvaraj et al., 2018). 
However, findings reported by (Moore et al., 2019) presented contradictory 
results, whereby ADAR2 was found to be misloclalised in induced pluripotent 
stem cells of ALS patients with C9ORF72 mutations. The mislocalisation of 
ADAR2 has resulted in RNA editing aberrations of various cellular pathways 
(Moore et al., 2019), thus suggesting that the repeat expansion of C9ORF72 
does indeed alter RNA processing events.
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1.4 ANTISENSE OLIGONUCLEOTIDES 
1.4.1 OVERVIEW 
 
Antisense oligonucleotides (ASOs) are synthetic single stranded chains 
of nucleic acids which are between 8 to 50 nucleotides in length. They bind to 
RNA through standard Watson-Crick base pairing. ASOs interfere with gene 
expression by altering RNA function. Subject to sequence and modifications, 
ASOs can alter RNA function through several distinct mechanisms, thus 
making them a diverse tool. They can be used to restore protein expression, 
reduce expression of a toxic protein, or modify mutant proteins to reduce their 
toxicity (Evers, Toonen, & van Roon-Mom, 2015).  
Antisense-mediated gene inhibition was first introduced by Stephenson 
and Zamecnik in 1978 (Stephenson & Zamecnik, 1978). Using a DNA 
molecule of 13 nucleotides in length with modifications at the 3′ and 5′ OH 
moieties, they exhibited inhibition of replication and cell transformation of the 
Rous sarcoma virus. Modifications to the backbone and sugar component 
have been made since then, which has improved stability, binding strength 
and specificity, making ASOs suitable for therapeutic application (Järver, 
O’Donovan, & Gait, 2014). For some neurodegenerative disorders, such as 
ALS and spinal muscular atrophy (SMA), antisense oligonucleotide therapy 
has now advanced from preclinical to clinical stage, aided by the significant 
widespread distribution and cellular uptake of ASOs once delivered into the 
brain (Evers et al., 2015). 
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1.4.2 FUNCTIONAL MECHANISMS 
 
ASOs can be used in different ways to modulate gene expression, 
depending on the chemistry and target site. One of the major functional 
mechanisms that can be used in neurodegenerative disorders is RNase H-
mediated degradation (Figure 1.10a and b). To induce gene knockdown 
through RNase H, a strategy using gapmer ASOs has been developed (Figure 
1.10a). These consist of a central DNA region with flanking 2’-modified 
nucleosides. Since the active site of an exonuclease binds only to two or three 
residues at the 3’- or 5’-end, a short stretch of 2’-modified RNA nucleosides at 
both ends is sufficient for protection against exonucleases (Teplova et al., 
1999). If the target protein enacts important cellular functions, general 
downregulation would be unfavourable. In such cases, decreasing the 
mutation-containing protein is preferred. Selective RNase H-mediated 
degradation can be achieved using antisense oligonucleotide gapmers 
targeting specific point mutations, structural differences between wild-type and 
mutant mRNA, or a single nucleotide polymorphism (SNP) that is unique to 
the mutant RNA (Evers et al., 2015) (Figure 1.10b). 
Another functional mechanism used in antisense technology is by 
interfering with RNA processes via steric hindrance (Figure 1.10c and d). 
Aside from RNase-mediated breakdown of mRNA, protein levels can also be 
lowered by inhibiting translation. Suppressing RNA translation to lower protein 
levels could be attained by ASOs that target the RNA translation initiation site 
or sterically blocking the binding of RNA protein complexes, such as ribosomal 
subunits (Kole, Krainer, & Altman, 2012) (Figure 1.10c). Since many RNA 
processes rely on the recognition sites or secondary structure of RNA 
molecules, adding short complementary sequences of modified nucleotides 
can disrupt these processes. The most well-known application of steric 
hindrance is manipulating splicing events (Van Ommen & Aartsma-Rus, 2013) 
(Figure 1.8d). Most human genes express more than one mRNA through 
alternative splicing and this is an important mechanism for gene regulation. 
There is a very high level of alternative splicing in the brain, and disruption of 
normal splicing patterns can cause or modify human disease. ASOs can be 
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used to hinder this naturally occurring regulatory mechanism by targeting 
splice sites or exonic/intronic inclusion signals that result in skipping or 
inclusion of the targeted exon and altering the RNA and protein sequence. 
This can have numerous applications for neurodegenerative disorders, such 
as switching from a harmful isoform to a less harmful isoform, skipping an 
aberrantly included exon to restore the normal transcript, removing diseas-
causing mutations from genes, or restoring the reading frame by removing a 
mutated exon (Evers et al., 2015).  
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Figure 1.10 Functional mechanisms of antisense oligonucleotides. 
ASOs can be used to alter gene expression depending on its chemistry and target site. a) ASO 
gapmers induce RNase H-mediated breakdown of target RNA. b) RNAse H-mediated 
breakdown by ASO gapmers that target specific point mutations. c) Suppression of RNA 
translation by ASOs that target RNA translation start site or sterically hindering binding of RNA 
binding protein complexes. d) ASOs that bind to splice sites, resulting in exon skipping or 
inclusion. SR, pre-mRNA splicing machinery. Figure adapted from Evers et. al. (2015). 
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1.4.3 CHEMICAL MODIFICATIONS 
 
ASOs were at first used in the form of synthetic unmodified DNA (Dias 
& Stein, 2002) (Figure 1.11a). Although effective, these types of 
oligonucleotides showed susceptibility to degradation by endo- and 
exonucleases. Thus, it became apparent that their pharmacological profile 
would have to be improved for ASOs to be used for clinical applications.  
 First-generation ASOs contain a phosphorothioate (PS)-modified 
backbone, where a non-bridging oxygen atom in the phosphodiester bond is 
replaced by a sulphur atom (Figure 1.11c). This modification confers higher 
resistance against nuclease degradation, giving rise to higher bioavailability of 
the oligonucleotide. PS-modified ASOs promote RNase-H mediated cleavage 
of target mRNA. PS modification is the most extensively performed chemical 
modification of ASOs for loss-of-function studies in vitro and in vivo for 
identification and validation of gene targets (Chan, Lim, & Wong, 2006). 
 To further improve nuclease resistance and increase binding affinity for 
target mRNA, second-generation ASOs with 2’-sugar modifications were 
developed (Figure 1.11b). 2’-O-Methyl (2’-OMe) and 2’-O-Methoxyethyl (2’-
MOE) modifications of PS-modified ASOs are the most broadly studied 
second-generation ASOs (Crooke, 2004). However, 2’ sugar modifications do 
not support RNase H cleavage. To overcome this shortcoming, ‘gapmer’ ASO 
structures were developed. They contain 2’-sugar modified residues on either 
side of a stretch of unmodified PS residues, referred to as the gap. The 
modified wings improve the binding and stability of the ASO, while the PS gap 
allows induction of RNase H activity. Binding affinity, and consequently ASO 
effectiveness, is further improved by using constrained analogs in which the 
2’ and 4’ positions of the sugar are linked. These include locked nucleic acid 
(LNA) and S-constrained ethyl (cEt) modifications (Southwell, Skotte, Bennett, 
& Hayden, 2012) (Figure 1.11b). 
 More radical changes to the backbone have also been developed for 
non-degradative mechanisms such as translation inhibition or splice 
modulation, resulting in high resistance to nuclease cleavage but inhibits 
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cleavage by RNase H. Such ASOs include phosphorodiamidate morpholinos 
(PMOs), where the furanose moiety is replaced with a morpholine ring 
connected to the 3’ residue through a phosphorodiamidate linkage 
(Summerton, 1999) (Figure 1.11c). Another example is peptide nucleic acids 
(PNAs), where a peptide backbone is in place instead of a phosphate 
backbone (Nielsen, Egholm, Berg, & Buchardt, 1991) (Figure 1.11c). Overall, 
these chemical alterations greatly enhance pharmacological properties of 
ASOs, allowing rational design of various and potent therapeutic tools with 
widespread clinical applications (Southwell et al., 2012). 
 
  
Figure 1.11 Chemical modifications of antisense oligonucleotides. 
a) Synthetic unmodified DNA. b) ASOs with modified sugar rings. Alterations to the sugar ring 
increase target binding affinity to improve pharmacological properties of ASOs. c) ASOs with 
modified backbone structures. First-generation ASOs contain a PS backbone, whilst more 
recent modifications resulted in ASOs with a morpholino backbone and a peptide backbone. 
Alterations to the phosphate backbone increases resistance to nucleases. 
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1.4.4 PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDES 
 
Phosphorodiamidate morpholino oligonucleotides (PMOs) are 
synthetic oligonucleotides made up of chains of around 25 subunits that are 
similar to DNA and RNA oligonucleotides, with a morpholine ring modification 
instead of a ribose ring (Figure 1.9c). This feature still allows PMOs to undergo 
Watson-Crick base pairing, but it offers major advantages over conventional 
oligonucleotides. MOs are particularly resistant to nucleases and are therefore 
remarkably stable due to its morpholine ring modification. Since they do not 
carry a negatively charged backbone, they are less likely to undergo non-
specific interactions with other components of the cell and may be less toxic 
as a result (Eisen & Smith, 2008). PMOs do not act through an RNase H 
mechanism, thus its effects are mainly mediated through steric hindrance of 
ribosomal assembly, causing translational arrest, or by preventing proper RNA 
splicing events from occurring (Eisen & Smith, 2008).  
 
1.4.5 ASO APPROACHES FOR NEURODEGENERATIVE DISORDERS 
 
While antisense technology has a long history, ASO drugs have 
recently shown progress in treating CNS diseases such as spinal muscular 
atrophy (SMA), Duchenne muscular dystrophy (DMD), and SOD1-related 
fALS. Further ASO chemistry and design optimisation is needed to enhance 
tolerability and pharmacology in the CNS. Thorough chemical design and 
screening of ASOs are essential for effective drug development (Bishop, 
2017).  
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1.4.5.1 ASOS IN SPINAL MUSCULAR ATROPHY 
 
SMA is an autosomal recessive neuromuscular disorder that occurs in 
infants due to loss and dysfunction of motor neurons in the anterior horn of the 
spinal cord and lower brain stem. A homozygous deletion of survival motor 
neuron SMN1 is the main cause of SMA. In humans, two forms of the SMN 
gene exist on each allele: a telomeric form (SMN1) and a centromeric form 
(SMN2) (Kolb & Kissel, 2011). SMN1 gene transcription results in full-length 
mRNA transcripts that encode the SMN protein. SMN2 is identical to SMN1, 
aside from a C to T substitution at position 840 which leads to the exclusion of 
exon 7 during transcription, resulting in a truncated protein and reduced 
expression of functional SMN protein (Lorson et. al., 2010). Recent therapeutic 
strategies aim to modify SMN2 splicing by hindering exonic splicing silencers 
(ESS) or intronic splicing silencers (ISS), thus increasing the inclusion of exon 
7. Exon 7 inclusion has been achieved by transfecting fibroblasts with an ASO 
that blocks an ISS in intron 7 of SMN2 (Singh et. al., 2006), as well as using 
2OMe-PS antisense oligonucleotides targeting the 3′ splice site region of exon 
8 SMA mouse models (S. R. Lim & Hertel, 2001). 
 
1.4.5.2 ASOS IN DUCHENNE MUSCULAR DUSTROPHY 
 
Other than exon inclusion, ASOs have also been utilised to induce exon 
skipping as a therapeutic approach for Duchenne muscular dystrophy (DMD), 
a severe X-linked muscle disease due to mutations in the gene encoding 
dystrophin. Exon skipping is achieved by masking exon-determining motifs 
found on frameshift exons to splice them out alongside nearby introns from 
the pre-mRNA. This helps restore the disrupted reading frame of DMD and 
synthesise shortened Becker muscular dystrophy (BMD)-like dystrophin 
protein (Jarmin et. al., 2014). Several ASOs designed for DMD treatment have 
entered clinical trials. Drisapersen, an 18-mer 2’O-methyl phosphorothioate 
ASO, was designed to target skipping of exon 51. However, drisapersen did 
not show a statistically significant improvement compared to placebo (Jarmin 
 61 
et. al., 2014). In another clinical study, eteplirsen, developed by Sarepta 
Therapeutics, showed significant benefit in walking ability of patients when 
compared to placebo/delayed controls. Eteplisersen differs from in that it is a 
30-mer phosphorodiamidate morpholino oligomer (PMO), hence it is neutrally 
charged. Eteplirsen was finally granted approval by the US Food and Drug 
Administration (FDA), thus making the first and currently only FDA-approved 
drug for DMD (Lim et. al., 2017). 
 
1.4.5.3 ASOS IN ALS 
 
ASOs that have been used in ALS were designed to lower mRNA levels 
of SOD1 transcripts. Constant infusion of MOE-PS gapmer ASOs into the 
ventricular system lowered levels of mutant SOD1 and considerably slowed 
down disease progression in ALS rodent models (Smith et al., 2006). Phase I 
studies demonstrated no adverse side effects in patients with SOD1-related 
fALS following intrathecal injection into the cerebrospinal fluid (Miller et al., 
2013). Another recent advance concerning ALS involves targeting the 
hexanucleotide repeat expansion (GGGGCC) located in the noncoding region 
of C9ORF72. Different types of MOE-PS gapmer ASOs were designed to 
target exon 2, which is common to all C9ORF72 transcripts, as well as intron 
1 adjacent to the repeat. The ASOs were found to reduce formation of RNA 
foci in motor neurons differentiated from ALS/FTD patient-derived fibroblasts 
and induced pluripotent stem cells (Donnelly et al., 2013; Lagier-Tourenne et 
al., 2013). 
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1.5 AIMS AND OBJECTIVES 
 
AMPA receptors with an unedited Q/R site at the GluA2 subunit are 
abnormally permeable to Ca2+, resulting in progressive neuronal death. 
Dysregulation of RNA editing, which generally occurs in the brain and motor 
neurons of affected patients with neurodegenerative diseases, can interfere 
with proper function of glutamate receptors and may be a contributing cause 
of neuronal death in sporadic ALS (Kawahara et al., 2006). However, the 
molecular mechanisms and cell death cascade that result in Ca2+-permeable 
AMPA receptor-mediated cell death remain to be clarified in detail. In this 
project, we investigate the effects of PMOs on manipulating splicing events of 
the ADAR enzyme by inducing exon skipping of a 120 bp AluJ cassette, as 
this cassette has been shown to reduce the catalytic activity of ADAR2. This, 
in turn, can indirectly improve RNA editing in SH-SY5Y cells. Inducing splicing 
of the ADAR2 transcript to a more active isoform by using PMOs can increase 
Q/R site RNA editing levels in SH-SY5Y cells, which endogenously express 
the GluA2 subunit. Splicing PMOs were designed to target the AluJ cassette 
(ADAR2 exon 5a), as excluding this cassette has shown to result in a more 
active isoform of ADAR2 (Gerber et al., 1997). The presence of a more active 
ADAR2 isoform can hence indirectly improve RNA editing levels, making this 
a possible therapeutic strategy for sporadic ALS.  
Meanwhile, Pin1 and WWP2 have been reported to regulate ADAR2 
editing at the Q/R site of GluA2 with opposing effects (Marcucci et al., 2011), 
suggesting a possible regulatory role of Pin1 and WWP2 in the editing 
process. Considering that the molecular mechanisms and biological function 
of underediting in ALS has not been fully elucidated, we then attempted to 
study the regulation of Pin1 and WWP2 following two separate events: 
improvement in Q/R site editing and a reduction in editing levels. This will thus 
provide a better understanding behind the downstream mechanisms behind 
the pathophysiology of sporadic ALS. 
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The objectives of this research are: 
1. To examine the effects of PMOs on manipulating ADAR2 splicing 
patterns, and hence RNA editing levels, in SH-SY5Y cells. 
2. To study the levels of ADAR2 protein expression in PMO-transfected 
SH-SY5Y cells. 
3. To investigate the regulatory pattern of both Pin1 and WWP2 mRNA 
and Pin1 protein in SH-SY5Y cells following PMO transfection. 
4. To study the effects of PMO transfection on splicing manipulation and 
gene regulation of Pin1 and WWP2 in differentiated SH-SY5Y cells, 
which possess a more neuronal-like phenotype. 
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CHAPTER 2 METHODOLOGY 
2.1 PHOSPHORODIAMIDATE MORPHOLINO 
OLIGONUCLEOTIDES 
2.1.1 DESIGN OF PMOS 
 
PMOs used in this project were previously designed by former PhD 
student, Helena Chaytow. RNA sequences for the human GRIA2 gene and 
human ADARB1 gene were exported from the Ensembl website 
(http://www.ensembl.org) in FASTA format (Table 2.1). The sequences were 
then entered into the MFold website (http://unafold.rna.albany.edu/?q=mfold) 
in order to predict the RNA secondary structure for both genes. Human Splice 
Finder (http://www.umd.be/HSF3/) was utilised to provide consensus 
sequences, splice donor and acceptor sites, and splice enhancer and silencer 
sequences of exon 6 (which contains the AluJ cassette) and surrounding 
introns of the ADARB1 gene. The Ensembl transcript number of the gene was 
inserted and exon 6 was specified for splice site analysis. The graphical output 
from Human Splice Finder can be seen in Figure 3.2. 
Table 2.1 Gene Ensembl entry numbers. 
 
  
Gene Ensembl Entry Number Transcript ID 
GRIA2 ENSG00000120251 ENST00000348831.9 
ADARB1 ENSG00000197381 ENST00000296526.12 
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2.1.2 PMO TARGET SITES 
 
The inclusion of the AluJ cassette in the ADAR2 sequence has been 
shown to reduce RNA editing levels of ADAR2 (Gerber et al., 1997). Hence, 
PMOs were designed to inhibit the inclusion of the AluJ cassette. The AluJ 
cassette is a 120 bp sequence that can be found in exon 6 of the ADAR2 gene. 
The PMOs against AluJ cassette inclusion were designed to target predicted 
Exon Splice Enhancer (ESE) sites and single-stranded loop structures, which 
was achieved by using Human Splice Finder (http://www.umd.be/HSF3/). The 
sequence and its surrounding introns were analysed to predict a suitable 
secondary structure, which resulted in the design of PMOs 9, 9A and 9B. 
Inducing exon skipping of the AluJ cassette in SH-SY5Y cells, which results in 
a more catalytically active isoform of ADAR2, will be able to increase RNA 
editing levels 
PMOs were also designed to disrupt Q/R site editing in cells in order to 
study its downstream effects. Secondary structures were generated by 
inputting the sequence of exon 11 and intron 11 of GRIA2 into MFold, resulting 
in the design of PMO E1. Sequences of PMOs are shown in Table 2.2. 
Table 2.2 PMO names and sequences 
 
  
PMO name Sequence (5’ to 3’) 
PMO 1 (GRIA2+284+308) AATGAGAATATGCAGCAAAAACACG 
PMO E1 (GRIA2+279+308) AATGAGAATATGCAGCAAAAACACGGTACC 
PMO 9 (AluJ+93+117) TAGTCCCAGCTCCTTGGAAGGTTGA 
PMO 9A (AluJ+94+118) GTAGTCCCAGCTCCTTGGAAGGTTG 
PMO 9B (AluJ+95+119) TGTAGTCCCAGCTCCTTGGAAGGTT 
PMO 10 (AluJ+96+120) CTGTATCCAGCTCCTTGGAAGGT 
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2.1.3 STORAGE OF PMOS 
 
Standard PMOs were supplied as sterile, salt-free, lypophilised solids 
at 300 nanomoles (Gene Tools LLC, Philomath, OR, USA). 1 mM stock 
solutions of the PMOs were made by adding 300 µL of nuclease-free water to 
300 nanomoles of solid PMO. The PMOs were vortexed to ensure they were 
readily dissolved. 1 mM stock solutions of PMO were kept at 4°C in sealed 
containers.  
 
2.2 CELL CULTURE 
 
All cell culture work was carried out using aseptic technique and sterile 
plasticware inside a class II laminar flow hood. 
 
2.2.1 PROLIFERATION MEDIA FOR SH-SY5Y CELL CULTURE 
• Dulbecco’s Modified Eagle’s Medium – high glucose (Sigma, 
#D671) 
• Foetal Bovine Serum (FBS), 10% final concentration (Gibco, 
#10500064) 
• L-glutamine, 2 mM final concentration (Gibco, #21051040) 
• Penicillin-streptomycin, 100 units/mL final concentration (Gibco, 
#15140122) 
The final volume was made up to 500 mL. Culture media was filtered through 
a sterile 0.45 µM disposable filter (Thermo, #124-0045) before being aliquoted 
and stored at 4°C.  
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2.2.2 DIFFERENTIATION MEDIA  
 
• Dulbecco’s Modified Eagle’s Medium – high glucose (Sigma-, 
#D671) 
• Foetal Bovine Serum (FBS), 1% final concentration (Gibco, 
#10500064) 
• L-glutamine, 2 mM final concentration (Gibco, #21051040) 
• Penicillin-streptomycin, 100 units/mL final concentration (Gibco, 
#15140122) 
The final volume was made up to 50 mL and media was stored at 4°C. 1 µM 
retinoic acid is added to differentiation media prior to differentiating cells. 
 
2.2.3 FREEZING MEDIA 
 
• Dulbecco’s Modified Eagle’s Medium – high glucose (Sigma, 
#D671) 
• Foetal Bovine Serum (FBS), 10% final concentration (Gibco, 
#10500064) 
• Dimethyl sulfoxide (DMSO), 10 % final concentration (Sigma, 
#D8418) 
Freezing media was made fresh prior to freezing cells at a final volume of 50 
mL. Freezing media was stored at 4°C protected from light by covering tubes 
with aluminum foil.  
 
2.2.4 CELL LINES 
 
The human neuroblastoma SH-SY5Y cell line was purchased from 
Sigma Aldrich (#94030304-1VL). 
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2.2.5 THAWING OF FROZEN CELL STOCKS 
 
Frozen cells were retrieved from liquid nitrogen storage and 
immediately defrosted by submerging the cryovial in a 37°C water bath for 2 
minutes. Once defrosted, cells were transferred into a 15 mL tube containing 
5 mLs of warm culture media and then spun at 3,000 rpm for 5 minutes to 
obtain a cell pellet. The media was then aspirated and the cell pellet 
resuspended in 1 mL of culture media. The cell suspension was next seeded 
in a T75 cm3 flask (Corning, #430372). Cells were kept at 37°C and 5% CO2 
and subcultured when they reached 80% confluency. 
 
2.2.6 SUB-CULTURING CELL LINES 
 
Cell confluency was checked daily and sub-cultured once cells were 
approximately 80% confluent. Growth media was aspirated and cells were 
washed with pre-warmed 1X phosphate buffered saline (PBS), which is 
composed of 0.01 M phosphate buffer, 0.0027 M potassium chloride, and 
0.137 sodium chloride (Sigma, #P4417). 1 mL of TrypLE (Thermo Fisher 
#12604021) was then added to detach the cells from the flask and incubated 
at 37°C and 5% CO2 for 1 minute. TrypLE activity was then neutralised by 
adding 9 mL of pre-warmed growth media. Next, cells were centrifuged at 3000 
rpm for 5 minutes to obtain a pellet. The media was aspirated and cells were 
resuspended in 1 mL of pre-warmed growth media, followed by another 9 mL 
of media to make up 10 mL total solution. A portion of the suspended cells (2 
mLs) was then seeded in a new T75 cm3 flask (Corning, #430372) and a 
further 10 mL of pre-warmed growth media was added before being incubated 
at 37°C and 5% CO2. Cells were sub-cultured when they reached 80% 
confluency. 
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2.2.7 CELL DIFFERENTIATION 
 
Prior to plating cells, 12-well plates were first coated with poly-D-lysine 
(PDL) (0.5 µg/mL in PBS) and incubated for at least 3 hours at 37°C before 
seeding. Plates were washed with 1X PBS and left to air dry. SH-SY5Y cells 
were seeded at 60,000 cells per well in a PDL-coated 12-well plate in 500 µL 
proliferation media. Proliferation media was removed 24 hours post-seeding 
and cells were washed with 1X PBS before being suspended in 700 µL 
differentiation media. 350 µL of the medium was replaced every 2 days for a 
period of 7 days and cell morphology was visualized under a light microscope 
at the same time points. Cell transfections were carried out at day 6 of 
differentiation.  
 
2.2.8 CRYOGENIC STORAGE OF CELL LINES 
 
 Once cells were 80% confluent, media was aspirated from flasks and 
cells were washed with 1X PBS. 1 mL of TrypLE was then added to detach 
cells from the flask, which was followed by incubation at 37°C and 5% CO2 for 
1 minute. 9 mL of pre-warmed growth media was added to inactivate after 
TrypLE inactivation. Cells were then counted with a haemocytometer, followed 
by centrifugation at 3000 rpm for 5 minutes to obtain a cell pellet. Cells were 
resuspended at 1x105 cells per mL in freezing media. Cells were aliquoted at 
1 mL per vial in screw-top cryovials and cooled overnight at -80°C, followed 
by storage in liquid nitrogen.  
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2.3 PLASMID GROWTH 
2.3.1 BACTERIAL TRANSFORMATION 
 
The plasmid expression vector containing the ADAR2 cDNA was kindly 
provided by the O’Connell group from the University of Edinburgh. The 
plasmid DNA was transformed and grown in E. coli competent cells. NEB 5α 
competent cells (New England Biolabs) stored at -80°C, were thawed on ice 
and gently mixed. 50 μL were pipetted into a microcentrifuge tube on ice with 
1 μg of plasmid DNA and mixed by flicking before being placed on ice for 30 
minutes. The bacteria were then heat shocked at 42°C for 30 seconds and 
placed on ice for a further 5 minutes. 950 μL of warm SOC media (Thermo 
Fisher) was added to the microcentrifuge tube which was then placed on a 
rotating shaker (250 rpm) at 37°C for 60 minutes. Cells were then mixed by 
flicking and inverting before being streaked on an LB agar plate with 100 
μg/mL of ampicillin. Plates were incubated overnight at 37°C. 
 
2.3.2 MAXIPREP OF PLASMID DNA 
 
Large scale preparation of plasmid cDNA was performed using the 
EndoFree Plasmid Maxi Kit (Qiagen) was used. A single colony was picked 
from a freshly streaked plate and a starter culture of 5 mL of ampicillin-
containing LB medium was inoculated. The culture was incubated for 
approximately 8 hours at 300 rpm at 37°C. 250 mL of medium was then 
inoculated with 250 µL of starter culture and grown at 37°C overnight at 300 
rpm. The bacterial cells were harvested by centrifugation at 6000 x g for 15 
minutes at 4°C. The supernatant was discarded and the bacterial pellet was 
resuspended in 10 mL of Buffer P1. 10 mL of buffer P2 was added and mixed 
thoroughly by inverting the sealed tube. The mixture was incubated at room 
temperature for 5 minutes. 10 mL of chilled Buffer P3 was added to the lysate 
and mixed by inversion. The lysate was poured into the barrel of the QIAfilter 
Cartridge and incubated at room temperature for 10 minutes. The cap was 
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removed from the QIAfilter cartridge outlet nozzle. The plunger was gently 
inserted into the QIAfilter Maxi Cartridge and the cell lysate was filtered into a 
50 mL tube. 2.5 mL of Buffer ER was added to the filtered lysate. The contents 
were mixed by inversion and incubated on ice for 30 minutes. A QIAGEN-tip 
500 was equilibrated by applying 10 mL of Buffer QBT and the column was 
emptied by gravity flow. The filtered lysate was then applied to the QIAGEN-
tip and washed with 30 mL of Buffer QC twice. DNA was eluted with 15 mL of 
Buffer QN and precipitated by adding 10.5 mL of room-temperature 
isopropanol, followed by centrifugation at 15,000 x g for 30 minutes at 4°C. 
The supernatant was discarded and the pellet washed with 5 mL of 70% 
ethanol, before another centrifugation at 5,000 rpm for 60 minutes at 4°C. The 
supernatant was removed and the pellet allowed to air dry for 5 to 10 minutes 
before being resuspened in 200 μL Buffer TE. The plasmid DNA was the 
quantified using a NanoDrop spectrophotometer (Thermo Scientific).  
 
2.3.3 RESTRICTION ENZYME DIGEST 
 
Restriction enzyme digests were carried out to validate the correct 
transformation of the ADAR2 plasmid into the bacteria, according to the 
ADAR2 gene plasmid map (Figure 2.2). All restriction enzymes used were 
purchased from Roche. Compatible buffers and digest reaction conditions for 
each restriction enzyme were found on their respective product pages on the 
Roche website. 
A digestion reaction was typically performed by mixing 0.5 µg of 
plasmid DNA, 0.5 µL of enzyme, 2 µL of stock buffer solution in a total reaction 
volume of 20 µL, which was made up with nuclease-free water. Negative 
control reactions were prepared by excluding the enzyme from the reaction. 
Digestion reactions were incubated at 37°C for 1 hour. Digestion products 
were resolved by agarose gel electrophoresis, where 10 µL of the digested 
plasmid DNA was mixed with 5X loading dye and run on a 1% gel in 1x TAE 
buffer and visualized under UV trans-illumination.  
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Figure 2.1 Plasmid map of pcDNA3.1 with its multiple cloning sites 
(MCS). 
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2.4 CELL TRANSFECTION 
2.4.1 LIPOFECTAMINE 2000 
 
SH-SY5Y cells were seeded at a density of 400,000 cells per well in 6-
well plates containing 2 mL of proliferation media per well and incubated with 
37°C with 5% CO2. Cells were transfected when 80% confluent. For SH-SY5Y 
transfection in 6-well plates, a ratio of 1 µL of Lipofectamine 2000 (Thermo 
Fisher, #11668019) and 1 µg of plasmid DNA per well was used. 
Lipofectamine 2000 and plasmid DNA were both diluted using 250 µL of 
serum-free DMEM and incubated at room temperature for 5 minutes. The 
reagent and plasmid DNA suspensions were mixed together and incubated for 
another 20 minutes at room temperature to form DNA-lipid complexes. The 
mixture was then added to the wells and the plate was incubated at 37°C and 
5% CO2. Proliferation media was replaced with fresh media after 4 hours. Cells 
were then processed 24-48 hours post-transfection. The volumes used were 
adjusted according to the number of wells to be transfected.  
 
2.4.2 ENDOPORTER 
 
Cells were trypsinised and suspended in media and were seeded in 24-
well plates at 200,000 cells per well. Cells were incubated for 24 hours at 37°C 
in 5% CO2 before transfection until 80-90% confluent. PMOs were suspended 
in nuclease-free water to a 1 mM stock concentration and were then stored at 
4°C. PMOs were transfected at a range of concentrations, from 0.5-5 µM, as 
discussed in the results chapters. Prior to transfection, the media was 
aspirated from each well and replaced with 500 µL of fresh proliferation media.  
Appropriate volumes of PMO were directly added to the cell media in each 
well, followed by 6 µM of EndoPorter in DMSO (GeneTools). Plates were 
swirled to ensure mixing before they were returned to the incubator at 37°C 
for 24 hours prior to RNA extraction.  
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2.4.3 PLASMID DNA AND PMO CO-TRANSFECTION 
 
SH-SY5Y cells that were co-transfected with both plasmid DNA and 
PMO were first seeded at a density of 400,000 cells per well in 6-well plates 
containing 2 mL proliferation media. Cells were first subjected to plasmid DNA 
transfection with Lipofectamine 2000, as described in Section 2.4.1. Prior to 
replacing proliferation media with fresh media after 4 hours of Lipofectamine 
transfection, cells were transfected with PMOs using EndoPorter, as described 
in Section 2.4.2. 
 
2.5 RNA EXTRACTION 
 
RNA extraction was carried out using the Promega ReliaPrep RNA Cell 
Miniprep System (Promega, #Z6011). Media in the wells was removed and 
wells were washed with 500 μL of ice cold PBS. 250 μL of lysis buffer was 
added to each well and cells were removed using a cell scraper. 85 μL of 100% 
isopropanol was added to each lysate and vortexed for 5 seconds to disrupt 
cell structures. The solution was transferred into a Minicolumn, placed inside 
a 2 mL collection tube and spun at 14,000 g for 30 seconds. The flow through 
liquid was discarded and 500 μL RNA wash solution was then added to the 
column, which was spun at 13,000 g for 30 seconds.  
DNase I incubation mix was prepared by combining 24 µL of Yellow 
Core Buffer, 3 µL of 0.09M MnCl2, and 3 µL of DNase I and mixed by gently 
pipetting the solution. Samples were incubated with the DNase incubation mix 
at 20-25°C for 15 minutes. 200 μL of Column Wash Solution was added to the 
column and spun at 13,000 g for 15 seconds. Next, 500 μL of RNA Wash 
Solution was added to the sample and spun at 13,000g for 30 seconds. The 
collection tube was then discarded and the Minicolumn was placed in a new 
tube. 300 μL of RNA wash solution was added to the sample and was spun at 
15,000 g for 2 minutes. The Minicolumn was then transferred to an elution 
tube. 25 μL of nuclease-free water was added to the Minicolumn membrane 
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and the sample was spun at 13,000 g for 1 minute to elute the RNA. RNA 
concentrations were measured using a NanoDrop spectrophotometer 
(Thermo Scientific). 
 
2.6 POLYMERASE CHAIN REACTION 
2.6.1 REVERSE TRANSCRIPTION CDNA SYNTHESIS 
 
1 µg of each DNase-treated total RNA sample was used for cDNA 
synthesis using the GoScript Reverse Transcriptase kit (Promega, #A5003) 
according to the manufacturer’s instructions. RNA was mixed with Oligo(dT)15 
(Promega, #C1101) and the final volume was made up to 10 µL with nuclease-
free water. Tubes were then heated at 70°C for 5 minutes and left to chill at 
4°C for a further 5 minutes. The reverse transcription mix was prepared by 
combining 4 µL of GoScript 5X Reaction Buffer, 1.2 µL of MgCl2, 0.5 mM of 
dNTP, 1 µL of GoScript Reverse Transcriptase, where the final volume was 
made up to 10 µL with nuclease-free water. 5 µL of the RNA mix was then 
added to the reverse transcription mastermix and placed in a PCR machine 
with the following heat cycle: annealing at 25°C for 5 minutes, extension at 
42°C for one hour, and reverse transcriptase inactivation at 70°C for 15 
minutes.  
 
2.6.2 FIRST ROUND AND SECOND ROUND NESTED PCR 
 
For human ADAR2 and GRIA2 gene amplification, two rounds of PCRs 
were carried out. Primers were obtained from Sigma Aldrich at stock 
concentrations of 10 µM. Primer stocks were then diluted down to a working 
concentration of 1 µM for PCR use. Primer target genes and sequences are 
shown in Table 2.3. 
5 µL of cDNA was used for the first round PCR. The GoTaq DNA 
Polymerase kit (Promega, #M3001) was used. A PCR master mix was 
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prepared by adding 1x GoTaq Reaction Buffer, 1 mM MgCl2, 0.2 mM of each 
dNTP, 1 µM of each primer and 0.125 µL of GoTaq DNA Polymerase, where 
the final volume was made up to 25 µL with nuclease-free water. The PCR 
was carried out in a G-Storm 482 Thermal Cycler (Gene Technologies, 
#GS00482) using the following heat steps: 95°C for 3 minutes, 25 cycles of 
94°C for 30 seconds, 60°C for 30 seconds and 72°C for 45 seconds, and a 
final annealing step of 72°C for 10 minutes.  
 A second round nested PCR was carried out to increase gene 
amplification of GRIA2 and ADAR2 transcripts. 1 µL of product from first round 
PCR was added to the PCR master mix as described above. The PCR was 
performed in a G-Storm 482 Thermal Cycler (Gene Technologies, #GS00482) 
using the following heat cycle: 95°C for 3 minutes, 18 cycles of 94°C for 30 
seconds, 60°C for 30 seconds and 72°C for 45 seconds, and a final annealing 
step of 72°C for 10 minutes. Samples were then stored at 4°C. 
Table 2.3 Sequences of PCR primers and expected product sizes. 
 
 
 
Primer target gene Sequence (5’ to 3’) PCR fragment size (bp) 
Human GRIA2 
Sense:  
CAAAGCCCTTCATGAGCCTC 
365 
Antisense:  
CCATGAATGTCCACTTGAGACC 
Human GRIA2 (nested 
primers) 
Sense:  
GCCTCAGAAGTCCAAACCAG 
323 
Antisense: 
CCATGAATGTCCACTTGAGACC 
ADAR2 AluJ cassette 
Sense:  
ATCCATCTTTCAGAAATCAGAGC 
247 
Antisense:  
TTTGGTCCGTAGCTGTCCTC 
ADAR2 AluJ cassette 
(nested primers) 
Sense:  
AGGCTGAAGGAGAATGTCCA 127 
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2.7 AGAROSE GEL ELECTROPHORESIS 
 
Agarose gel electrophoresis was used to determine the inclusion of the 
AluJ cassette and verify the presence of the GRIA2 gene. A 50X stock solution 
of Tris-acetate-EDTA (TAE) buffer was prepared (242 g Tris base, 57.1 mL 
glacial acetic acid, 100 mL 500 mM pH 8.0 EDTA made up to 1 L with ddH2O). 
1.5% agarose gels were prepared by adding 0.9 g of agarose to 60 mL of 1X 
TAE buffer until fully dissolved by heating the mixture in a microwave. 3 µL of 
SYBR Safe DNA Gel Stain was added to the gel mixture before being poured 
into a casting tray with a gel comb and left to set. Gels were submerged in 1X 
TAE buffer in an electrophoresis tank (Bio-Rad).  10 µL of each sample was 
loaded into wells alongside 5 µL of HyperLadder I (Bioline, #BIO-33025). Gels 
were run at 90V for 35 minutes and the DNA bands visualized under UV light 
in a GELDOC system. 
 
2.8 BBVI RESTRICTION DIGEST 
 
In order to quantify RNA editing levels in cells, RT-PCR cDNA products 
of the Q/R editing site were digested with the BbvI restriction endonuclease 
(New England Biolabs). 1 µL SmartCut buffer and 2 μL of BbvI (2U/μL) was 
made up to a total volume of 5 μL mastermix with nuclease-free water. 15 μL 
of PCR product was then added to the master mix and digest samples were 
incubated for 1 hour at 37°C. The enzyme was then inactivated by adding 
0.1% SDS to each sample and incubated for another 5 minutes at room 
temperature before adding 5X loading dye. Samples were then run on a 2.5% 
(w/v) agarose gel at 90 V in 1X TAE buffer for 60 minutes alongside 5 µL 
Hyperladder I (Bioline). 
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2.9 DENSITOMETRIC ANALYSIS 
 
Gel images were taken under ultraviolet light using the GELDOC 
imaging system and saved as JPEG files. Analysis was carried out using the 
Fiji image processing package (http://fiji.sc/). Each band in the image was 
highlighted and the fluorescence of each pixel was measured by the software. 
The mean pixel value was calculated per band, and the background 
fluorescence was subtracted. Further analysis of the data was then carried out 
using Microsoft Excel.  
 
2.9.1 ALUJ CASSETTE INCLUSION QUANTIFICATION 
 
Once the fluorescence intensity of each band had been calculated, the 
relative intensity of AluJ exon-including ADAR2 transcripts to exon-excluding 
transcripts were compared. Primers used in the PCR targets the exons 
surrounding the AluJ cassette. ADAR2 transcripts containing the AluJ cassette 
are of a larger size (247 bp) than transcripts without the AluJ cassette (127 
bp). Exon skipping percentages were calculated using the following formula: !"#$%&'(&)(&	$+	&,$)	'-.//&0	+%123&)4'5$41"	+"#$%&'(&)(&	 	× 	100%																																							= ;,$)	'-.//.)2	/&%(&)412&	.)	(&""'																																		 
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2.9.2 Q/R SITE EDITING QUANTIFICATION 
 
Editing percentages were calculated using the same method as 
described above. The relative intensity of edited to unedited DNA was 
compared, where band sizes were based on the recognition sequence of the 
BbvI restriction enzyme (GCAGC). Edited cDNA copies do not contain a 
recognition sequence for BbvI and hence remains undigested and are seen 
on the gel image as a full-length transcript (323 bp). Unedited cDNA copies 
are cleaved into two smaller sized fragments (238 bp and 83 bp), as they are 
digested by BbvI. Q/R site editing percentages were calculated using the 
following formula:  !"#$%&'(&)(&	$+	&0.4&0	+%123&)4'5$41"	+"#$%&'(&)(&	 	× 	100%																																		= <=>	&0.4.)2	/&%(&)412&	.)	(&""'																																		 
 
2.10 PROTEIN ANALYSIS 
2.10.1 REAGENTS AND SOLUTIONS 
 
• DC protein assay (Bio-Rad, #5000111) 
• 30% Protogel (Bis-acrylamide solution; National Diagnostics, #EC890) 
• Absolute methanol (VWR) 
• Marvel Dried Milk Powder 
• NuPAGE Sample Reducing Agent (Invitrogen, #NP0009) 
 
 
 
 
 
 80 
Solution Components 
RIPA lysis buffer 
150 nM NaCl, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 25 mM Tris pH 7.4, 1 
protease inhibitor tablet per 10 mL 
1X Tris-glycine transfer 
buffer 
25 mM Tris, 192 mM glycine, 10% methanol 
1X Tris-glycine running 
buffer 
25 mM Tris, 192 mM glycine, 0.1% SDS; pH 8.3 
4X resolving buffer 
1.5 M Tris-base, 8 mM EDTA, 0.4% SDS, pH 
8.8 
4X stacking buffer 0.5 M Tris-base, 8mM EDTA, 0.4% SDS, pH 6.8 
1X Tris-buffered saline 
(TBS) 
50 mM Tris base, 150 nM NaCl 
1X phosphate-buffered 
saline (PBS) 
1 PBS tablet (Gibco, #003002) dissolved in 500 
mL ddH2O 
Table 2.4 Western blot solution recipes 
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2.10.2 ANTIBODIES 
 
Table 2.5 Primary and secondary antibodies used for protein detection. 
 
2.10.3 PROTEIN EXTRACTION 
 
SH-SY5Y and HeLa cells were transfected and treated as previously 
described is section 2.5. Following 48 hours of Lipofectamine 2000 and 
EndoPorter transfection, 6-well plates were removed from the incubator and 
placed on ice. The media was removed and cells were washed with 1X PBS 
before 100 µL of RIPA lysis buffer was added. Each well was scraped using a 
cell scraper to detach cells adhering to the bottom of the well. The lysate was 
 Antibody Host Dilution Catalog number 
Primary 
anti-
ADAR2 
Rabbit 1:100 GeneTex, #GTX114237 
anti-
ADAR2 
Mouse 1:100 Santa Cruz, #SC-514581 
anti-
ADAR2 
Mouse 1:100 Santa Cruz, #SC-10012 
anti-Pin1 Mouse 1:100 Santa Cruz, #SC-46660 
anti-β-
actin 
Mouse 1:5000 Sigma, #A1978 
anti-FLAG Rabbit 1:1000 Sigma, #F7425 
Secondary 
anti-rabbit Goat 1:5000 Cell Signalling, #5151S 
anti-
mouse 
Goat 1:5000 Cell Signalling, #5470S 
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then collected and spun at 13250 rpm for 20 minutes before the supernatant 
was extracted and stored at -20°C. 
 
 
2.10.4 DC ASSAY 
 
The concentrations of the protein extracts were determined by using a 
DCTM (detergent compatible) protein assay (Bio-Rad) as per the 
manufacturer’s instructions. Firstly, known concentrations of bovine serum 
albumin (BSA) of 0.2-1.5 mg/mL were prepared to use as a standard curve.  
Next, 20 µL of reagent S was added to each mL of reagent A that was needed 
for the run in order to form reagent A’. 1 µL of the standards and protein 
samples were pipetted into each well of a 96-well plate. 25 µL of reagent A’ 
was then added into each well, followed by the addition of reagent B. The plate 
was then left to stand for 15 minutes before the absorbance was measured in 
a plate reader at 750 nm.  
 
2.10.5 SAMPLE PREPARATION 
 
Protein lysates were diluted to final concentrations of 1 μg/mL. Each 
protein sample was prepared to a final volume of 100 μL by diluting the lysate 
in 25 μL of LDS Sample Buffer (Invitrogen, #NP0008, 4X final), 10 μL NuPAGE 
Reducing Agent (Invitrogen, #NP0009) and adjusting the volume to 100 μL 
with molecular grade water. Samples were denatured on a heat-block shaker 
at 75°C for 8 minutes and kept on ice. 
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2.10.6 WESTERN BLOTTING 
2.10.6.1 SODIUM DODCEYL SULFATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
 
10% resolving gel solutions were prepared following the recipe shown 
in Table 2.6. The resolving gel was prepared by casting the solution between 
two glass-plate cassettes of 1 mm thickness (Mini-PROTEAN Tetra handcast 
system, Bio-Rad) and overlayed with 100% isopropanol. Once the gel was set, 
isopropanol was removed by washing with ddH2O. A 4% stacking gel solution 
was then prepared and a comb inserted into the glass-plate cassette. Once 
the stacking gel has set, the glass-plate cassette was transferred into a Mini-
PROTEAN Tetra Electrode Assembly, which was then placed into a buffer 
tank. The chambers were filled with 1X Tris-glycine running buffer and the 
comb was removed from the stacking gel. 50 μg of protein was loaded into 
each well alongside 1 μL of BLUeye Prestained Protein Ladder (GeneFlow, 
#S60024). The gel was then left to run at 125V until the bromophenol blue dye 
band ran off the gel.   
Table 2.6 Recipes for resolving and stacking gels for SDS-PAGE. 
  
 Resolving gel (10%) Stacking gel (4%) 
Buffer 2 mL 1 mL 
Protogel 2.6 mL 0.65 mL 
ddH2O 3.4 mL 4.6 mL 
TEMED 6 µL 20 µL 
10% APS 40 µL 160 µL 
Total volume 8 mL 6.25 mL 
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2.10.6.2 PRE-CAST BIS-TRIS SDS-PAGE 
 
10% pre-cast Bis-Tris SDS-PAGE gels (Invitrogen, #NP0303) were 
used for the detection of Pin1 protein in SH-SY5Y cells. The comb and gel 
wells were first rinsed with ddH2O. The white tape located at the bottom of the 
gel cassette was removed and the gel cassette was then placed in an XCell 
SureLock Mini-Cell gel running tank. 200 mL of 1X NuPAGE MES SDS 
Running Buffer (containing 500 µL NuPAGE Antioxidant) was then filled into 
the upper chamber of the tank. The lower chamber was filed with 600 mL of 
1x NuPAGE MES SDS Running Buffer. 50 µg of protein was loaded into each 
well alongside 1 µL of BLUeye Prestained Protein Ladder (GeneFlow, 
#S60024). The gel was then left to run at 200V until the bromophenol blue dye 
band ran off the gel.   
 
2.10.6.3 NITROCELLULOSE MEMBRANE TRANSFER 
 
Following protein electrophoresis, the transfer cassette was 
assembled. The gel was carefully removed from the glass-plate cassette and 
placed onto a 0.2 µM pore size nitrocellulose membrane (Amersham, 
#15249794). The membrane was sandwiched between 2 filter papers 
(Whatman, and 2 blotting sponges that have been soaked in 1X Tris-glycine 
transfer buffer. Pressure was applied on the sandwich to remove air bubbles 
and excess liquid. The transfer cassette was then closed and placed into a 
transfer tank filled with 1X Tris-glycine transfer buffer and left to run at 10V 
overnight.  
 
2.10.6.4 IMMUNOBLOTTING 
 
Following protein transfer, the membranes were then blocked with 5% 
non-fat dried milk in TBS containing 0.05% Tween-20 at a final volume of 5 
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mL. The membranes were sealed in a plastic bag and agitated for 90 minutes 
at room temperature. Next, the membranes were incubated with primary 
antibody diluted in 5% non-fat dried milk in 1X TBS with 0.05% Tween-20 at a 
final volume of 5 mL overnight at 4°C with gentle agitation. The membranes 
were then washed twice with 1X TBS for 10 minutes each, followed by 
incubation with secondary antibody diluted in 5% nonfat dried milk in TBS 
containing 0.05% Tween-20 at a final volume of 5 mL for 1 hour at room 
temperature away from light. The two wash steps were repeated and the damp 
membrane was scanned using the Odyssey CLx Imaging System (LI-COR 
Biosciences) to visualise the protein bands at 560 nm, 700 nm or 800 nm 
wavelength. The blots were then stored at -20°C in 1X TBS in sealed bags 
after scanning.  
2.11 QUANTITATIVE REVERSE TRANSCRIPTASE 
POLYMERASE CHAIN REACTION (QRT-PCR) 
 
For quantitative RT-PCR of mRNAs, 600 ng of RNA was generated 
using 0.5 µg of random primers (Invitrogen, #48190011)  and 0.5 µg oligo(dT) 
(Promega, #C1101) and the final volume was made up to 10 µL with nuclease-
free water. The tubes were then heated at 70°C for 5 minutes and left to chill 
at 4°C for another 5 minutes. A mastermix was then made up using the 
GoScript Reverse Transcriptase kit (Promega, #A5003) according to the 
manufacturer’s instructions. RNA was added to 5x GoScript buffer, 2.5 mM 
MgCl2, 0.5 mM dNTP, 8 units of reverse transcriptase, and the final volume 
was made up to 15 µL with nuclease-free water. The mixture was incubated 
in the following RT-PCR cycle: annealing at 25°C for 5 minutes, extension at 
42°C for 1 hour, and a final inactivation step of 70°C for 15 minutes. cDNA 
was then stored at 4°C before use. 
The expression levels of target genes were assessed with qRT-PCR 
using the LightCyclerÒ 480 SYBR Green I Mastermix (Roche, 
#04887352001). The cDNA produced was first diluted 1:50 in nuclease-free 
water for the qPCR reactions. 0.5 µM of each forward and reverse primer 
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(Table 2.8) was added to 5 µL of mastermix before being mixed with diluted 
cDNA in a 384-well plate. The PCR reaction was conducted at 95°C for 10 
minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C for 15 seconds, 
and 70°C for 15 seconds. All samples were amplified in technical triplicates. 
Primer sequences were obtained from Primer Bank 
(https://pga.mgh.harvard.edu/primerbank/) and made by Sigma Aldrich (Table 
2.7). The expression levels of b-actin were used as a reference gene. The 
gene expression levels were defined based on the threshold cycle (Ct), and 
relative expression levels were calculated using the 2-DDCt method, where fold-
change was inferred from Ct level fluctuations of target genes made against 
reference genes. 
 
Table 2.7 Primer sequences for genes used in qRT-PCRs. 
 
2.12 DATA ANALYSIS AND STATISTICS 
 
Percentages and ratio-fold changes were calculated on Microsoft Excel 
from raw values. Calculated values were then inputted in GraphPad Prism 7.0 
(GraphPad Software, La Jolla CA, USA) for statistical analysis. Statistical 
significance was tested using either one-way ANOVA followed by Dunnett’s 
multiple comparison test or unpaired t-test. IC50 and EC50 values were 
calculated by fitting the Hill equation using GraphPad Prism 7.0. Graphs were 
Gene Forward sequence (5’-3’) Reverse sequence (5’-3’) 
PIN1 TCAGGCCGAGTGTACTACTTC TCTTCTGGATGTAGCCGTTGA 
WWP2 CAAAGCCCAAGGTGCATAATCG CCAATGCGCTTCCCAGTCT 
ACTB GACGACATGGAGAAAATCTG ATGATCTGGGTCATCTTCTC 
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plotted with GraphPad Prism 7.0, where all error bars show standard error of 
the mean (SEM). 
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CHAPTER 3 EXON SKIPPING OF THE 
ALUJ CASSETTE IN SH-SY5Y CELLS AND 
THE EFFECT ON RNA EDITING 
3.1 INTRODUCTION 
 
Alternative splicing refers to the process where exons of primary 
transcripts are spliced into alternative arrangements, resulting in structurally 
and functionally different mRNA and protein variants (Siva, Covello, & Denti, 
2014). An estimated 70% or more of human multiexon genes undergo 
alternative splicing (Johnson et al., 2003), and most of these splicing events 
are regulated in a tissue-specific manner (Clark et al., 2007). The adult human 
brain expresses more alternatively spliced transcripts compared to any other 
tissue (Yeo, Holste, Kreiman, & Burge, 2004). Point mutations in a gene can 
weaken or strengthen splice sites, thus causing modification in splicing events 
and subsequent disease (Siva et al., 2014). Splicing deficiencies are being 
increasingly associated with neurodegenerative and neurological diseases, 
highlighting the need to better comprehend these regulatory processes 
(Vuong, Black, & Zheng, 2016).  
There are two main steps involved in basic splicing events: 
spliceosome assembly, followed by pre-mRNA splicing. The spliceosome is 
primarily comprised of U1 and U2 small nuclear ribonucleic proteins (snRNPs), 
as well as the U4/U5/U6 tri-snRNP. The snRNPs configure and identify the 5’ 
splice site, the branch point sequence, and the 3’ splice site. Spliceosome 
complexes E, A, B and eight evolutionary conserved DExD/H-type RNA-
dependent ATPases/helicases assemble in a gradual manner and carry out 
multiple splicing steps, resulting in exon ligation and intron excision (Y. Wang 
et al., 2014). Various steps in the pathway are reversible. 
Whilst the splicing mechanism has been determined in great detail, it 
has not yet been fully understood how splice sites are selected (Stamm et al., 
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2005). This is due to the degeneracy of regulatory splicing sequences, such 
as 5’ and 3’ splice sites, branch points, and exonic/intronic sequence 
elements, which can only be described as loosely followed consensus 
sequences (Black, 2003). As a consequence, it is not possible to predict 
accurate splicing patterns from genomic sequence. A combinatorial regulatory 
mechanism results from accurate recognition of splice sites in vivo (C. W. J. 
Smith & Valcárcel, 2000). Since splice sites are degenerate, additional 
sequence elements found in the exon or in adjacent intronic elements assist 
in their recognition through binding to regulatory proteins, which are 
subdivided into serine-arginine-rich SR proteins and hnRNPs. The proteins 
generally bind to RNA weakly. Increased specificity is accomplished by 
binding multiple proteins to RNA, with the aid of protein-protein interactions. 
Several regulatory proteins bind to spliceosome components, such as the U1 
and U2 snRNP, which defines the 5’ splice-site and branch point respectively 
(Stamm et al., 2005). Considering that splicing factors bind to various weakly 
conserved sequences, a single factor can regulate numerous target genes. 
Target genes for the neuron-specific splicing factor NOVA-1 are highly 
functionally related. These genes were linked to the function of inhibitory 
synapses, post- and pre-synaptic structures, and signaling and protein 
synthesis. This implies that a single splicing factor regulates isoform 
expression of different genes in inhibitory neurons (Stamm et al., 2005).  
Splicing processes are regulated by different cis- and trans-acting 
factors, which affects splice site selection. Positive trans-acting factors, such 
as SR proteins (serine/arginine-rich family of nuclear phosphoproteins) bind to 
cis-acting elements including exonic splicing enhancers (ESEs) and intronic 
splicing enhancers (ISEs). Conversely, intronic splicing silencers are bound 
by negative acting factors, such as heterogenous nuclear ribonucleoproteins 
(hnRNPs). The association of these elements leads to the promotion or 
inhibition of spliceosome assembly of weak splice sites (Y. Wang et al., 2014). 
Although there is a large potential for errors, splicing processes occur 
with high fidelity, indicating the extensive involvement of transcript features 
aside from core splice signals involved in splice site selection. This information 
is thought to largely derive from the presence of numerous cis-regulatory 
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elements that act as either splicing enhancers or silencers (Z. Wang & Burge, 
2008). Enhancer elements play an important role in constitutive splicing, 
whereas silencer elements are relatively more dominant in alternative splicing 
(Y. Wang et al., 2014). Aside from the coupling of SR proteins to enhancer 
elements, SR proteins also interact with U1 snRNP and the 35 kDa subunit of 
the heterodimeric factor U2AF. U2AF65, the second subunit of U2AF, binds 
splicing factor 1 (SF1) and the pyrimidine tract simultaneously, resulting in 
recognition and stability of the branch point and polypyrimidine tract 
sequences (Figure 3.1). Roughly 10-12 serines located in the N-terminal 
region of the RS domain undergo rapid phosphorylation by the binding of SR-
specific protein kinase to SF1 with a remarkably high affinity. This constant 
cycle of phosphorylation/dephosphorylation of SR proteins aids the transport 
of SR proteins between the nucleus and cytoplasm, and is crucial for the 
regulation of alternative splicing by growth signals transduced to the nucleus 
(Ghosh & Adams, 2011; Twyffels, Gueydan, & Kruys, 2011). 
The most common splicing event in mammals is exon skipping, 
accounting for 40% of alternative splicing events in humans and mice (Sugnet, 
Kent, Ares, & Haussler, 2004). Exon skipping is the process where an exon 
cassette is excised from the transcript alongside the flanking introns 
(Gamazon & Stranger, 2014). Nine splice sites, located at different exons in 
human ADAR2 pre-mRNA, have been discovered so far. Among these 
splicing events, five of them are shown to affect the catalytic function of 
ADAR2 (Li et al., 2015). One such alternative splicing event results in two 
major ADAR2 isoforms, which differ by the inclusion or exclusion of an Alu 
cassette within the deaminase domain, located between exons 5 and 6 of 
ADAR2 pre-mRNA. Characterisation of both ADAR2 isoforms showed that 
they identical substrate specificity. However, inclusion of the AluJ-containing 
exon caused a twofold reduction in ADAR2 activity on a GluA2 R/G site 
substrate in vitro (Gerber et al., 1997). Another major transcript lacking the last 
two amino acids was isolated and this isoform was found to be catalytically 
inactive (Lai, Chen, Lee, & Nishikura, 1997).  
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Figure 3.1 Mechanisms of spliceosome assembly.  
The process starts with the base pairing of U1 snRNA to the 5’ splice site (ss) and the binding 
of splicing factor 1 (SF1) to the branch point to form the E’ complex. The E’ complex is converted 
into the E complex through recruitment of U2 auxiliary factor (U2AF) heterodimer (composed of 
U2AF65 and U2AF35) to the polypyrimidine tract and 3’ terminal AG. The ATP-independent E 
complex is converted into the ATP-dependent pre-spliceosome A complex by the substitution 
of SF1 by U2 snRNP at the branch point. Additional recruitment of the U4/U6-U5 tri-snRNP 
generates the formation of the B complex, containing spliceosomal subunits responsible for pre-
mRNA splicing. This is ensued by extensive conformational changes and remodeling, such as 
the loss of U1 and U4 snRNPs, resulting in the formation of the C complex, the catalytically 
active spliceosome.  
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The use of antisense oligonucleotides as agents for downregulation of 
gene expression is now well-established. Antisense compounds have been 
developed to manipulate alternative splicing patterns, thus altering both the 
ratio of different splice variants and gene function (Sazani & Kole, 2003). ASOs 
that have been designed to bind to splice sites or to ESEs or ISEs causes the 
masking of these regions, leading to ineffective binding of trans-splicing 
regulatory factors, thus leading to switching between alternative splice 
isoforms through exon skipping. In principle, ASOs designed to block exonic 
or intronic splicing silencers (ESSs or ISSs) can also promote exon inclusion 
in the context of disease-associated exon skipping (Siva et al., 2014). Exon 
inclusion ASOs has been used in the treatment for spinal muscular atrophy, 
where the drug Nusinersen promotes inclusion of SMN2 exon 7 by 
sequestering the ISS (N. N. Singh, Howell, Androphy, & Singh, 2017). Exon 
skipping approaches have now been utilized in the treatment of DMD by the 
drug Eteplirsen, which targets exon 51 of DMD (K. R. Q. Lim et al., 2017).  
The design of ASOs is vital to effective exon skipping. The optimum 
length of the ASO is dependent on the antisense chemistry. For example, 
locked nucleic acid (LNA) oligomers are 8-14mer in length as they are known 
to have particularly high binding energy, and longer LNAs can form 
undesirable secondary structures. PMOs however have a lower binding 
affinity, thus requiring longer sequences (25-30mer) (Shimo, Maruyama, & 
Yokota, 2017). Other key parameters in designing ASOs include target site 
selection, mRNA secondary structure, and the melting temperature versus the 
RNA strand (Aartsma-Rus et al., 2009). Predicting target sequences of the 
ASO can be carried using in silico tools such as the ESE finder and the 
RESCUE-ESE. Assessment of off-target effects should also be included in the 
design process (Shimo et al., 2017).  
In this chapter, several different exon skipping PMOs have been used 
to measure its effectiveness in excluding the AluJ cassette from the final 
mRNA transcript. These PMOs have previously been tested in HeLa cells that 
have been transfected with the B13 minigene, which contains a partial 
fragment of the GluA2 subunit. Transfected HeLa-B13 cells resulted in a 30% 
increase in Q/R site editing when compared to controls (Chaytow, 2015). 
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However, we have not examined the efficacy of these PMOs in cells 
endogenously expressing edited GluA2 and partly replicate neuronal 
conditions. Human neuroblastoma SH-SY5Y cells were used here as they 
endogenously express the GluA2 subunit. This cell line is generally used as a 
neuronal cell model in studies of Parkinson’s and Alzheimer’s disease since 
they can be differentiated to resemble dopaminergic neurons (Dwane, Durack, 
& Kiely, 2013). Following transfection with PMOs, exon skipping levels were 
calculated and any changes in Q/R site editing levels were measured in the 
cells. The data presented here shows how PMOs were able to successfully 
alter exon skipping levels in these cells, consequently increasing Q/R site 
editing levels. Improving RNA editing levels in cells could be a potential 
therapeutic strategy for ALS as reduced Q/R site editing has been 
demonstrated in spinal grey matter and neurons of patients with ALS 
(Kawahara, Ito, Sun, Kanazawa, & Kwak, 2003; Takuma, Kwak, Yoshizawa, 
& Kanazawa, 1999). Hence, the work here provides support for the use of ASO 
exon skipping technology for the treatment of sporadic ALS. 
  
 94 
3.2 RESULTS 
3.2.1 EFFECTS OF PMOS ON ALUJ CASSETTE INCLUSION 
 
SH-SY5Y cells were transfected with four different PMOs - PMO 9 
(AluJ+93+117), PMO 9A (AluJ+94+118), PMO 9B (AluJ+95+119), and PMO 
10 (AluJ+96+120) - at concentrations ranging from 0.05 µM to 5 µM for 24 
hours. The PMOs were designed to target the exon splice enhancer (ESE) 
motifs surrounding the AluJ cassette, as this will facilitate exon exclusion 
(Figure 3.2). Exon splice silencer (ESS) regions were avoided as covering this 
region could induce exon inclusion (Figure 3.2) The sequence of the PMOs 
also targets the 25 nucleotides at the 3’ end of the exon, thus covering the 
splice consensus sequence (Figure 3.2). 
RNA was harvested from these cells and PCRs were performed to 
determine the presence of the two different isoforms of ADAR2 present – one 
containing the AluJ cassette, and one with the AluJ cassette excluded from 
the final transcript. For AluJ cassette inclusion analysis, nested primers 
surrounding exons 5 and 7 of the ADAR2 gene, which surrounds the 120 bp 
AluJ cassette, were used. AluJ cassette inclusion levels were measured by 
comparing the intensities of PCR fragments that contain the AluJ casstte (247 
bp) to those that exclude the cassette (127 bp).  
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Figure 3.2 Graphical output from Human Splice Finder.  
The above figure shows the graphical output of splice enhancer and silencer motifs. The grey 
box (outlined in green) represents the AluJ cassette-containing exon 6 of ADARB1 and its 
surrounding introns. Red and pink boxes represent exon splice enhancer (ESE) regions, while 
blue and green boxes represent exon splice silencer (ESS) regions. A cluster of ESE binding 
sites at the 3’ end of exon 6 (outlined in blue) indicate potential PMO design targets as covering 
these sequences may prevent exon inclusion. Yellow peaks above the x-axis illustrate strong 
ESE regions and yellow troughs below the x-axis illustrate strong ESS regions. 
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CCTTCCACCTCAACCTTCCAAGGAGCTGGGACTACAG
GTTGGAGGTTCCTCGACCCTGATG
TTGGAGGTTCCTCGACCCTGATGT
TGGAGGTTCCTCGACCCTGATGTC
AGTTGGAGGTTCCTCGACCCTGAT PMO 9 (AluJ+93+117)
PMO 9A (AluJ+94+118)
PMO 9B (AluJ+95+119)
PMO 10 (AluJ+96+120)
Figure 3.3 Sequences of PMOs that are complementary to the 3’ end of the AluJ-
containing exon of the ADAR2 gene. 
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Figure 3.4 Schematic diagram illustrating the outcome of PMO transfection. 
a) Pre-spliced mRNA of ADAR2 containing the AluJ cassette. Inclusion of this cassette results 
in reduced catalytic ADAR2 activity, which can be restored by b) using PMOs that target the 
AluJ cassette to manipulate ADAR2 splicing by exon skipping. This results in c) an ADAR2 
isoform which does not contain the AluJ cassette, hence d) improving RNA editing in SH-
SY5Y cells. 
Exon 5 AluJ cassette Exon 6
Exon 5 AluJ cassette Exon 6
PMO 9
PMO 9A
PMO 9B
Pre-spliced mRNA 
(AluJ-including 
isoform; 247 bp)
PMOs 
targeting the 
AluJ cassette
Exon 5 Exon 6
Alternatively spliced 
mRNA (AluJ-absent 
isoform;  127 bp)
Improved RNA editing
a.
b.
c.
d.
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3.2.1.1 PMO 9 (ALUJ+93+117) 
 
PMO 9 (AluJ+93+117) was previously tested alongside several other 
PMOs in HeLa cells, and it was shown to have the strongest effects on 
cassette exon exclusion. PMO 9 (AluJ+93+117) was then further tested in SH-
SY5Y cells to evaluate its ability to promote exon skipping in these cells. SH-
SY5Y cells were transfected with PMO 9 (AluJ+93+117) at concentrations 
varying from 0.05 µM to 5 µM. Concentrations of 50 nM, 100 nM and 300 nM 
(p>0.05) did not show any significant difference in exon inclusion when 
compared to untreated cells (87.12 ± 1.5%) (Figure 3.5c). Increasing the PMO 
concentration to 500 nM significantly reduced AluJ cassette inclusion down to 
73.56 ± 2.9% (Figure 3.5c). This is apparent in the gel image shown in Figure 
3.5a, where the intensity of full-sized transcripts (247 bp) of 100 to 300 nM 
PMO-transfected samples was stronger than that seen in cassette-excluding 
transcripts (127 bp). 
Treatment with 1 µM of PMO 9 (AluJ+93+117) showed similar levels of 
exon inclusion to treatment with 500 nM PMO 9 (AluJ+93+117) (71.8 ± 1.6%) 
(Figure 3.5c). Increasing the concentrations to 2.5 µM and 5 µM showed the 
strongest effects of PMO 9 (AluJ+93+117) on exon inclusion. 2.5 µM of PMO 
9 (AluJ+93+117) reduced exon inclusion levels down to 60.9 ± 0.92%, while 5 
µM of PMO 9 (AluJ+93+117) resulted in even lower exon inclusion at 35.1 ± 
4.8% (Figure 3.5b). The gel image shown in Figure 3.4b shows how 5 µM of 
PMO 9 (AluJ+93+117) resulted in similar fragment intensities for both full-
sized and cassette-excluding transcripts. 
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Figure 3.5 The effect of PMO 9 on AluJ insertion in SH-SY5Y cells. 
Figure shows images of RT-PCR products of SH-SY5Y cells treated with a) 50-500 nM PMO 9 
and b) 1-5 µM PMO 9. c) Bar graph depicting AluJ cassette inclusion percentages in SH-SY5Y 
cells treated with 0.5-5 µM PMO 9 for 24 hours compared to untreated cells. 
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of exon-skipped transcripts (127 bp, 
yellow arrow) against exon-including transcripts (247 bp, red arrow).  
n=3-6, *** = p≤0.001, **** = p≤0.0001. Statistical comparisons were carried out using one-way 
ANOVA. All data points correspond to mean ± SEM values. 
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3.2.1.2 PMO 9A (ALUJ+94+118) 
 
Once the effects of PMO 9 (AluJ+93+117) on exon skipping were 
tested, PMO 9A (AluJ+94+118) was then used to measure its ability to 
promote exon skipping. PMO 9A (AluJ+94+118) was designed as its 
sequence covers the end of the 3’ end of the AluJ cassette and is shifted one 
base pair 3’ of the sequence of PMO 9 (AluJ+93+117). 
Treatment of SH-SY5Y cells with 50-300 nM of PMO 9A (AluJ+94+118) 
resulted in no significant reduction in AluJ cassette inclusion levels when 
compared to control cells (88.5 ± 1.5%, p>0.05) (Figure 3.6c). 500 nM of PMO 
9A (AluJ+94+118) managed to significantly decrease AluJ cassette inclusion 
down to 81.05±1.4% when compared to untreated samples. The PCR gel 
image shown in Figure 3.5a shows how both exon-including transcripts (247 
bp) have higher fragment intensities than that of exon-skipped transcripts (127 
bp) in both transfected and control cells, thus demonstrating that low 
concentrations of PMO 9 (AluJ+93+117) were ineffective at excluding the AluJ 
cassette. 
Treatment of cells with 1 µM of PMO 9A (AluJ+94+118) managed to 
significantly decrease AluJ cassette inclusion compared to control cells (64.15 
± 0.6%) (Figure 3.6c). Lower cassette inclusion levels were seen in cells 
transfected with 2.5 µM PMO 9A (AluJ+94+118) (43.83 ± 3.6%). The strongest 
effect of PMO 9A (AluJ+94+118) was seen at 5 µM concentration, where near 
complete exon-skipping levels was achieved, and AluJ cassette inclusion 
levels decreased down to 4.09 ± 2.3%. The PCR gel image in Figure 3.6b 
displays how the band intensities of exon-skipped transcripts (127 bp) of 5 µM-
treated cells are much higher compared to those of exon-including transcripts 
(247 bp). 
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Figure 3.6 The effect of PMO 9A on AluJ insertion in SH-SY5Y cells. 
Figure shows gel images of RT-PCR products of SH-SY5Y cells treated with a) 50-500 nM PMO 
9A and b) 1-5 µM PMO 9A. c) Bar graph depicting AluJ cassette inclusion percentages in SH-
SY5Y cells treated with 0.5-5 µM PMO 9A for 24 hours compared to untreated cells.  
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized under 
UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes negative 
control. Sample gel images show the intensity of exon-skipped transcripts (127 bp, yellow arrow) 
against exon-including transcripts (247 bp, red arrow).  
n=3-6, * = p≤0.05, **** = p≤0.0001. Statistical comparisons were carried out using one-way 
ANOVA. All data points correspond to mean ± SEM values. 
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3.2.1.3 PMO 9B (ALUJ+95+119) 
 
Further to testing PMO 9A (AluJ+94+118), PMO 9B (AluJ+95+119) was 
also used to measure its effects on cassette exon inclusion as the sequence 
for this PMO shifts by two base pairs towards the 3’ splice site of the cassette 
from the sequence of PMO 9 (AluJ+93+117). SH-SY5Y cells were transfected 
with PMO 9B (AluJ+95+119) at the same concentration ranges as previously 
described. Compared to PMO 9 (AluJ+93+117) and PMO 9A (AluJ+94+118), 
where a significant decrease in AluJ inclusion was observed even in 500 nM-
treated cells, no significant change in AluJ cassette inclusion levels were 
observed at PMO concentrations of 50 nM to 2.5 µM when compared to control 
samples (81.99 ± 3.4%, p>0.05) (Figure 3.7c). Increasing the PMO 
concentration to 2.5 µM significantly lowered cassette inclusion levels down to 
45.22 ± 2.3%.The most potent effect of PMO 9B (AluJ+95+119) was seen at 
5 µM concentration, where AluJ inclusion decreased to 34.2 ± 1.8% (Figure 
3.7c). This is similar to thelevels of exon skipping that were observed in PMO 
9-transfected cells. 
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Figure 3.7 The effect of PMO 9B on AluJ insertion in SH-SY5Y cells. 
Figure shows gel images of RT-PCR products of SH-SY5Y cells treated with a) 50-500 nM 
PMO 9B and b) 1-5 µM PMO 9B. c) Bar graph depicting AluJ cassette inclusion percentages 
in SH-SY5Y cells treated with 0.5-5 µM PMO 9B for 24 hours compared to untreated cells. 
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of exon-skipped transcripts (127 bp, 
yellow arrow) against exon-including transcripts (247 bp, red arrow).  
n=3-6, **** = p≤0.0001. Statistical comparisons were carried out using one-way ANOVA. All 
data points correspond to mean ± SEM values. 
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3.2.1.4 PMO 10 (ALUJ+96+120) 
 
In these sets of experiments, PMO 10 (AluJ+96+120) was also used to 
transfect SH-SY5Y cells as a control PMO. This PMO has previously been 
tested for its exon skipping abilities and was found to have no effect on 
cassette exon inclusion levels. The base sequence for PMO 10 (AluJ+96+120) 
is shifted one base 3’ of PMO 9B (AluJ+95+119), thus completely covers the 
3’ end of the splice site of the AluJ cassette. As seen in the gel images in 
Figures 3.8a and 3.8b, both full-sized and exon-skipped transcripts have the 
same intensities in transfected and non-transfected cells, indicating that PMO 
10 (AluJ+96+120), even in higher concentrations, was unable to induce any 
change in AluJ inclusion levels when compared to control cells (87.08 ± 3.2%). 
This thus ensures that any alteration in AluJ cassette inclusion levels seen in 
cells transfected with PMO 9 (AluJ+93+117), PMO 9A (AluJ+94+118), and 
PMO 9B (AluJ+95+119) were all an effect of the PMOs alone, and not caused 
by the transfection reagent. 
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Figure 3.8 The effect of PMO 10 on AluJ insertion in SH-SY5Y cells.  
Gel images of RT-PCR products of SH-SY5Y cells treated with a) 50-500 nM PMO 10 and b) 
1-5 µM PMO 10. c) Bar graph depicting AluJ cassette inclusion percentages in SH-SY5Y cells 
treated with 0.5-5 µM PMO 10 for 24 hours compared to untreated cells. 
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of exon-skipped transcripts (127 bp, 
yellow arrow) against exon-including transcripts (247 bp, red arrow).  
n=3-6. Statistical comparisons were carried out using one-way ANOVA. All data points 
correspond to mean ± SEM values. 
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3.2.1.5 INCREASING CONCENTRATIONS OF PMOS 
 
Since a major difference in exon skipping efficacy was observed 
between PMO concentrations of 1 µM and 5 µM, the effects of an even higher 
PMO concentration was investigated to determine whether even higher levels 
of exon skipping can be attained. SH-SY5Y cells were transfected with 10 µM 
of PMO and its effects on cassette exon inclusion were compared with cells 
transfected with 5 µM of PMO. Although the levels of AluJ cassette inclusion 
in 10 µM-treated samples were reduced slightly compared to those seen in 5 
µM-treated samples (Figure 3.9), there was no significant difference in AluJ 
cassette inclusion levels between the two concentrations.  
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Figure 3.9 Bar graph depicting AluJ cassette inclusion levels in SH-SY5Y cells 
trated with 5 µM and 10 µM PMO.  
n=3-4, *** = p≤0.001, **** = p≤0.0001, . Statistical comparisons were carried out using 
one-way ANOVA. All data points correspond to mean ± SEM values. 
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3.2.1.6 INHIBITORY DOSE RESPONSE CURVE FOR ALUJ 
CASSETTE INCLUSION FOLLOWING PMO TRANSFECTION 
 
Following individual analysis of each PMO and its effects exon skipping, 
a dose-response curve was plotted in order to calculate the IC50 of each PMO 
(Figure 3.10). The IC50 values here represent the concentration of PMO 
needed to inhibit half of the maximum AluJ cassette inclusion. As PMO 9A 
(AluJ+94+118) demonstrated the strongest effect on exon skipping, the IC50 
was found to be the lowest (1.49 ± 0.15 µM). PMO 9 (AluJ+93+117) had a 
higher IC50 (3.13 ± 0.42 µM) than PMO 9B (AluJ+95+119) (2.16 ± 0.33 µM), 
even though PMO 9 (AluJ+93+117) demonstrated significant exclusion of the 
AluJ cassette at lower concentrations (500 nM and 1 µM). However, both 
PMOs resulted in similar AluJ cassette inclusion levels following 5 µM of PMO 
treatment (35.1 % for PMO 9 (AluJ+93+117) and 34.2% for PMO 9B 
(AluJ+95+119)). Since PMO 10 (AluJ+96+120) had no effect on exon 
skipping, it was not possible to calculate the IC50 for this PMO. 
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Figure 3.10 Dose response curves of log PMO concentration against AluJ inclusion. 
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3.2.2 EFFECTS OF EXON SKIPPING ON Q/R SITE EDITING 
3.2.2.1 OPTIMISATION OF THE BBVI DIGEST RNA EDITING ASSAY 
 
In order to measure Q/R site editing levels in SH-SY5Y cells, a 
restriction enzyme digest of RT-PCR cDNA products of the Q/R editing site in 
SH-SY5Y cells was performed using the restriction enzyme BbvI. BbvI was 
used in this assay as the enzyme contains the recognition sequence for 
unedited adenosine in cDNA (GCAGC). Thus, the enzyme will then cut 
unedited transcripts in the cDNA, whilst edited copies will remain uncut as they 
do not contain the recognition sequence for BbvI. This will result in digest 
products with three different fragment sizes: 323 bp (edited cDNA) and 238 bp 
and 85 bp (unedited cDNA) (Figure 3.11). 2 units of enzyme were used for 
each PCR reaction product, followed by an incubation step at 37°C for 1 hour. 
10% SDS was initially used to inactivate BbvI before running digest products 
on a gel. However, it was found that this concentration affected migration of 
DNA in the agarose gel, resulting in smeared bands in both edited and 
unedited cDNA transcripts (Figure 3.12). Different concentrations of SDS were 
then tested in order to determine the optimal concentration needed to 
inactivate BbvI (Figure 3.13). It was then found that addition of 1% SDS 
resulted in sharper, more distinct bands, allowing for Q/R site editing 
quantification using densitometric analysis with the following equation: 
 
  
!"#$%&'(&)(&	$+	&,-.&,	+%/01&).'2$./"	+"#$%&'(&)(& 	×	100%	 = 8,-.-)0	9&%(&)./0&	-)	(&""'		
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Figure 3.11 Schematic diagram representing cut sites for BbvI. 
BbvI recognises unedited adenosine. If the sequence is present, it will then be cut by the 
enzyme, resulting in PCR digest products of two smaller fragments – 238 bp and 85 bp. 
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Figure 3.12 Gel image of a BbvI digest of SH-SY5Y cells inactivated with 10% SDS.  
Smeared bands can be seen in digest products in lanes indicated by green arrows. 
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Figure 3.13 Gel image of a BbvI digest of SH-SY5Y cells inactivated with 0.1% and 1% 
SDS. 
0.1% SDS resulted in completely indistinct bands whilst 1% SDS resulted in digest products 
with two distinct fragments.  
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3.2.2.2 PMO 9 (ALUJ+93+117) 
 
Gerber et. al. (1997) previously demonstrated how ADAR2 isoforms 
that contain a 120 bp AluJ cassette have reduced catalytic activity compared 
to isoforms that do not contain the cassette. Reduction in the catalytic activity 
of ADAR2 leads to lower Q/R site editing levels. Hence, inducing alternative 
splicing using PMOs to promote AluJ cassette inclusion could possibly 
improve RNA editing levels in SH-SY5Y cells. Following exon skipping PCR 
assays and analysis of PMO-transfected SH-SY5Y cells, a BbvI digest RNA 
editing assay was performed to measure the effects on exon skipping on Q/R 
site editing. Q/R site editing levels were normalised to control levels, as shown 
in Figure 3.14c. No change in editing levels were seen in cells transfected with 
50-500 nM of PMO 9 (AluJ+93+117), even though 500 nM PMO 9 
(AluJ+93+117) was able to reduce cassette exon inclusion levels. Increased 
concentrations of PMO 9 (AluJ+93+117), however, significantly increased Q/R 
site editing levels compared to controls. 1 µM and 2.5 µM PMO 9 
(AluJ+93+117) showed similar increase in RNA editing, at 125.7 ± 7.7% and 
124.8 ± 2.6%, respectively. Although 5 µM PMO 9 (AluJ+93+117) managed 
to greatly decrease AluJ cassette inclusion levels compared to 1 µM and 2.5 
µM of PMO, the increase in RNA editing is only slightly higher than that 
observed in 1 and 2.5 µM PMO 9 (AluJ+93+117) (131.7 ± 4.2%).  
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Figure 3.14 The effect of PMO 9 on RNA editing in SH-SY5Y cells. 
Figure shows gel images of BbvI digest products of SH-SY5Y cells treated with a) 50-500 nM 
PMO 9 and b) 1-5 µM PMO 9. c) Bar graph depicting Q/R site editing percentages in SH-SY5Y 
cells treated with 0.5-5 µM PMO 9 for 24 hours compared to untreated cells. 
Gels were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of edited transcripts (323 bp, red arrow) 
against unedited transcripts (238 bp and 85 bp, yellow arrow).  
n=3-6, ** = p≤0.01, **** = p≤0.0001. Statistical comparisons were carried out using one-way 
ANOVA. All data points correspond to mean ± SEM values. 
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3.2.2.3 PMO 9A (ALUJ+94+118) 
 
Lower concentrations of PMO 9A (AluJ+94+118) did not result in any 
RNA editing increase in cells (Figure 3.15c). This is expected as the same 
concentrations (50-300 nM) did not result in AluJ cassette exclusion levels, 
although as with PMO 9, 500 nM of PMO 9A (AluJ+94+118) did slightly reduce 
AluJ cassette level inclusion down to 81.05 ± 1.4%. These results demonstrate 
that the reduction in AluJ cassette levels were too low to improve RNA editing 
levels in the cells. Higher concentrations of PMO 9A (AluJ+94+118) did 
however improve RNA editing levels in the cells, where 1 µM transfections 
increased editing to 166.6 ± 13.8%, and 2.5 µM transfections increased editing 
to 159.6 ± 3.3%. 5 µM of PMO 9A (AluJ+94+118) resulted in an increase of 
167.9 ± 6% in RNA editing. Although 5 µM PMO 9A (AluJ+94+118) showed 
much higher exon skipping effects than 1 µM and 2.5 µM PMO 9A 
(AluJ+94+118), the levels of RNA editing among the three concentrations are 
approximately the same, suggesting that RNA editing levels may have 
reached saturation in the presence of high levels of AluJ sequence exclusion. 
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Figure 3.15 The effect of PMO 9A on RNA editing in SH-SY5Y cells. 
Figure shows gel images of BbvI digest products of SH-SY5Y cells treated with a) 50-500 nM 
PMO 9A and b) 1-5 µM PMO 9A. c) Bar graph depicting Q/R site editing percentages in SH-
SY5Y cells treated with 0.5-5 µM PMO 9A for 24 hours compared to untreated cells. 
Gels were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of edited transcripts (323 bp, red 
arrow) against unedited transcripts (238 bp and 85 bp, yellow arrow).  
n=3-6, * = p≤0.05, ** = p≤0.01. Statistical comparisons were carried out using one-way 
ANOVA. All data points correspond to mean ± SEM values. 
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3.2.2.4 PMO 9B (ALUJ+95+119) 
 
 Compared to PMOs 9 (AluJ+93+117) and 9A (AluJ+94+118), 
transfection of SH-SY5Y cells with PMO 9B (AluJ+95+119) did not result in 
any increase in Q/R site editing levels compared to normalised controls 
(p>0.05) (Figure 3.16c). In fact, RNA editing levels remained at roughly the 
same levels compared to controls, ranging at values from 91.6 ± 5% (50 nM) 
to 109.3 ± 2% (5 µM). The results were somewhat expected as the effects of 
PMO 9B (AluJ+95+119) on AluJ cassette inclusion (Figure 3.7) were not as 
potent as seen with PMOs 9 (AluJ+93+117) and 9A (AluJ+94+118) (Figures 
3.5 and 3.6). Although 2.5 µM and 5 µM of PMO 9B (AluJ+95+119) were able 
to significantly decrease AluJ cassette inclusion (Figure 3.7c), the PMO was 
unable to result in any improvement on RNA editing levels in these cells. 
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Figure 3.16 The effect of PMO 9B on RNA editing in SH-SY5Y cells.  
Figure shows gel images of BbvI digest products of SH-SY5Y cells treated with a) 50-500 nM 
PMO 9B and b) 1-5 µM PMO 9B. c) Bar graph depicting Q/R site editing percentages in SH-
SY5Y cells treated with 0.5-5 µM PMO 9B for 24 hours compared to untreated cells. 
Gels were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of edited transcripts (323 bp, red arrow) 
against unedited transcripts (238 bp and 85 bp, yellow arrow).  
n=3-6. Statistical comparisons were carried out using one-way ANOVA. All data points 
correspond to mean ± SEM values. 
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3.2.2.5 PMO 10 (ALUJ+96+120) 
 
Since PMO 10 (AluJ+96+120) acts as a control PMO and did not have 
any effect on AluJ cassette inclusion levels, transfection of SH-SY5Y cells with 
this PMO was not expected to have any change in RNA editing levels as well 
(p>0.05) when compared to normalised controls (Figure 3.17c). Levels of RNA 
editing remained approximately the same, ranging from 88.11 ± 4.5% (1 µM) 
to 95.12 ± 2.6% (50 nM), with the exception of 100 nM PMO 10 (AluJ+96+120), 
which reduced editing levels down to 63.85 ± 4.1%, although this could simply 
be an outlier effect, as seen from the large variability. The levels of RNA editing 
observed here is consistent with the lack of exon skipping levels previously 
observed in Figure 3.8c. 
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Figure 3.17 The effect of PMO 10 on RNA editing in SH-SY5Y cells. 
Figure shows gel images of BbvI digest products of SH-SY5Y cells treated with a) 50-500 nM 
PMO 10 and b) 1-5 µM PMO 10. c) Bar graph depicting Q/R site editing percentages in SH-
SY5Y cells treated with 0.5-5 µM PMO 9B for 24 hours compared to untreated cells. 
Gels were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of edited transcripts (323 bp, red 
arrow) against unedited transcripts (238 bp and 85 bp, yellow arrow).  
n=3-6, *** = p≤0.001. Statistical comparisons were carried out using one-way ANOVA. All data 
points correspond to mean ± SEM values. 
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3.2.2.6 DOSE RESPONSE CURVES FOR RNA EDITING LEVELS 
FOLLOWING PMO TRANSFECTION 
 
To better compare the effects of PMOs on RNA editing levels, a dose-
response curve was plotted to calculate the EC50 of each PMO (Figure 3.17). 
In this context, the EC50 values represent the concentration of PMO needed to 
produce half of the maximum RNA editing levels observed in the cells. As PMO 
9A (AluJ+94+118) was able to increase RNA editing levels at 1-5 µM 
concentrations (Figure 3.15c) and demonstrated the most potent exon 
skipping effects (Figure 3.6c), the EC50 value for PMO 9A (AluJ+94+118) was 
calculated to be the lowest (0.66 µM). The EC50 for PMO 9 (AluJ+93+117) was 
only slightly higher than that found in PMO 9A (AluJ+94+118) (0.69 µM). This 
is however indicative of the RNA editing levels observed in PMO 9-treated 
cells, where a significant increase in editing was seen at the same 
concentration range (1-5 µM) (Figure 3.14c) as that of PMO 9A-treated cells 
(Figure 3.15c). PMO 9B (AluJ+95+119) demonstrated a non-sigmoidal 
relationship, which was expected as this PMO had no effect in improving RNA 
editing in cells (Figure 3.16c), and its ineffectiveness on RNA editing can be 
seen on how a sigmoidal curve could not be plotted through the data points 
(Figure 3.18). Since PMO 10 (AluJ+96+120) had no effect on both exon 
skipping and RNA editing, the EC50 for this PMO could not be calculated. 
  
 121 
-1.5 -1.0 -0.5 0.0 0.5 1.0
20
40
60
80
100
120
log concentration PMO (µM)
R
N
A 
ed
iti
ng
 %
PMO 9
PMO 9A
PMO 9 EC50 = 0.69±0.14 µM
PMO 9A EC50 = 0.66±0.08 µM
-1.5 -1.0 -0.5 0.0 0.5 1.0
20
40
60
80
100
120
log concentration PMO (µM)
R
N
A 
ed
iti
ng
 %
PMO 9B
PMO 10
PMO 9B EC50 = 0.78±0.67 µM
-1.5 -1.0 -0.5 0.0 0.5 1.0
20
40
60
80
100
120
log concentration PMO (µM)
R
N
A 
ed
iti
ng
 %
PMO 9B
PMO 10
Figure 3.18 Dose-response curves of PMO concentration against RNA editing levels. 
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3.3 DISCUSSION 
 
The work presented here was performed to investigate the efficacy of 
the different PMOs designed to exclude the AluJ cassette from the final mRNA 
transcript of ADAR2, and its subsequent effects on RNA editing levels. The 
data shown here confirms how PMOs 9 (AluJ+93+117) and 9A (AluJ+94+118) 
were successful in inducing alternative splicing in these cells and thus 
increase RNA editing. As the presence of the AluJ cassette was previously 
reported to reduce the catalytic activity of ADAR2 (Gerber et al., 1997), the 
exon skipping technique using ASOs was applied here in order to manipulate 
splicing events in ADAR as to result in an isoform that lacks the AluJ cassette. 
Since one of the possible theories behind ALS pathophysiology is 
underediting at the GluA2 subunit of AMPA receptors, it is essential to validate 
that a reduction in AluJ cassette levels (which can be found in exon 5a of the 
ADAR pre-mRNA transcript) can indeed aid in improving RNA editing levels in 
the GluA2 subunit. In fact, a study carried out by (Li et al., 2015) demonstrated 
how the relative expression of ADAR transcripts containing the AluJ cassette 
found in gliomas were higher than that seen in normal human astrocytes 
(NHAs), thus concluding that an aberrant splicing pattern in ADAR2 pre-mRNA 
contributes to the downregulation of A-to-I editing in gliomas. 
 The PMOs tested for exon skipping (9 (AluJ+93+117), 9A 
(AluJ+94+118) and 9B (AluJ+95+119)) were previously designed in that they 
all target the 3’ end of the AluJ cassette, where the sequences differ by one 
base pair each. PMO 10 (AluJ+96+120) was used as a control PMO as it was 
previously found to be ineffective at promoting cassette exon exclusion. PMO 
9A (AluJ+94+118) demonstrated the most efficient exon skipping abilities, 
where a near-complete exon exclusion was found in cells treated with 5 µM of 
PMO 9A (AluJ+94+118) (4.09 ± 2.3%). In comparison, PMOs 9 (AluJ+93+117) 
and 9B (AluJ+95+119) resulted in 35.1 ± 4.8% and 34.2 ± 1.8% exon inclusion, 
respectively, at the same concentration. A dose response curve was plotted 
to compare the potencies of the PMOs on exon inclusion (Figure 3.10).  The 
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IC50 of PMO 9A (AluJ+94+118) was calculated to be the lowest, at 1.49 µM, 
whilst PMOs 9 (AluJ+93+117) and 9B (AluJ+95+119) had higher IC50 values 
(3.13 µM and 2.16 µM, respectively). At lower concentrations (500 nM and 1 
µM), a significant effect on exon skipping was observed with PMOs 9 
(AluJ+93+117) and 9A (AluJ+94+118) (Figures 3.5 and 3.6), although this was 
not the case with PMO 9B (AluJ+95+119), where significant exon skipping 
effects were seen only at 2.5 µM and 5 µM PMO treatment (Figure 3.7). We 
have attempted to see whether increasing the PMO concentrations up to 10 
µM would result in an even greater exon skipping effect; however, no 
significant difference in exon skipping levels were calculated between 5 µM 
and 10 µM PMO concentrations (Figure 3.9), suggesting that there is a 
saturation effect of the PMOs.  
Since the efficacy of the PMOs at inducing AluJ cassette exclusion was 
established, our hypothesis on how exon skipping can improve RNA editing 
levels was tested. This was proven in the cases of both PMO 9 (AluJ+93+117) 
and 9A (AluJ+94+118), where an increase up to 131.7 ± 4.2% was observed 
in cells compared to normalized controls for PMO 9 (AluJ+93+117), and 167.9 
± 6% editing for PMO 9A (AluJ+94+118). Interestingly, although PMO 9B 
(AluJ+95+119) managed to exclude the AluJ cassette, no increase in RNA 
editing was observed. The sequence of PMO 9B (AluJ+95+119) covers the 3’ 
end of the AluJ cassette even further than PMOs 9 and 9A (AluJ+94+118), 
and is one base pair different than the sequence of PMO 10 (AluJ+96+120), 
which could possibly indicate that PMOs designed to bind the region towards 
the end of the AluJ cassette are less effective at improving RNA editing. The 
inability of PMOs 9B (AluJ+95+119) and 10 (AluJ+96+120) to improve RNA 
editing can also be seen in the dose response curve drawn in Figure 3.18, 
where the curves for both PMOs did not produce a good fit.  
One thing to note here is how transfections of 1 µM, 2.5 µM, and 5 µM 
of PMOs resulted in similar levels of RNA editing, even though there is a clear 
quantifiable difference in exon skipping levels between the increasing 
concentrations. This also correlates with the very similar EC50 values 
calculated for PMOs 9 (AluJ+93+117) and 9A (AluJ+94+118) (0.69 µM and 
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0.66 µM respectively) (Figure 3.18), showing that even a substantial difference 
in the ability of the PMOs to induce exon skipping only results in a marginal 
increase in RNA editing levels. This trend could be due to low levels of 
constitutive endogenous expression of ADAR in SH-SY5Y cells, which were 
confirmed through western blot experiments (discussed in Chapter 4). It 
seems as if the upper limits on RNA editing through the action of the ADAR 
enzyme have been reached with this cell model.  
Another possible reason behind the small difference in editing levels 
seen in the cells between the different concentrations, as well as the inability 
of PMO 9B (AluJ+95+119) to increase editing despite being efficient at exon 
skipping, is the RNA editing assay used in this study. Restriction enzyme 
assays are limited in the sense that they rely on the presence of a recognition 
site for the enzyme, and this site could be formed or destroyed during the A-
to-I editing process (Wong, Lyddon, & Dracheva, 2009). Sequencing has also 
been proven to be successful in assessing A-to-I editing, however, both 
restriction enzyme assays and sequencing can result in systematic errors in 
measurements, as they involve multiple steps (Wong et al., 2009). Thus, 
(Chen et al., 2008) came up with a method to assess editing levels at the Q/R 
site using a SYBR Green detection-based quantitative PCR (qPCR). (Wong et 
al., 2009) then invented a novel qPCR assay using TaqMan probes. Their 
method utilizes two different probes with the same primer pair to distinguish 
the two transcript variants with a one nucleotide difference at the editing site 
(A®G), which is comparable to existing single nucleotide polymorphism 
(SNP) assays that applies qPCR (Gilbert et al., 2007). The results of their 
assay have shown how there is less bias in detection of Q/R site editing levels 
in the GluR5 subunit of the kainate (KA) receptor. when compared to 
sequencing and the restriction enzyme digest. Hence, employing the TaqMan 
qPCR method to measure editing levels at the Q/R site of the GluA2 subunit 
is a possibility.  
Alternative ADAR2 splicing events in rats include the insertion of a 30-
nt cassette, where, as seen in humans, the presence or absence of this 
cassettes results in the formation of two different ADAR isoforms (ADAR2a 
and ADAR2b, respectively). A study performed by (Filippini et al., 2018b) 
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aimed to characterize the two ADAR isoforms, as well as their expression and 
RNA editing activity. Their results show a 12% increase in RNA editing levels 
in ADAR2a compared to ADAR2b at the R/G site of the GluA2 subunit in rat 
primary cortical neurons, which is a more representative model. This small but 
significant increase in RNA editing observed is consistent with the findings in 
this chapter, where even when similar levels of the two ADAR isoforms are 
detected in the SH-SY5Y cells, the increase in RNA editing still remains 
approximately the same even at higher exon skipping levels of the AluJ 
cassette.  
The editing efficiency in ALS motor neurons were found to vary 
between 38% to 75%, whereas editing was complete in control motor neurons 
(100%) (Kawahara et al., 2004). Quantitative analyses of AMPA receptor 
mRNA showed that both ALS motor neurons and control motor neurons 
express similar levels of GluA2 mRNA relative to b-actin expression, indicating 
that GluA2 mRNA expression is not altered in motor neurons of individuals 
with ALS (Kawahara, Kwak, et al., 2003). However, this reduction in RNA 
editing was found to be caused by low levels of ADAR2 expression in ALS 
motor neurons (Takuto Hideyama et al., 2012). Although SH-SY5Y cells 
endogenously express low ADAR2 expression levels, an increase in RNA 
editing was still observed following PMO treatment, thus implying that 
treatment of ALS motor neurons with PMOs could possibly have a large impact 
on editing efficiency. However, testing this hypothesis on a more 
representative and neuronal-like cell model would be ideal. Rats also undergo 
alternative ADAR splicing events, where an insertion of a 30-nt cassette 
results in a less active ADAR2 isoform. The splicing isoforms of ADAR2a and 
ADAR2b have been recently characterised in rat primary neurons (Filippini et 
al., 2018b), making it a possible cell model to test the effects of the PMOs on 
RNA editing. Another possibility would be to use patient-specific induced 
pluripotent stem cells (iPSCs), although currently, only one study has reported 
the isolation and characterisation of iPSC-derived motor neurons from 
sporadic ALS cases (S. Lee & Huang, 2017). Expression levels of 
alternatively-spliced ADAR2 transcripts as well as Q/R site editing levels in 
iPSCs would however still need to be fully elucidated, and a more effective 
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way of delivering antisense oligonucleotides into iPSCs would have to be 
developed.
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CHAPTER 4 INVESTIGATING THE 
EFFECTS OF PMO TRANSFECTION ON 
ENDOGENOUS AND ARTIFICIAL ADAR2 
PROTEIN EXPRESSION IN SH-SY5Y 
CELLS 
4.1 INTRODUCTION 
 
 The efficiency of RNA editing at the Q/R site of GluA subunits 
(specifically human brain GluA2) is correlated to the total amount of ADAR2 
mRNA expressed (Kawahara, Ito, et al., 2003). This infers that the levels of 
ADAR2 mRNA might be one of the regulatory factors behind GluA2 Q/R site 
RNA editing. However, the amount of total ADAR2 mRNA does not 
necessarily illustrate its editing activity in vivo, since several alternative human 
ADAR2 mRNA splice variants have been identified (Kawahara et al., 2005). 
Reports have shown that the ADAR2 gene consists of 14 exons, which 
includes two 5’ untranslated exons (exons -2 and -1) and one 3’ untranslated 
region (UTR) within exons 9 and 10 (Slavov & Gardiner, 2002). Three 
alternative splice sites have been identified in elementary studies: alternative 
splicing of exon 5a (incorporation of an Alu cassette) (Gerber et al., 1997); 
splicing at the long C-terminus and short C-terminus (Lai, Chen, Lee, et al., 
1997); and the RNA editing-dependent addition of 47 nucleotides to exon 2 
(Rueter et al., 1999). Most splicing variants were generally derived from two 
main splicing events, where the alternative splice isoforms were classified as 
ADAR2a to ADAR2f (Lai, Chen, Carter, & Nishikura, 1997; Rueter et al., 1999). 
 A splicing event that concerns the 5’ end of the coding sequence occurs 
due to a self-editing process, allowing ADAR2 to act in its own pre-mRNA. An 
alternative 3’ acceptor site is created by the conversion of an intronic AA to an 
AI, which is read as an AG dinucleotide by the splicing machinery. This 
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acceptor site introduces 47 nucleotides in the transcript, generating a stop 
codon in the mRNA (Figure 4.1). A truncated and inactive form of the protein 
is produced (ADAR2e and ADAR2f), adding 82 amino acids in rats and mice 
(31 amino acids in humans). This self-editing mechanism is meant to have a 
role in ADAR2 regulation (Rueter et al., 1999). Splicing at the 3’ end of the 
catalytic domain of the protein results in the inclusion of 32 nucleotides in rat 
and mouse and 120 nucleotides (also known as the AluJ cassette) in humans 
(Figure 4.1). This splicing event produces two different isoforms of ADAR2, 
where exclusion of the 120 bp AluJ cassette from the ADAR2 transcript is the 
more catalytically active isoform of the enzyme (Gerber et al., 1997). The 
generation of isoforms ADAR2c and ADAR2d occurs at the end of the coding 
sequence and is only observed in humans, where the insertion of a truncated 
C terminus forms an isoform with no editing activity (Lai, Chen, Carter, et al., 
1997) (Figure 4.1). Additionally, inclusion of exon 0 has been demonstrated to 
extend the open reading frame by inserting 49 amino acids at the N-terminus, 
but this isoform is not greatly expressed (Stefan Maas & Gommans, 2009) 
(Figure 4.1). 
  
Exon -2 Exon -1 Exon 1 Exon 2
47 nt
Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8
AluJ cassette
Exon 9 Exon 10
Truncated C-terminusExon 0
Figure 4.1 Schematic diagram representing possible alternative splicing events in the 
ADAR2 transcript.  
Grey boxes indicate insertions from the intronic sequence. Exon 0 is inserted between exon -1 and 
exon 1. The 47 nt cassette is inserted at the start of exon 2. The AluJ cassette is inserted between 
exons 5 and 6. Insertion of a truncated C-terminus occurs at the end of the coding sequence.  
 129 
 Although expression of ADAR proteins and splice forms has not been 
comprehensively investigated at the protein level, in situ hybridisation studies, 
RT-qPCR, northern blotting, and microarray experiments have shown that 
ADAR1 and ADAR2, despite being ubiquitously expressed across cell types, 
are present in differing amounts in individual tissues and cell types (S. Maas 
& Gommans, 2009). Whilst the developmental expression of ADAR2 protein 
has been fully elucidated in rat primary neurons (Behm et al., 2017; Filippini et 
al., 2018b), the endogenous expression of ADAR2 in SH-SY5Y cell lines have 
not been studied. Data from previous chapters have indicated that PMOs 
designed to manipulate splicing of the AluJ cassette (PMO 9 (AluJ+93+117) 
and PMO 9A (AluJ+94+118)) were successfully able to indirectly increase Q/R 
site RNA editing levels by increasing exon skipping levels in SH-SY5Y cells. 
However, although there is an increase in exon skipping levels measured in 
PMO-transfected cells, the improvement in RNA editing levels remain at 
similar levels between cells transfected with 1-5 µM of PMO. Hence, we 
studied the expression levels of ADAR2 protein in SH-SY5Y cells to determine 
its constitutive expression. In this chapter, we assessed the specificity of 
different antibodies against ADAR2 in cells that have been co-transfected with 
both the ADAR2 cDNA and PMOs 9 (AluJ+93+117), 9A (AluJ+94+118), and 
10 (AluJ+96+120), which were then lysed for protein isolation and western 
blotting. Cells were also transiently transfected with ADAR2 cDNA as a 
positive control for ADAR2 protein detection. We have found significantly low 
expression levels of endogenous ADAR2 in SH-SY5Y cells when compared 
to ADAR2 cDNA-transfected cells. The results presented here show that 
despite the high levels of exon skipping observed in PMO-transfected cells, 
the increase in RNA editing levels have reached saturation as the quantity of 
ADAR2 in the cells were simply too low.  
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4.2 RESULTS 
4.2.1 TESTING DIFFERENT PRIMARY ANTIBODIES FOR ADAR2 
DETECTION 
  
The successful transfection of ADAR2 in SH-SY5Y cells was first 
verified. Cells were transfected with 2 µg of the ADAR cDNA for 48 hours, 
followed by protein extraction. As the ADAR2 cDNA is FLAG-tagged at the N-
terminal, the expression of the cDNA was confirmed with both anti-ADAR2 C-
15 (Santa Cruz) and anti-FLAG (Sigma #F7425) primary antibodies through 
SDS-PAGE and immunoblotting. Figure 4.2 shows the resulting western blot 
image of SH-SY5Y cells transfected with ADAR2 cDNA, thus verifying the 
successful transfection of the ADAR2 cDNA plasmid and protein expression 
of ADAR2 in the cells.  
  
SH-SY5Y + ADAR2 SH-SY5Y only
90 kDa
ADAR 
anti-FLAG
90 kDa
Figure 4.2 Confirmation of ADAR2 transfection in SH-SY5Y cells.  
Figure shows western blot gel images of SH-SY5Y cells transfected with 2 µg of ADAR2 
cDNA. Immunoblots were incubated with 1:250 ADAR2 C-15 primary antibody (top image) 
and 1:250 anti-FLAG antibody (bottom image) overnight at 4°C. The transfection was 
confirmed through visualisation of the blot at 560 nm (bottom image). 
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In order to examine the expression levels of ADAR2 in SH-SY5Y cells, 
we first tested three different primary antibodies for optimal ADAR2 detection. 
Cells were transfected with 2 µg of ADAR2 cDNA for 48 hours, followed by 
protein extraction. Cells transfected with ADAR2 acted as positive controls, 
and the detection of ADAR2 protein was compared in the following conditions: 
cells co-transfected with PMO and ADAR2 cDNA, cells transfected with 
ADAR2 cDNA only, cells transfected with PMO only and non-transfected cells. 
The antibodies used for ADAR2 detection can be found in Table 4.1. 
Table 4.1 Primary antibodies used for the detection of ADAR2. 
 
 
 
  
Antibody Host Company 
ADAR2 C-15 Mouse polyclonal 
Santa Cruz, #SC-
10012 
ADAR2 C-6 Mouse monoclonal 
Santa Cruz, #SC-
514581 
ADAR2 GTX114237 Rabbit polyclonal 
GeneTex, 
#GTX114237 
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 Hand-cast Tris-glycine 10% acrylamide gels were used for SDS-PAGE. 
Following electrophoresis, blots were all blocked in 2.5% non-fat milk for 1.5 
hours. Membranes were then incubated with ADAR2 primary antibodies at a 
concentration of 1:100 at 4°C overnight. Figure 4.3 shows the gel images of 
blots incubated with the different antibodies listed in Table 4.1. Non-
transfected cells showed very faint ADAR2 signals in the cells following 
primary antibody incubation, which indicates very low levels of endogenous 
ADAR2 expression in SH-SY5Y cells. Incubation with ADAR2 C-15 (Santa 
Cruz) was able to detect ADAR2 signals in ADAR2-transfected cells (Figure 
4.3a). The same results were also obtained in blots incubated with ADAR2 
GTX (GeneTex) (Figure 4.3c), where slightly more distinct ADAR2 bands were 
detected compared to ADAR2 C-15 incubation. However, this was not the 
case for ADAR2 C-6 (Santa Cruz), where no bands were detected in 
transfected SH-SY5Y cells (Figure 4.3b). Following these findings, we then 
proceeded to use ADAR2 GTX as the primary antibody for ADAR2 detection 
in further experiments. 
 
  
 133 
 
  
SH-SY5Y + ADAR2 SH-SY5Y only
40 kDa
Actin 
a. 90 kDa
ADAR 
ADAR2 C-15
SH-SY5Y + ADAR2 SH-SY5Y only
90 kDa
40 kDa
ADAR 
Actin 
b.
ADAR2 C-6
SH-SY5Y + ADAR2 SH-SY5Y only
c.
40 kDa
Actin 
90 kDa
ADAR 
ADAR2 GTX
Figure 4.3 Trialling different antibodies for ADAR2 detection. 
Figure shows representative western blot gel images for the detection of ADAR2 in transfected 
and non-transfected SH-SY5Y cells. ADAR2 transfected cells were used as a positive control 
whilst actin was used as an internal loading control. a) Blots incubated with ADAR2 C-15; b) 
Blots incubated with ADAR2 C-6; c) Blots incubated with ADAR2 GTX. 
Protein samples were run in a 10% Tris-glycine acrylamide gel against BLUeye Prestained 
Protein Ladder and visualised with the Odyssey CLx Imaging System.  
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4.2.2 ADAR2 PROTEIN EXPRESSION IN SH-SY5Y CELLS 
 
 As previously described in Section 4.2.1, full-length expression of 
ADAR2 (90 kDa) was confirmed through the use of ADAR2 GTX antibody. The 
specificity of this antibody was confirmed in cells transfected with 2 µg of 
ADAR2 cDNA. Since we were attempting to measure differences in ADAR2 
expression between PMO-transfected and non-transfected SH-SY5Y cells, 
cells were subjected to different conditions as follows: 
 
i) Cells co-transfected with both 2 µg of ADAR2 cDNA and 2 µM 
of PMO using Lipofectamine and EndoPorter; 
ii) Cells transfected with only 2 µg of ADAR2 using Lipofectamine; 
iii) Cells transfected with only 2 µM of PMO using EndoPorter; 
iv) Non-transfected cells.  
 
Protein bands for ADAR2 were detected in cells transfected with 
ADAR2 cDNA as previously shown in Figure 4.3, however a very weak signal 
was detected in cell lysates that did not contain a copy of the ADAR2 cDNA 
(Figures 4.4-4.7). The expression levels of ADAR2 following PMO treatment 
were compared between the following conditions: ADAR2-transfected cells 
and non-ADAR2-transfected cells. Levels of ADAR2 expression were 
normalised to levels of β-actin (40 kDa), which acted as an internal loading 
control, in order to determine any modification in ADAR2 levels in PMO-
transfected cells compared to non-PMO-transfected cells.  
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4.2.2.1 PMO 9 (ALUJ+93+117) 
 
Since PMO 9 (AluJ+93+117) resulted in reduced AluJ cassette 
inclusion and increased Q/R site RNA editing levels (as described in Chapter 
3), this PMO was then used for protein expression analysis of ADAR2. 2 µM 
of PMO 9 (AluJ+93+117) was transfected in ADAR2-transfected and non-
transfected SH-SY5Y cells. The levels of ADAR2 expression were all 
normalised to endogenous ADAR2 levels measured in non-transfected cells 
(Figure 4.4a). The resulting western blot image is depicted in Figure 4.4a. 
PMO 9-transfected cells had a mean ADAR2 protein expression of 0.73 ± 0.05 
(Figure 4.4b). ADAR2 protein expression measured in cells co-transfected 
with both ADAR2 cDNA and PMO 9 (AluJ+93+117) were revealed to be at 
12.98 ± 2.3, whilst cells transfected with only ADAR2 cDNA showed ADAR2 
levels to be at 11.93 ± 0.9 (Figure 4.4b). Cultures that were transfected with 
ADAR2 cDNA all showed significantly higher ADAR2 protein expression 
compared to non-ADAR2-transfected cells (Figure 4.4b). Statistical analysis 
suggested that the difference in ADAR2 expression levels between cells 
transfected with PMO 9 (AluJ+93+117) and non-PMO-transfected cells were 
not significant (p>0.05) in both ADAR2-transfected and non-ADAR2-
transfected cells. 
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Figure 4.4 Expression of ADAR2 protein in ADAR2- and PMO 9-transfected cells.  
Figure shows a) representative western blot gel image of SH-SY5Y cells transfected with 
ADAR2 and PMO 9. Actin was used as an internal loading control and to normalise expression 
levels of ADAR2 within each lane; b) Bar graph depicting relative ADAR2 protein expression 
levels transfected with ADAR2 and PMO 9 compared to non-transfected cells.  
Protein samples were run in a 10% Tris-glycine acrylamide gel against BLUeye Prestained 
Protein Ladder and visualised with the Odyssey CLx Imaging System. Images were quantified 
using Image Studio 4.0. 
n=3, ** = p≤0.01, *** = p≤0.001. Statistical comparisons were carried out using unpaired t-test. 
All data points correspond to mean ± SEM values. 
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4.2.2.2 PMO 9A (ALUJ+94+118) 
 
PMO 9A (AluJ+94+118) was also used to measure ADAR2 protein 
expression as this PMO has also managed to successfully promote AluJ 
cassette exclusion and henceforth Q/R site RNA editing. The transfection 
conditions of PMO 9A (AluJ+94+118) were as described in Section 4.2.1. The 
resulting western blot image is shown in Figure 4.5a. The levels of ADAR2 
protein expression in different conditions were all normalised to ADAR2 
expression in non-transfected cells (Figure 4.5b). Cells that were transfected 
with both ADAR2 cDNA and PMO 9A (AluJ+94+118) showed mean ADAR2 
protein expression of 14.38 ± 0.6, whilst mean protein levels in ADAR2-
transfected cells were measured to be at 13.76 ± 0.5 (Figure 4.5b). Cultures 
transfected with only PMO 9A (AluJ+94+118) resulted in mean ADAR2 protein 
levels of 1.08 ± 0.1 (Figure 4.5b). Cultures transfected with ADAR2 cDNA all 
displayed significantly higher expression of ADAR2 protein compared to their 
non-ADAR2-transfected counterparts (Figure 4.5b). Treatment with PMO 9A 
(AluJ+94+118) does not affect ADAR2 expression levels, as supported by 
statistical analysis, where no significant difference in expression (p>0.05) 
between PMO-transfected and non-PMO-transfected samples were found.  
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Figure 4.5 Expression of ADAR2 protein in ADAR2- and PMO 9A-transfected cells.  
Figure shows a) representative western blot gel image of SH-SY5Y cells transfected with 
ADAR2 and PMO 9A. Actin was used as an internal loading control and to normalise 
expression levels of ADAR2 within each lane; b) Bar graph depicting relative ADAR2 protein 
expression levels transfected with ADAR2 and PMO 9A compared to non-transfected cells.  
Protein samples were run in a 10% Tris-glycine acrylamide gel against BLUeye Prestained 
Protein Ladder and visualised with the Odyssey CLx Imaging System. Images were quantified 
using Image Studio 4.0. 
n=3, **** = p≤0.0001. Statistical comparisons were carried out using unpaired t-test. All data 
points correspond to mean ± SEM values. 
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4.2.2.3 PMO 10 (ALUJ+96+120) 
 
 As previously mentioned in Chapter 3, PMO 10 (AluJ+96+120) did not 
promote AluJ cassette exclusion, and hence RNA editing levels did not 
improve in transfected SH-SY5Y cells. PMO 10 (AluJ+96+120) thus acts as a 
further control in our protein experiments to ensure that ADAR2 protein 
expression is not affected by the presence of PMOs. The resulting western 
blot image is depicted in Figure 4.6a. ADAR2 protein expression levels in 
differing conditions were normalised to ADAR2 expression in non-transfected 
cells (Figure 4.6b). Transfection with both ADAR2 and PMO 10 (AluJ+96+120) 
resulted in mean ADAR2 protein expression levels of 24.7 ± 3.7 (Figure 4.6b). 
ADAR2-transfected cells showed mean protein expression of 15.35 ± 0.3. 
Mean ADAR2 protein levels in cultures transfected with PMO 10 
(AluJ+96+120) were measured to be at 1.03 ± 0.8 (Figure 4.6b). Cultures 
transfected with ADAR2 cDNA all showed significantly higher ADAR2 protein 
expression compared to cultures that do not contain a copy of the ADAR2 
cDNA (Figure 4.6b). The difference in ADAR2 protein expression was not 
statistically significant when comparing levels measured between PMO-
transfected and non-PMO-transfected cultures (p>0.05). 
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Figure 4.6 Expression of ADAR2 protein in ADAR2- and PMO 10-transfected cells. 
Figure shows a) representative western blot gel image of SH-SY5Y cells transfected with 
ADAR2 and PMO 10. Actin was used as an internal loading control and to normalise 
expression levels of ADAR2 within each lane; b) Bar graph depicting relative ADAR2 protein 
expression levels transfected with ADAR2 and PMO 10 compared to non-transfected cells.  
Protein samples were run in a 10% Tris-glycine acrylamide gel against BLUeye Prestained 
Protein Ladder and visualised with the Odyssey CLx Imaging System. Images were quantified 
using Image Studio 4.0. 
n=3, ** = p≤0.01, **** = p≤0.0001. Statistical comparisons were carried out using unpaired t-
test. All data points correspond to mean ± SEM values. 
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4.2.2.4 ENDOPORTER 
 
In our PMO experiments, we found that cells co-transfected with PMO 
and ADAR2 cDNA always displayed slightly higher protein expression 
compared to cells only transfected with ADAR2 cDNA. We then investigated 
the possible reason for this effect by examining ADAR2 expression with only 
EndoPorter without including PMOs. The resulting western blot image is 
shown in Figure 4.7a. ADAR2 protein levels were all normalised to the 
expression of ADAR2 protein in non-transfected cells (Figure 4.7b). 
Transfection of cells with both ADAR2 and EndoPorter resulted in mean 
protein expression levels of 31.74 ± 2.5, whilst ADAR2-transfected cells 
showed mean protein ADAR2 levels of 23.04 ± 1.5. Protein levels in cultures 
transfected with EndoPorter were measured to be at 0.95 ± 0.1. Transfection 
of ADAR2 cDNA in cells resulted in significantly higher ADAR2 protein 
expression compared to their non-ADAR2-transfected counterparts. Statistical 
analysis revealed that ADAR protein expression levels between cells co-
transfected with both ADAR2 and EndoPorter were significantly higher than 
levels measured in ADAR2-transfected cells (Figure 4.7b). This contradicts 
the results we previously observed in PMO-transfected cells (Figures 4.4-4.6); 
where cultures that were transfected with both ADAR2 cDNA and PMOs did 
not result in any significant difference in ADAR2 protein expression when 
compared against cultures transfected with ADAR2 cDNA. However, the 
protein expression of ADAR2 in cells transfected with only EndoPorter and 
non-transfected cells did not result in any significant difference among the two 
conditions (Figure 4.7b), consistent with the results previously observed 
(Figures 4.4-4.46). 
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Figure 4.7 Expression of ADAR2 protein in ADAR2- and EndoPorter-transfected cells. 
Figure shows a) representative western blot gel image of SH-SY5Y cells transfected with 
ADAR2 and EndoPorter. Actin was used as an internal loading control and to normalise 
expression levels of ADAR2 within each lane; b) Bar graph depicting relative ADAR2 protein 
expression levels transfected with ADAR2 and EndoPorter compared to non-transfected cells.  
Protein samples were run in a 10% Tris-glycine acrylamide gel against BLUeye Prestained 
Protein Ladder and visualised with the Odyssey CLx Imaging System. Images were quantified 
using Image Studio 4.0. 
n=3, * = p≤0.05, *** = p≤0.001. Statistical comparisons were carried out using unpaired t-test. 
All data points correspond to mean ± SEM values. 
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4.3 DISCUSSION 
 
Based on the results obtained from ADAR2 protein expression analysis 
in SH-SY5Y cells, we can conclude that endogenous ADAR2 protein 
expression in these cells is very low. This is apparent by the very weak 
expression of ADAR2 in cells that were not transfected with the ADAR2 
plasmid, where essentially no signal was detected by the anti-ADAR2 antibody 
(Figures 4.4a-4.7a). In fact, an ADAR2 signal was only picked up in cells 
transfected with 2 µg of ADAR2 plasmid. Transfecting SH-SY5Y cells with the 
ADAR2 plasmid resulted in overall significant increase in ADAR2 protein 
expression compared to non-transfected SH-SY5Y cells (Figures 4.4b-4.7b). 
The endogenous ADAR2 levels measured in non-transfected SH-SY5Y cells 
here corroborates the results we previously observed in Chapter 3. In Chapter 
3, we demonstrated that although PMOs 9 (AluJ+93+117) and 9A 
(AluJ+94+118) were able to result in substantial decrease in ADAR2 RNA 
expression containing the AluJ cassette in SH-SY5Y cells (Figures 3.5 and 
3.6), only a slight (although significant) increase in RNA editing was observed 
in these cells amongst the different concentrations tested (Figures 3.14 and 
3.15). Hence, the marginal increase in RNA editing levels may have been due 
to the low constitutive ADAR2 expression in the cells, where the effects of the 
PMOs on increasing RNA editing have reached saturation. The pool of ADAR2 
expressed in SH-SY5Y cells were simply not high enough to further improve 
RNA editing levels.  
Since RNA editing requires the formation of an RNA duplex caused by 
the base-pairing between intron and exon sequences (Bass, 2002), editing is 
presumed to occur at sites of pre-mRNA transcription prior to splicing (Rueter 
et al., 1999). This implies that the PMOs are meant to interact with ADAR2 at 
the pre-mRNA level before the enzyme is translated into protein. Thus, the 
expression levels of ADAR2 protein should not be altered following 
transfection with PMOs. Transfection of SH-SY5Y cells with PMOs 9 
(AluJ+93+117), 9A (AluJ+94+118), and 10 (AluJ+96+120) did not affect the 
levels of ADAR2 expression when compared to non-transfected cells (Figures 
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4.4-4.6). No significant difference was found in ADAR2 protein expression 
between PMO-transfected cells and non-PMO-transfected cells in ADAR2-
transfected cultures as well (Figures 4.4-4.6). However, EndoPorter-
transfected cells in cultures that express the ADAR2 plasmid displayed a 
significant increase in ADAR2 protein expression compared to cultures that 
were not transfected with EndoPorter (Figure 4.7b). It seems as if the presence 
of the EndoPorter transfection reagent itself, has somehow increased ADAR2 
expression in the cells. 
One of the reasons behind the extremely low endogenous levels of 
ADAR2 protein expressed in SH-SY5Y cells here is the localisation of ADAR2 
itself. ADAR2 has been demonstrated to accumulate in the nucleolus 
(Sansam, Wells, & Emeson, 2003). This occurs in an rRNA-dependent 
manner and can shuttle between subnuclear compartments rapidly (Sansam 
et al., 2003). In fact, the translocation of endogenous ADAR2 to the nucleolus 
from the nucleoplasm corresponds to improved editing of pre-mRNA 
substrates. This illustrates that the nucleolar localisation of ADAR2 describes 
an important mechanism that sequesters editing activity from pre-mRNA 
transcription sites (Sansam et al., 2003). A pool of editing activity is thus 
accessible for response to changes in the expression of potential RNA 
substrates, yet concurrently inhibiting aberrant editing activity by maintaining 
low ADAR2 concentrations in the nucleoplasm (Sansam et al., 2003). In fact, 
cells that were treated with actinomycin D (which induces translocation of 
ADAR2) resulted in a 30% increase in the editing of endogenous ADAR2 pre-
mRNA. However, no significant alteration was found in ADAR2 protein levels 
of NIH 3T3 cells treated with actinomycin D (Sansam et al., 2003), similar the 
results we have obtained here, wherein ADAR protein levels do not change 
even with improved RNA editing following PMO treatment. This suggests that 
the nucleolus acts as a site of functional sequestration for the activity of 
ADAR2 (Sansam et al., 2003). Aside from that, studies carried out in mouse 
neurons also revealed that although RNA editing increases in developing 
mouse brain, the protein levels of both ADAR2 isoforms (ADAR2a and 
ADAR2b) remain consistent and cannot be the major cause for the levels of 
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increased editing (Behm et al., 2017; Filippini et al., 2018b; Wahlstedt et al., 
2009). 
 Considering that ADAR2 is a nuclear protein, we used 
radioimmunoprecipitation assay (RIPA) buffer as a lysis buffer for protein 
extraction, as this buffer is more potent at disrupting nuclear membranes 
compared to other lysis buffers (Ngoka, 2008). However, protein lysates of 
SH-SY5Y cells extracted using RIPA buffer still did not enable us to detect 
sufficient levels of ADAR2 protein. One way to overcome this is by carrying 
out nuclear fractionisation of SH-SY5Y cells, which separates nuclear fractions 
from cytosolic fractions (Suzuki, Bose, Leong-Quong, Fujita, & Riabowol, 
2010). This will consequently be able to result in better constitutive ADAR2 
protein detection in SH-SY5Y cells. 
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CHAPTER 5 REGULATION OF PIN1 AND 
WWP2 DURING RNA EDITING 
5.1 INTRODUCTION 
 
Protein phosphorylation is an important cellular signalling mechanism 
which promotes modifications in protein conformation. One common signalling 
mechanism in cell proliferation and transformation is proline (Pro)-directed 
serine (Ser)/threonine (Thr) phosphorylation (pSer/Thr-Pro) (Lu & Zhou, 
2007). A breakthrough in the insights of the conformational significance of Pro-
directed phosphorylation motifs was the discovery of a unique and conserved 
peptidyl-prolyl cis/trans isomerase (PPIase), Pin1 (protein interacting with 
NIMA (never in mitosis A-1) (Lu, Hanes, & Hunter, 1996). PPIases are 
evolutionary conserved enzymes which catalyse the cis/trans isomerisation of 
peptidyl-prolyl peptide bonds (Lu & Zhou, 2007). Although several PPIases 
have been discovered, currently, Pin1 is the only one known to specifically 
target the pSer/ Thr-Pro sequence (Driver, Zhou, & Lu, 2015). The specificity 
of Pin1 derives from its two-domain structure. The double-trytophan (WW) 
domain binds only to specific pSer/Thr-Pro motifs, while the PPIase domain 
catalyses the conformational change (Driver et al., 2015) (Figure 5.1).  
The identification of Pin1 resulted in the hypothesis of a new signalling 
mechanism, by which Pin1 regulates substrate post-phosphorylation 
conformation to further control protein function (Ranganathan, Lu, Hunter, & 
Noel, 1997). Ensuing studies showed that Pin1-catalysed conformational 
regulation has a significant impact on many vital proteins involved in cell 
growth regulation, genotoxic and other stress responses, immune response, 
germ cell development, neuronal differentiation, and survival (Lu & Zhou, 
2007).  
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Pin1 has risen as a novel molecular timer that regulates its numerous 
targets at various steps of a given cellular process to synergistically control 
the amplitude and duration of a cellular response or process. Essentially, Pin1 
is highly regulated at numerous levels and its deregulation plays a role in a 
rising number of pathological conditions, such as cancer, Alzheimer’s disease 
(AD), ageing, asthma, and microbial infection (Lu & Zhou, 2007). In cancers, 
Pin1 was found to be overexpressed in human cancer tissues, including 
breast, prostate, lung, and colon cancer (Bao et al., 2004). Pin1 promotes 
oncogenesis by activating various oncogenes or growth enhancers and by 
inactivating a large number of tumour suppressors or growth inhibitors (T. H. 
Lee, Pastorino, & Lu, 2011). In contrast, Pin1 plays a protective role against 
AD, where reduced Pin1 expression correlates with increased vulnerability 
during neurodegeneration. Knockdown of Pin1 expression in mice results in 
an AD type age-dependent neurodegeneration, causing increased 
phosphorylated tau levels and increased APP pathogenic processing and 
insoluble β-amyloid (Liou et al., 2003). The same can also be found in ageing, 
where Pin1-deficient mice eventually display extensive premature ageing 
phenotypes compared to wild-type mice, such as reduced body size, retina 
atrophy, motor coordination and behavioural defects, and accelerated 
telomere loss (T. H. Lee, Pastorino, et al., 2011). Recent studies demonstrated 
that phosphorylation-independent prolyl isomerisation functions as a 
molecular timer to modulate several biological and pathological processes, 
Figure 5.1 Two-domain structure of Pin1. 
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namely cell signalling, ion channel gating, gene expression, and phage 
infection (Lu & Zhou, 2007).  
Pin1 has been shown to interact with ADAR2 as a positive regulator 
essential for the nuclear localisation and stability of ADAR2, where it binds to 
the amino-terminus of ADAR2 in a phosphorylation dependent manner. 
ADAR2 protein is more labile and will mislocalise to the cytoplasm when Pin1 
is absent, resulting in its inability to edit pre-mRNAs and thus decreasing Q/R 
and R/G site editing in GluA2 transcripts. Hence, Pin1 is a positive regulator 
of ADAR2 editing activity (Marcucci et al., 2011).  
Protein ubiquitination is a post-translational modification that regulates 
various cellular processes such as protein turnover, trafficking, sub-cellular 
localisation, transcriptional function, and DNA repair mechanisms (Kerscher, 
Felberbaum, & Hochstrasser, 2006). Ubiquitin conjugation comprises a series 
of events sequentially catalysed by E1 (ubiquitin-activating), E2 (ubiquitin-
conjugating), and E3 (ubiquitin ligase) enzymes. E3 ligases are sub-divided 
into RING type and HECT domain ligases (Chantry, 2011). Within the HECT 
E3 sub-division contains a small group known as the Nedd4 superfamily. 
Nedd4 E3s contain a HECT ligase domain as well as a membrane-targeting 
Ca2+/phospholipid-binding C2 and up to four WW (double tryptophan) 
domains. WW domains interact with PPXY, phosphor-Ser-Pro and Pro-Arg 
motifs. They are mainly responsible for the recruitment of specific target 
substrates. These features make Nedd4 E3s not only functionally diverse, but 
also makes them a suitable therapeutic target by disrupting specific substrate 
recruitment (Chantry, 2011).  
Although several specific substrates have been identified for individual 
Nedd4 family members (Rotin & Kumar, 2009), their biological and 
pathological roles are still not well understood. However, there have been 
recent reports that feature novel functional roles for one member of the Nedd4 
family, the WWP2 E2 ligase. Knockout studies reveal main developmental 
roles for WWP2 in craniofacial development and chondrogenesis, while 
molecular approaches uncovered two new WWP2 substrates, PTEN and 
Smads, that are associated with critical oncogenic signalling pathways 
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responsible for cell survival and epithelial-to-mesenchymal transition (EMT), 
respectively (Chantry, 2011). Additionally, the characterisation of two new 
WWP2 isoforms, WWP2-N and WWP2-C, highlights novel intra-molecular 
mechanisms that control WWP2 biological activity (Soond & Chantry, 2011). 
WWP2 has also been identified as a negative regulator of ADAR2 activity, 
where increased WWP2 expression results in reduced ADAR2 protein levels 
(Marcucci et al., 2011).  
Since both Pin1 and WWP2 were found to regulate GluA2 Q/R site 
editing in an opposing manner (Marcucci et al., 2011), work here was carried 
out to investigate whether increased RNA editing in SH-SY5Y cells (which was 
attained through transfections with PMO 9 (AluJ+93+117) and 9A 
(AluJ+94+118)) through the exclusion of the AluJ cassette plays a role in the 
regulation of both Pin1 and WWP2 gene expression. Furthermore, whilst 
WWP2 negatively regulates RNA editing, it is not known how a reduction in 
RNA editing (due to steric hindrance of the Q/R editing site) can affect the 
expression of either regulatory protein. Hence, we also studied how 
transfecting SH-SY5Y cells with PMOs that inhibit RNA editing influence both 
Pin1 and WWP2 gene expression. Additionally, since Pin1 expression levels 
were altered at the mRNA level, we also attempted to measure the 
expressional changes in Pin1 protein levels following PMO transfection. 
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5.2 RESULTS 
5.2.1 VALIDATION OF RT-QPCR PRIMER TARGET GENES 
 
Reverse transcriptase-quantitative PCR (RT-qPCR) was the method 
utilised in this chapter to study the expression levels of Pin1 and WWP2 in SH-
SY5Y cells. Prior to carrying out qPCRs on transfected cells, the primers used 
for the PCR were first validated to ensure target gene specificity and efficiency. 
Primer sequences for Pin1 (PrimerBank ID: 336285452c1) and WWP2 
(PrimerBank ID: 5902156a1) were obtained from PrimerBank 
(https://pga.mgh.harvard.edu/primerbank/) (Figure 5.2). PrimerBank primers 
are compatible with SYBR Green I detection methods (as described in Section 
2.11) and primers were designed based on an algorithm previously used to 
design oligonucleotide probes for DNA microarrays (Spandidos, Wang, Wang, 
& Seed, 2009). All primer sequences from this database have been validated 
through qPCR as well as sequencing and agarose gel electrophoresis (X. 
Wang, Spandidos, Wang, & Seed, 2012). An agarose gel electrophoresis was 
performed on PCR products of SH-SY5Y cells to ensure that no multiple PCR 
product bands and primer dimers were formed. Distinct PCR products of the 
expected sizes were detected using both sets of primers (Figure 5.3). 
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Figure 5.2 Primer sequences and PrimerBank IDs. 
Figure shows the sequences and PrimerBank IDs for Pin1 (left) and WWP2 (right) obtained 
from https://pga.mgh.harvard.edu/primerbank/. 
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Figure 5.3 Validation of Pin1 and WWP2 RT-qPCR primers. 
a) Gel image RT-PCR products of control SH-SY5Y cells amplified with Pin1 primers. The 
yellow arrow denotes the expected band size for Pin1 (232 bp). b) Gel image RT-PCR products 
of control SH-SY5Y cells amplified with WWP2 primers. The yellow arrow denotes the expected 
band size for WWP2 (103 bp).  
 
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualised 
under UV light using a GELDOC system.  
232 bp
103 bp
a.
b.
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5.2.2 QUANTIFYING PIN1 AND WWP2 EXPRESSION FOLLOWING 
EXCLUSION OF THE ALUJ CASSETTE 
 
Once the primer sets for Pin1 and WWP2 were validated, the primers 
were then utilised for qPCR experiments. We investigated whether a reduction 
in AluJ cassette incorporation in SH-SY5Y cells influences the expression of 
Pin1 and WWP2 following transfection of PMOs 9 (AluJ+93+117), 9A 
(AluJ+94+118) and 10 (AluJ+96+120). qPCRs were performed on cells that 
have been transfected with 5 µM of each PMO, with β-actin used as a 
housekeeping reference gene. Transfection of SH-SY5Y cells with 5 µM of 
PMO 9 (AluJ+93+117) increased the level of Pin1 mRNA (11.52 ± 2.1 fold-
change vs cells only) (Figure 5.4a) while the mRNA levels of WWP2 were 
reduced (0.41 ± 0.08 fold-change vs cells only) (Figure 5.4b). Similar results 
were observed with 5 µM PMO 9A-transfected cells, where an increase in Pin1 
mRNA expression was detected (6.26 ± 0.7 fold-change vs cells only) (Figure 
5.3c), whereas a downregulation in WWP2 mRNA expression was observed 
(0.17 ± 0.04 fold-change vs cells only) (Figure 5.4d). Transfections with 5 µM 
of PMO 10 (AluJ+96+120), however, did not result in any significant fold-
change in both Pin1 (0.81 ± 0.02 fold-change vs cells only) (Figure 5.4e) and 
WWP2 expression (0.82 ± 0.3 fold-change vs cells only) (Figure 5.4f) 
compared to control cells. The change in both Pin1 and WWP2 expression 
here are consistent with the results obtained in Chapter 3, where an increase 
in RNA editing levels caused by a reduction in AluJ cassette incorporation 
plays a role in the regulation of both Pin1 and WWP2 expression levels. Pin1 
mRNA expression showed significant upregulation following PMO 9 
(AluJ+93+117) and 9A (AluJ+94+118) treatment while WWP2 mRNA 
expression was significantly downregulated.  
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Figure 5.4 Pin1 and WWP2 expression in SH-SY5Y cells. 
RT-qPCR analysis of mRNA isolated from cells transfected with 5 µM of PMOs 9, 9A and 10. 
Bar graphs a and b show expression levels of Pin1 and WWP2 in PMO 9-transfected cells; 
bar graphs c and d show expression levels of Pin1 and WWP2 in PMO 9A-transfected cells; 
and bar graphs e and f show expression levels of Pin1 and WWP2 in PMO 10-transfected 
cells. 
Expression of Pin1 and WWP2 was assessed using the LightCycler 480 (Roche) and 
reactions were performed using the LightCycler SYBR Green I Mastermix (Roche). The 
expression levels of β-actin were used as a reference gene. The gene expression levels were 
defined based on the threshold cycle (Ct), and relative expression levels were calculated using 
the 2-DDCt method. Measurements were made from three separate transfections in triplicate. 
n=3-4, * = p≤0.05, ** = p≤0.01. Statistical comparisons were carried out using an unpaired t-
test. All data points correspond to mean ± SEM values.  
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5.2.3 DISRUPTING Q/R SITE EDITING IN SH-SY5Y CELLS 
 
In this section, PMOs that were designed to disrupt the internal 
secondary structure of GluA2 RNA via steric hindrance were utilised. These 
PMOs are therefore able to inhibit GluA2 Q/R site editing in SH-SY5Y cells, 
which resembles low editing efficiency in motor neurons of ALS patients (Kwak 
& Kawahara, 2005). Since the downstream effects of disrupted Q/R site editing 
in ALS is still largely unknown, using PMOs to sterically inhibit editing could 
be used to study regulatory changes at the molecular level, thus giving a better 
understanding on the pathophysiology of ALS.  
Two PMOs were used for these sets of experiments: first, PMO E1 
(GRIA2+279+308), which covers the double-stranded region located around 
the Q/R site of GluA2; second, PMO 1 (GRIA2+284+308), which is used as a 
control PMO as it has previously been shown to have no effect on RNA editing 
levels (Chaytow, 2015). Both PMOs were designed to complement the Exon 
Complementary Sequence located in intron 11 of GRIA2 (Figure 5.5). SH-
SY5Y cells were transfected with 5 µM of PMOs E1 and 1 for 24 hours, and 
its effects on both AluJ cassette inclusion and RNA editing, as well as Pin1 
and WWP2 expression, were assessed.  
  
Intron 11Exon 11
PMO 1 (GRIA+284+308)
PMO E1 (GRIA+279+308)
Figure 5.5 Schematic diagram showing the PMO binding positions on intron 11 of 
GRIA2. 
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5.2.3.1 EFFECT OF Q/R SITE EDITING DISRUPTION ON ALUJ 
INSERTION AND RNA EDITING 
 
 AluJ cassette inclusion in RT-PCR products of cells treated with PMOs 
E1 (GRIA2+279+308) and 1 (GRIA2+284+308) were quantified to determine 
whether transfection with these PMOs will result in any changes in exon 
skipping levels. Figure 5.6 shows the results of the RT-PCR. As expected, 
treatment with 5 µM of both PMO E1 (GRIA2+279+308) and PMO 1 
(GRIA2+284+308) did not result in any reduction in AluJ cassette inclusion 
levels compared to control cells (p>0.05). 
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Figure 5.6 The effect of PMO E1 and PMO 1 on AluJ insertion in SH-SY5Y cells.  
Figure shows a sample gel image of a) RT-PCR products of SH-SY5Y cells transfected with 5 
µM of PMO E1 (left) and a bar graph depicting AluJ cassette inclusion percentages (right) and 
b) RT-PCR products of SH-SY5Y cells transfected with 5 µM of PMO 1 (left) and a bar graph 
depicting AluJ cassette inclusion percentages (right). 
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of exon-skipped transcripts (127 bp, 
yellow arrow) against exon-including transcripts (247 bp, red arrow).  
n=4. Statistical comparisons were carried out using unpaired t-test. All data points correspond 
to mean ± SEM values. 
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Since PMO E1 (GRIA2+279+308) was designed to disrupt Q/R site 
editing in the GluA2 subunit, the editing levels in cells transfected with this 
PMO significantly decreased to 41.53 ± 1.5% when compared to control cells 
(Figure 5.7a). RNA editing levels in cells transfected with PMO 1 
(GRIA2+284+308) remained approximately the same compared to non-
transfected cells (p>0.05) (Figure 5.7b). This is in agreement with previous 
findings (Chaytow, 2015). 
 
 
 
a.
b.
Figure 5.7 The effect of PMO E1 and PMO 1 on RNA editing in SH-SY5Y cells.  
Figure shows a sample gel image of a) BbvI digest products of SH-SY5Y cells transfected 
with 5 µM of PMO E1 (left) and a bar graph depicting Q/R site editing percentages in SH-
SY5Y cells (right) and b) BbvI digest products of SH-SY5Y cells transfected with 5 µM of 
PMO 1 (left) and a bar graph depicting Q/R site editing percentages in SH-SY5Y cells (right). 
Gels were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of edited transcripts (323 bp, red 
arrow) against unedited transcripts (238 bp and 85 bp, yellow arrow).  
n=4, * = p≤0.05. Statistical comparisons were carried out using unpaired t-test. All data points 
correspond to mean ± SEM values. 
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5.2.3.2 EFFECT OF Q/R SITE EDITING DISRUPTION ON PIN1 AND 
WWP2 EXPRESSION 
 
The mRNA levels of Pin1 and WWP2 were then evaluated in PMO E1- 
and PMO 1-transfected cells. Pin1 mRNA levels in PMO E1-transfected cells 
showed no significant difference in expression compared to control cells (1.74 
± 0.4 fold-change vs cells only) (Figure 5.8a), even though a reduction in RNA 
editing levels were observed. WWP2 mRNA levels did, however, significantly 
increase following PMO E1 (GRIA2+279+308) transfection (2.01 ± 0.2 fold-
change vs cells only) (Figure 5.8b). Since PMO 1 (GRIA2+284+308) did not 
have any effect on RNA editing levels, no difference in both Pin1 (1.44 ± 0.2 
fold-change vs cells only) and WWP2 (1.19 ± 0.2 fold-change vs cells only) 
expression were observed in transfected cells compared to controls (Figures 
5.8c and 5.8d). 
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Figure 5.8 Pin1 and WWP2 expression in PMO E1- and PMO 1-transfected SH-SY5Y cells. 
RT-qPCR analysis of mRNA isolated from cells transfected with 5 µM of PMO E1 and PMO 1. 
Bar graphs a and b show expression levels of Pin1 and WWP2 in PMO E1-transfected cells; 
bar graphs c and d show expression levels of Pin1 and WWP2 in PMO 1-transfected cells. 
Expression of Pin1 and WWP2 was assessed using the LightCycler 480 (Roche) and reactions 
were performed using the LightCycler SYBR Green Mastermix (Roche). The expression levels 
of β-actin were used as a reference gene. The gene expression levels were defined based on 
the threshold cycle (Ct), and relative expression levels were calculated using the 2-DDCt method. 
Measurements were made from three separate transfections in triplicate. 
n=4, ** = p≤0.01. Statistical comparisons were carried out using unpaired t-test. All data points 
correspond to mean ± SEM values.  
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5.2.4 OVEREXPRESSION OF ADAR2 IN SH-SY5Y CELLS 
 
A study carried out by Hideyama and colleagues (2010) demonstrated 
that ADAR2-knockout mice resulted in death of motor neurons. Furthermore, 
ADAR2 expression was also found to be downregulated in motor neurons of 
ALS patients, indicating that ADAR2 downregulation is involved in the 
pathology of neuronal death in ALS (Takuto Hideyama et al., 2012). Hence, 
restoration of ADAR2 activity could be a possible therapeutic strategy for ALS, 
where gene delivery of ADAR2 was shown to prevent ALS phenotype 
progression (Yamashita et al., 2013). HeLa cells transfected with ADAR2 
cDNA showed a significant increase in RNA editing levels compared to non-
ADAR-transfected HeLa cells (Chaytow, 2015). Here, we have transfected 
SH-SY5Y cells with an ADAR2 cDNA plasmid (provided by the O’Connell lab) 
to identify whether RNA editing levels can be improved, and how RNA editing 
activity in ADAR2-transfected cells affects the expression of both Pin1 and 
WWP2. 
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5.2.4.1 EFFECT OF ADAR2 OVEREXPRESSION ON ALUJ 
CASSETTE INCLUSION AND RNA EDITING 
 
The delivery of ADAR2 cDNA to motor neurons has been shown to 
restore its activity to a level that is sufficient for improved Q/R site editing 
(Yamashita et al., 2013). We then tested whether increasing ADAR2 
expression in SH-SY5Y cells can increase RNA editing levels. SH-SY5Y cells 
were transfected with 2 µg of ADAR2 plasmid over a period of 24 hours. 
Overexpression of ADAR2 cDNA in SH-SY5Y cells resulted in the expression 
of ADAR2 without the AluJ cassette, whist control samples displayed typical 
AluJ cassette levels (Figure 5.9). 
 
Figure shows a sample gel image of RT-PCR products of SH-SY5Y cells transfected with 2 
µg of ADAR2 plasmid (left) and a bar graph depicting AluJ cassette inclusion percentages in 
SH-SY5Y cells transfected with 2 µg of ADAR2 plasmid for 24 hours compared to non-
transfected cells (right). 
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of exon-skipped transcripts (127 bp, 
yellow arrow) against exon-including transcripts (247 bp, red arrow).  
n=4, **** = p≤0.0001. Statistical comparisons were carried out using unpaired t-test. All data 
points correspond to mean ± SEM values. 
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Figure 5.9 The effect of ADAR2 overexpression on AluJ insertion in SH-SY5Y cells. 
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In order to examine the effects of ADAR2 overexpression on RNA 
editing, a BbvI RNA editing digest was then performed. However, no 
improvement in RNA editing levels were observed in ADAR2-transfected cells 
when compared to controls (103.2 ± 2.5% vs cells only) (p>0.05) (Figure 5.10). 
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Figure 5.10 The effect of ADAR2 overexpression on RNA editing in SH-SY5Y cells. 
Figure shows a sample gel image of BbvI digest products of SH-SY5Y cells transfected with 2 
µg of ADAR plasmid (left) and a bar graph depicting Q/R site editing percentages in SH-SY5Y 
cells in SH-SY5Y cells transfected with 2 µg of ADAR2 plasmid for 24 hours compared to non-
transfected cells (right). 
Gels were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” denotes 
negative control. Sample gel images show the intensity of edited transcripts (323 bp, red arrow) 
against unedited transcripts (238 bp and 85 bp, yellow arrow).  
n=3-4. Statistical comparisons were carried out using unpaired t-test. All data points 
correspond to mean ± SEM values. 
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5.2.4.2 EFFECT OF ADAR2 OVEREXPRESSION ON PIN1 AND 
WWP2 REGULATION 
 
Next, we proceeded to examine whether there were any changes in 
both Pin1 and WWP2 expression in ADAR2-transfected cells when compared 
to controls. Since no improvement in RNA editing levels were observed in 
ADAR2-transfected cells, we examined whether the expression of these 
genes would be affected by the overexpression of ADAR2 protein. Therefore 
an RT-qPCR was performed to evaluate the underlying cause behind the lack 
in RNA editing improvement. Figure 5.11 shows the outcomes of the RT-
qPCR. In SH-SY5Y cells, overexpression of ADAR2 did not result in any 
changes in Pin1 mRNA levels (1.09 ± 0.39 fold-change vs cells only) (Figure 
5.11a). Similarly, no significant difference in WWP2 mRNA levels were 
observed between the two sets of conditions (0.83 ± 0.14 fold-change vs cells 
only) (Figure 5.11b) The results obtained indicated that Pin1 and WWP2 
regulation is indeed influenced by RNA editing in cells, and not necessarily 
directly caused by the expression of a more catalytically active ADAR2 
isoform. 
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Figure 5.11 Pin1 and WWP2 expression in ADAR2-transfected SH-SY5Y cells. 
RT-qPCR analysis of mRNA isolated from cells transfected with 2 µg of ADAR2 plasmid. 
Expression of Pin1 and WWP2 was assessed using the LightCycler 480 (Roche) and 
reactions were performed using the LightCycler SYBR Green Mastermix (Roche). The 
expression levels of β-actin were used as a reference gene. The gene expression levels were 
defined based on the threshold cycle (Ct), and relative expression levels were calculated 
using the 2-DDCt method. Measurements were made from three separate transfections in 
triplicate. 
n=3-4. Statistical comparisons were carried out using unpaired t-test. All data points 
correspond to mean ± SEM values.  
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5.2.5 PIN1 PROTEIN EXPRESSION IN SH-SY5Y CELLS 
 
 The RT-qPCR results obtained in Sections 5.2.1 to 5.2.4 describes the 
regulatory expression of Pin1 mRNA in SH-SY5Y cells in PMO-transfected 
cells. Cells that were transfected with PMO 9 (AluJ+93+117) showed 
upregulation in Pin1 mRNA expression compared to non-transfected cells 
(Figure 5.4a), whilst PMO 10 (AluJ+96+120) did not have any effect on Pin1 
mRNA expression (Figure 5.4e). Hence, we decided to determine whether any 
alterations of Pin1 expression at the protein level will be observed following 
transfection with PMO 9 (AluJ+93+117) and PMO 10 (AluJ+96+120). SH-
SY5Y cells were transfected with 2 µM PMO for 48 hours, after which cells 
were lysed for protein extracts and western blotting. 10% pre-cast Bis-Tris 
SDS-PAGE gels were used for the detection of Pin1 protein in cell lysates. 
Blots were then incubated with 1:100 concentration of anti-Pin1 primary 
antibody for the detection of Pin1 signals in the cells. Primary antibody 
incubation was carried out overnight at 4°C.  
The protein expression of Pin1 in PMO-transfected cells was then 
normalised to endogenous Pin1 levels of SH-SY5Y cells. Figure 5.12a depicts 
the resulting western blot image of cells transfected with PMO 9 
(AluJ+93+117). Transfection with PMO 9 (AluJ+93+117) did not result in any 
significant change in mean Pin1 protein expression compared to non-
transfected cells (0.75±0.08 vs cells only) (Figure 5.12b). This is in contrast 
with the fold-change in Pin1 mRNA levels observed in Figure 5.4a, where a 
significant increase in Pin1 mRNA expression was measured. The mean 
protein expression in PMO 10-transfected cells was then compared to non-
transfected cells. The resulting western blot image of PMO 10-transfected 
cells is shown in Figure 5.13a. In line with results we observed in Figure 5.3e, 
no significant difference in Pin1 protein expression was measured amongst 
PMO 10-transfected and non-transfected cells (0.65±0.07 vs cells only) 
(Figure 5.13b). 
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Figure 5.12 Expression of Pin1 protein in PMO 9-transfected cells. 
Figure shows a) representative western blot gel image of SH-SY5Y cells transfected with 2 µM 
PMO 9. Actin was used as an internal loading control and to normalise expression levels of Pin1 
within each lane; b) Bar graph depicting relative Pin1 protein expression levels transfected with 
PMO 9 compared to non-transfected cells.  
Protein samples were run in a 10% pre-cast Bis-Tris acrylamide gel against BLUeye Prestained 
Protein Ladder and visualised with the Odyssey CLx Imaging System. Images were quantified 
using Image Studio 4.0. 
n=3. Statistical comparisons were carried out using unpaired t-test. All data points correspond 
to mean ± SEM values. 
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Figure 5.13 Expression of Pin1 protein in PMO 10-transfected cells. 
Figure shows a) representative western blot gel image of SH-SY5Y cells transfected with 2 
µM PMO 10. Actin was used as an internal loading control and to normalise expression levels 
of Pin1 within each lane; b) Bar graph depicting relative Pin1 protein expression levels 
transfected with PMO 10 compared to non-transfected cells.  
Protein samples were run in a 10% pre-cast Bis-Tris acrylamide gel against BLUeye 
Prestained Protein Ladder and visualised with the Odyssey CLx Imaging System. Images 
were quantified using Image Studio 4.0. 
n=3. Statistical comparisons were carried out using unpaired t-test. All data points correspond 
to mean ± SEM values. 
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5.3 DISCUSSION 
5.3.1 HOW IMPROVING AND DISRUPTING Q/R SITE EDITING 
AFFECTS PIN1 AND WWP2 EXPRESSION 
 
At the outset of this study, we had hypothesised that alterations in RNA 
editing levels induced by PMO transfection in SH-SY5Y cells could be 
correlated to the levels of both Pin1 and WWP2 expression. Any downstream 
effects on GluA2 function is therefore considered to be the consequence of 
this ADAR2-caused regulation of Pin1 and WWP2 (Marcucci et al., 2011). A 
study carried out by (Marcucci et al., 2011) has demonstrated that ADAR2 
protein levels and catalytic activity are regulated correlatively by Pin1 in a 
positive fashion, whilst WWP2 is negatively regulated (Figure 5.14). The 
results of our RT-qPCRs have shown that this is indeed the case for both PMO 
9- and PMO 9A-transfected cells (Figure 5.4), as the gene expression of both 
Pin1 and WWP2 showed regulatory alteration as a result of improved RNA 
editing (as discussed in Chapter 3). As expected, no change in Pin1 and 
WWP2 expression was observed in PMO 10-transfected cells (Figure 5.4), 
further confirming that an increase in ADAR2 catalytic activity (hence also 
RNA editing) is required to induce any regulatory expressional changes in Pin1 
and WWP2.  
The data presented in section 5.2.2 shows that there is significant 
upregulation in Pin1 levels in PMO 9 and 9A-transfected cells, which is likely 
as the result of increased ADAR2 catalytic activity, indirectly caused by 
decreased AluJ cassette inclusion levels. Conversely, WWP2 levels were 
significantly downregulated in these cells. Pin1 post-translationally regulates 
ADAR2-specific editing, and so the interaction between these two proteins is 
dependent on the phosphorylation of a Ser/Thr-Pro motif located in the N-
terminal region of ADAR2 (Marcucci et al., 2011). It is possible that a 
developmentally-timed phosphorylation event stimulates an ADAR2 
conformational change, which in turn prompts its stabilisation in the nucleus 
(Behm et al., 2017). Hence, in the case of PMO 9 and 9A-transfected cells, 
the high relative expression levels of Pin1 in these cells may have triggered 
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ADAR2 stabilisation which led to the increase in RNA editing (Figure 5.14). It 
is still crucial to further understand how this feedback mechanism operates – 
is the PMO transfection itself causing the increase in Pin1 expression, thus 
leading to the phosphorylation and transport of ADAR2 in the nucleus, eliciting 
RNA editing? Or is the increased expression of Pin1 simply due to the 
presence of a more catalytically active ADAR isoform? As aforementioned, 
WWP2 has been reported to negatively regulate ADAR2 activity and Q/R site 
editing. Since PMO 9 and 9A-transfected cells have shown increased RNA 
editing levels, the mRNA levels of WWP2 are relatively lower in these cells 
compared to controls (Figure 5.4). WWP2 triggers ADAR2 degradation by 
poly-ubiquitination (Marcucci et al., 2011). However, when WWP2 is unable to 
bind to ADAR2, a high level of accumulated ADAR2 in the cytoplasm is 
observed (Marcucci et al., 2011). The localisation of ADAR2 into the nucleus, 
which results in increased RNA editing (Sansam et al., 2003), is reported to 
be stabilised by Pin1 (Marcucci et al., 2011). Hence, it would be worth looking 
into the localisation of ADAR2, Pin1, and WWP2 following PMO transfection 
in the cells. This can further clarify how the levels and localisation of WWP2 
plays a role in the translocation of ADAR2 between the cytoplasm and the 
nucleus.  
When transfected with PMO E1 (GRIA2+279+308), a reduction in RNA 
editing levels was observed (Figure 5.7b), which in turn resulted in a significant 
increase in WWP2 mRNA expression compared to control cells (Figure 5.8b). 
No significant difference was seen in Pin1 mRNA levels in these cells (Figure 
5.8a). Pin1 catalytic activity is essential in order to localise and stabilise 
ADAR2 in the nucleus. ADAR2 becomes unstable and will pool in the 
cytoplasm when Pin1 is absent, causing the interaction of ADAR2 with WWP2, 
resulting in its subsequent degradation by the proteasome (Marcucci et al., 
2011). This directly results in the reduction of both Q/R site and R/G site editing 
in the GluA2 subunit. The results presented in Section 5.2.3.1 confirms, in part, 
that a regulatory feedback mechanism may exist between WWP2 expression 
and Q/R site editing activity. This decrease in Q/R site editing in the cells may 
have been due to the cytoplasmic accumulation of ADAR2 in the cells, making 
ADAR2 accessible for degradation by WWP2 (Figure 5.14). Cytoplasmic 
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mature ADAR mRNAs or miRNAs are no longer substrates for A-to-I editing, 
making them more susceptible to WWP2 degradation (Behm et al., 2017). 
Although PMO E1 (GRIA2+279+308) has been designed to sterically hinder 
Q/R site editing in these cells, there may be another regulatory mechanism 
involved in the disruption pathway that has somehow caused ADAR2 to be 
aggregated in the cytoplasm. Most ADAR2 substrates must be edited in their 
premature nuclear transcript state since the editing reaction requires the 
presence of intronic sequences for the formation of necessary double-
stranded structures (Behm et al., 2017), which have been disrupted by the 
actions of PMO E1 (GRIA2+279+308). Ultimately, further experiments need to 
be performed to determine the localisation of WWP2 in cells after transfection 
with PMO E1 (GRIA2+279+308).  
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Figure 5.14 Possible regulatory mechanisms behind Pin1 and WWP2 expression 
following PMO transfection and altered RNA editing. 
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One of the positive regulators of ADAR2 localisation is importin-α4 
(Behm et al., 2017). Importins are a type of karyopherin that transports protein 
molecules into the nucleus by binding to the nuclear localisation sequence 
(NLS) (Görlich, Prehn, Laskey, & Hartmann, 1994). It is also worth studying to 
find out whether expression of importin-α4 is affected by PMO treatment. 
Essentially, using PMO E1 (GRIA2+279+308) in SH-SY5Y cells is ideal for the 
study of downstream effects of acutely disrupting Q/R site editing, considering 
that there are still various factors and regulatory processes involved in the 
expression and function of both negative and positive regulators of ADAR2 
transport, and subsequently RNA editing efficiency. Would the expression 
levels of WWP2, or Pin1, have any direct effects on GluA2 subunit trafficking 
into the synapse? This would ultimately aid in the understanding as to how 
and why the reduction in Q/R site editing occurs in ALS motor neurons in the 
first place, and possibly allow us to discover more therapeutic targets for 
disease treatment. Similarly, the same regulatory processes can also be 
studied by utilising PMOs that enhance Q/R site editing, therefore allowing 
insights into the downstream effects of PMO treatment for ALS. 
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5.3.2 EFFECT OF ADAR OVEREXPRESSION ON PIN1 AND WWP2 
LEVELS 
 
One possible strategy of gene therapy for ALS is by enhancing ADAR2 
activity in mouse motor neurons by using adeno-associated virus serotype 9 
(AAV9) as a vector to deliver the ADAR2 gene (Yamashita et al., 2013). The 
results obtained in this study demonstrated the restoration of ADAR2 activity 
in ADAR-deficient anterior horn cells (AHCs) of ADAR2 knockout mice (AR2) 
caused exogenous ADAR2 expression to a level that is satisfactory to edit Q/R 
sites of essentially all GluA2 mRNAs expressed in AR2 mice, which 
subsequently prevented progressive motor dysfunction (Yamashita et al., 
2013). The motor neurons of AR2 mice were notably rescued from death 
through the normalisation of TDP-43 expression (Yamashita et al., 2013). 
Accordingly, we hypothesised that by transfecting SH-SY5Y cells with a copy 
of the ADAR2 cDNA, Q/R site editing in these cells will be restored and 
possibly increased. However, the opposite result was observed. 
Although increasing ADAR2 levels in SH-SY5Y cells completely altered 
the detection of certain ADAR2 splice variants in the cells (Figure 5.9) 
(presumably due to overexpression of the ADAR2 cDNA), there was no 
increase observed in RNA editing levels compared to non-transfected cells 
(Figure 5.10). It is interesting, then, that whilst the more catalytically-active 
ADAR2 isoform was conferred by the transient overexpression of ADAR2, for 
some reason, this was translated differentially in terms of Q/R site editing 
levels observed in ADAR2-transfected cells.  
Seeing as transfection with different PMOs resulted in altered 
expression levels of Pin1 and WWP2 (as discussed in Sections 5.2.2 and 
5.2.3), we proceeded to examine if Pin1 and WWP2 levels were altered in 
ADAR2-transfected cells. RT-qPCR analysis has revealed how Pin1 and 
WWP2 levels show similar expressional profiles in both ADAR2-transfected 
and control cells. The results here somewhat corroborate the editing levels 
observed in Figure 5.10, which explains that the lack of improvement in Q/R 
site editing is consistent with the unaffected levels of both Pin1 and WWP2 
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mRNA. This also further supports the RT-qPCR results of PMO 10-transfected 
cells (Figures 5.4e and 5.4f), whereby unvarying AluJ splicing and subsequent 
unaltered ADAR2 catalytic activity does not have any regulatory effect on Pin1 
and WWP2 levels.  
ADARs deaminate adenosines mainly found in base-paired RNA. The 
ability of ADARs to deaminate substrates is due to the fact that the dsRNA-
binding domains (dsRBDs) of ADARs essentially recognise target RNAs by 
shape instead of sequence (Deffit & Hundley, 2016). Initial biochemical 
experiments have identified that binding of ADARs to dsRNA and editing are 
two distinct events (Kallman, Sahlin, & Ohman, 2003). The immediate 
structure that surrounds the editing site is crucial, whereby a purine located 
opposite to the binding site has a negative effect on both editing selectivity and 
efficiency (Kallman et al., 2003). In the pre-mRNA of GluA2, the unique 
position of the second dsRBD of ADAR2 (located near two bulged bases 
adjacent to the R/G editing site), may contribute to the adenine selected for 
editing (Nishikura, 2010). This editing-site selectivity of ADAR1 and ADAR2 
may be mediated by functional interactions between monomers of ADAR1 and 
ADAR2, since these interactions can possibly position specific adenosine 
residues relative to the ADAR catalytic center (Nishikura, 2010). Aside from 
that, studies in the neurons of developing mice have shown that although 
editing increases during development, the rise in Q/R site editing does not 
correlate with ADAR2 expression, which have been found to be constant 
throughout development (Wahlstedt et al., 2009). It seems that simply 
increasing ADAR2 expression alone cannot improve RNA editing levels. 
Instead, other factors, such as regulatory and competing proteins, RNA 
helicases, or the local RNA environment itself may be the underlying cause 
behind editing level regulation (Licht, Kapoor, Mayrhofer, & Jantsch, 2016).  
Many genes display “isoform switching” under experimental or 
physiological perturbation (Trapnell et al., 2013). However, the levels of 
ADAR1-dependent editing and transcript expression were found to be 
uncorrelated (I. X. Wang et al., 2013). For instance, IKZF3, a transcription 
factor that regulates proliferation and differentiation of B lymphocytes, 
demonstrated increased expression levels following ADAR1 knockdown, whist 
 175 
its editing levels decreased. Conversely, both the editing and expression 
levels of CENPN (a gene essential for kinetochore assembly) decreased after 
ADAR1 knockdown. The position and number of edited sites in the transcript 
did not correspond to expressional changes ensuing ADAR1 knockdown. 
These results indicate that ADAR proteins affect editing and gene expression 
independently (I. X. Wang et al., 2013).  
A change in the conformation of ADAR2 may also explain the results 
we obtained. Pin1 functions to isomerise a specific proline from the cis to trans 
conformation or vice versa (Ranganathan et al., 1997). Nearly all biological 
processes necessitate proline to be in the trans conformation. However, when 
a protein undergoes translation, the choice in conformation is subject to the 
surrounding amino acids. Hence, if there is a pool of ADAR2 that is 
unphosphorylated, it will not be a Pin1 substrate, making the protein not fully 
active (Marcucci et al., 2011). There may be enough Pin1 present, but the 
kinase essential for Pin1-binding site phosphorylation is limited, hence the 
transfected ADAR2 here may be inactive as it still requires phosphorylation 
and subsequent Pin1 activity. For instance, ADAR2 is well-expressed in 
undifferentiated NT2 cells; but for efficient Q/R site editing to occur, NT2 cells 
need to undergo differentiation. This arises without any considerable alteration 
in ADAR2 expression, suggesting that a post-translational regulatory 
mechanism is involved (Lai, Chen, Lee, et al., 1997). Moreover, the ADAR2 
cDNA transfected in the cells was only left incubated for 24 hours, which may 
not be sufficient enough time for all of the ADAR2 to be effectively 
phosphorylated and be transported into the nucleus, where it will become 
more active. It is therefore worth optimising the protocol by adjusting certain 
conditions, such as increasing transfection times, as well as increasing 
concentrations of the ADAR2 cDNA plasmid.  
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5.3.3 PIN1 PROTEIN EXPRESSION IN SH-SY5Y CELLS 
 
 Our RT-qPCR findings has revealed that PMO 9-transfected cells show 
increased levels of Pin1 mRNA expression, which is a result of improved RNA 
editing in these cells (Figure 5.4a). PMO 10-transfected cells did not result in 
any change in Pin1 expression (Figure 5.4e) as this PMO did not show any 
effects on excluding AluJ cassette expression in SH-SY5Y cells. The protein 
expression profiles of Pin1 were then studied in both PMO 9- and PMO 10-
transfected cells to observe whether any changes in expression occurred. 
Considering that Pin1 mRNA levels improved in PMO 9-transfected cells, we 
expected to see an increase in Pin1 protein levels as well. However, no 
significant alteration in mean Pin1 protein expression was found in these cells 
(Figure 5.12). This is in contrast to findings presented by (Behm et al., 2017), 
where western blot analysis revealed that Pin1 expression increased during 
maturation of developing neurons (13 DIV) compared to 1-3 DIV neurons. The 
increased Pin1 protein expression is concurrent with the increase in RNA 
editing levels found in cultured primary neurons as they mature (Behm et al., 
2017). Pin1 and ADAR2 localisation was detected in the nucleus of mature 
neurons, whereby a striking increase in the number of interactions between 
the two proteins was observed at 13 DIV. It was established that the nuclear 
import of ADAR2 is mediated by the gradual increase in importin-α4 
expression during development, and ADAR2 localisation is further stabilised 
by increased Pin1 expression, resulting in a rise in editing levels (Behm et al., 
2017). 
 The lack of increase in Pin1 protein expression may be due to the weak 
correlation between mRNA and protein expression profiles. Differential studies 
in mRNA expression essentially assume that mRNA expressional changes are 
most likely mediated by corresponding changes in protein levels 
(Koussounadis, Langdon, Um, Harrison, & Smith, 2015). However, genome-
wide correlation between mRNA and protein expression levels are notoriously 
poor, accounting for roughly 40% of explanations across various studies 
(Vogel & Marcotte, 2012). The discrepancy is generally associated with levels 
of regulation between transcript and protein product (Maier, Güell, & Serrano, 
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2009). However, certain classes of genes have higher correlations, such as 
secreted proteins (only requires transcription when needed); cell cycle genes 
(which are time dependent; and bacterial genes optimised for quick translation 
(Koussounadis et al., 2015).  
 Whilst the nucleotide sequence of a gene determines the sequence of 
its mRNA product, and subsequently the sequence of an mRNA determines 
the amino acid sequence of the resulting polypeptide, a significant relationship 
takes place between the transcript concentration and the protein concentration 
derived from a specific locus (Yansheng Liu, Beyer, & Aebersold, 2016). 
Systematic studies that have quantified transcripts and proteins at genomic 
scales show the importance of various processes beyond transcript 
concentration that contribute to protein expression levels (McManus, Cheng, 
& Vogel, 2015). These processes include 1) rate of translation, as they are 
significantly influenced by the mRNA sequence ; 2) modulation of translation 
rates, which occurs through the protein binding to regulatory elements on the 
transcript, binding of non-coding RNAs, or relative transcript availability; 3) 
modulation of a protein’s half-life; 4) protein synthesis delay; and 5) transport 
of proteins (Yansheng Liu et al., 2016). Hence, direct comparisons between 
protein and mRNA expression from the same location or the same cell type 
may not be applicable.  
 In the case of Pin1 protein expression, the lack of correlation between 
the mRNA levels and protein levels observed may be due to the fact that 
proteins have very contrasting half-lives, as a consequence of varied protein 
synthesis and degradation (Greenbaum, Colangelo, Williams, & Gerstein, 
2003). Protein turnover can differ substantially depending on several factors; 
where the cell can control the degradation or synthesis rates of a given protein. 
Significant heterogeneity is even observed within proteins with similar 
functions (Greenbaum et al., 2003). Since we have transfected the cells with 
PMO 9 (AluJ+93+117) for only 48 hours before protein isolation, the incubation 
time may have not been long enough for Pin1 to be translated into protein, 
resulting in no significant difference in Pin1 protein expression in PMO 9-
transfected cells compared to non-transfected cells. However, we have 
observed that incubation of cells for 72 hours has resulted in significant cell 
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death, which is likely caused by cell over-confluency and prolonged exposure 
to EndoPorter. Therefore, optimisation of a protocol for Pin1 protein detection 
is worth performing in order to measure any changes in protein expression 
levels in cells following PMO 9 (AluJ+93+117) transfection.  
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CHAPTER 6 THE EFFECTS OF 
ANTISENSE OLIGONUCLEOTIDES IN 
DIFFERENTIATED SH-SY5Y CELLS 
6.1 INTRODUCTION 
 
The subjects of neurobiology and neuroscience have been vastly 
improved due to the use of in vitro model systems. Cultured cells allow 
researchers to characterise protein function and the molecular mechanisms 
behind certain biological occurrences, which in turn aids in the understanding 
of disease and infection pathology and carry out preliminary drug testing 
(Shipley, Mangold, & Szpara, 2016). In vitro cell culture models are often used 
for the study of neurotoxin properties and the development of novel 
therapeutic compounds for disease management, where the neuroblastoma 
SH-SY5Y cell line has frequently been utilised to study the pathogenesis of 
neurodegeneration and drug screening (Cheung et al., 2009). This is due to 
the ability of the cells to mimic both morphological and biochemical 
characteristics of primary neurons (Shastry, Basu, & Rajadhyaksha, 2001).  
Although proliferative SH-SY5Y cells are extensively used as a model 
for neurodegenerative diseases, these cells are usually locked in an early 
neuronal differentiation stage, as they lack many neuron-defining features, 
such as neuronal morphology, inhibited cell division, and expression of 
neuronal markers (Agholme, Lindström, Kgedal, Marcusson, & Hallbeck, 
2010). As a result, proliferative SH-SY5Y cells do not represent a wholly 
suitable model for studying molecular and cellular mechanisms of 
neurodegenerative diseases (Lopes et al., 2010). While primary neurons are 
a more apt cell model for neurological disease study, its use for general 
screening is limited as it contains mixed cell populations (Shastry et al., 2001). 
Furthermore, they are notoriously difficult to transfect and standard 
transfection techniques are not suitable for neuronal work, hence requiring the 
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testing and optimisation of other methods, such as calcium-phosphate 
transfection or electroporation (Karra & Dahm, 2010).  
The differentiation of SH-SY5Y cells into a more mature, neuron-like 
phenotype has added numerous benefits in neuroscience research. Cell 
differentiation allows the capacity for extensive expansion of cells before 
differentiation, with relative easiness and lower cost compared to culturing 
primary neurons (Kovalevich & Langford, 2013). Undifferentiated SH-SY5Y 
cells rapidly proliferate and appear to be non-polarised with very few and short 
neurites, growing in clumps (Shipley et al., 2016). When differentiated, these 
cells decrease in proliferation, extend long and branched neurites, and 
polarise in some cases (Kovalevich & Langford, 2013). The removal of the 
neurotrophin brain-derived neurotrophic factor (BDNF) results in cellular 
apoptosis, suggesting that the survival of differentiated SH-SY5Y cells 
depends on trophic factors, akin to mature neurons (Encinas et al., 2000). 
Depending on media conditions, SH-SY5Y cells can be differentiated into 
different adult neuronal phenotypes, such as cholinergic, adrenergic, or 
dopaminergic neurons (Xie, Hu, & Li, 2010), making these cells practical for a 
multitude of neurobiological experiments. Additionally, the cell cycle in 
undifferentiated SH-SY5Y cells and other frequently used cell lines can 
radically fluctuate. Hence, cell differentiation can synchronise the cell cycle to 
generate a homogenous neuronal cell population (Encinas et al., 2000). 
Numerous publications have demonstrated that SH-SY5Y cells are able 
to attain neuron-like phenotype with neurite outgrowth and branching when 
treated with all-trans-retinoic acid (RA) (Lopes et al., 2010). Retinoic acid is a 
derivative of vitamin A, which has been identified to contain potent growth-
inhibiting and cellular differentiating-promoting features (Kovalevich & 
Langford, 2013). RA is vital in embryonic development and growth and 
differentiation maintenance of epithelial, fibroblastic, and myelomonocytic 
cells (Lopes et al., 2010). RA governs cellular differentiation processes 
through alteration of expression of several RA-responsive genes by activating 
retinoic acid/retinoic nuclear receptors (RARs and RXRs) (Lopes et al., 2010). 
The transition from proliferating precursor cell to post-mitotic differentiated cell 
is regulated by RA in vitro, where it was also shown to downregulate mRNA of 
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various differentiation-inhibiting transcription factors (López-Carballo, Moreno, 
Masiá, Pérez, & Barettino, 2002).  
As we have previously studied and quantified the effects of PMOs in 
undifferentiated cells, we next proceeded to characterise the effects of the 
same PMOs in differentiated SH-SY5Y cells. Since differentiated cells 
possess more neuronal-like characteristics, these cells have a more 
appropriate neuronal environment which is suitable to study the effects of 
PMOs on both splicing manipulation and henceforth RNA editing. In this 
chapter, we show that we have successfully differentiated the SH-SY5Y cell 
line through treatment with RA. The cells were then successfully transfected 
with PMOs 9 and 9A, since these two PMOs were demonstrated to have a 
positive effect on both exon skipping and RNA editing. Next, the expression 
levels of Pin1 and WWP2 were quantified to determine whether any change 
in RNA editing plays a role in their regulatory expression.   
 
  
 182 
6.2 RESULTS 
6.2.1 OPTIMISATION OF A DIFFERENTIATION PROTOCOL 
 
Our first step was to ensure that the SH-SY5Y cell line could be 
successfully differentiated following treatment with RA. Differentiated cells are 
expected to show decreased proliferation and show long, neurite-like 
projections (Kovalevich & Langford, 2013). Any changes in morphology were 
confirmed through microscopic visualisation. Cells were seeded at a 
concentration of 60,000 cells per well in a 6-well plate and were left to grow in 
differentiation media, which contained reduced serum (1% FBS) and 1 µM RA. 
Media was changed every two days and cells were visualised under a light 
microscope at the same time points.  
In order to determine the optimum conditions for successful cell 
differentiation, SH-SY5Y cells were all subjected to different conditions as 
follows: 
i) Cells grown in plates coated with 0.5 µg/mL poly-D-lysine (PDL) 
and differentiation media; 
ii) Cells grown in plates coated with 0.5 µg/mL PDL which were left 
to grow in proliferation media for 24 hours before being replaced 
with differentiation media; 
iii) Cells grown in non-coated plates in differentiation media. 
The different conditions were tested as previous work carried out on 
differentiating SH-SY5Y cells have shown that different plate coatings can 
influence the morphological and biochemical characteristics of differentiated 
SH-SY5Y cells (Pedrioli, 2015). The neurite length of the cells day 5 post-
plating were measured and compared between each condition. RNA was then 
extracted from the cells and used for cDNA synthesis, followed by exon 
skipping and RNA editing PCRs to measure endogenous exon skipping and 
RNA editing levels in differentiated cells.  
The microscope images shown in Figure 6.1 revealed that cells cultured 
in PDL with differentiation media, PDL with proliferation media replaced with 
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differentiation media, and non-coated plates showed variation in neurite 
projection length at Day 5. Neurite-like projections were more apparent in cells 
cultured in PDL with proliferation media replaced with differentiation media 
(Figure 6.1b) compared to cells cultured in other conditions (Figures 6.1a and 
6.1c). Cells cultured in PDL with proliferation replaced with differentiation 
media resulted in mean neurite lengths of 105.9 ± 5.7 µm, whilst the mean 
neurite lengths of cells cultured in PDL with differentiation media were 59.0 ± 
2.8 µm. (Figure 6.2) Cells cultured in non-coated plates demonstrated the 
shortest mean neurite lengths (44.1 ± 2.1 µm) (Figure 6.2). 
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Conditions Day 1 Day 5
a) PDL + 
differentiation 
media
b) PDL + 
differentiation 
media + 
proliferation 
media
c) 
Differentiation 
media only
Figure 6.1 Effect of differentiation conditions on 
SH-SY5Y cell morphology.  
Figure shows microscope images of SH-SY5Y cells 
in varying differentiation conditions at Day 1 and 
Day 5 Neurite projections are indicated by orange 
arrows. Scale bars represent 400 µm.  
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Figure 6.2 Mean neurite lengths of SH-SY5Y cells in differentiation conditions. 
Bar graph shows the mean lengths of neurite projections from SH-SY5Y cells in 
differentiation conditions at Day 5. 
Neurite lengths were quantified using NeuronJ. For each condition, the neurite lengths 
of n>6 cells were measured. 
**** = p≤0.0001. Statistical comparisons were carried out using one-way ANOVA. All 
data points correspond to mean ± SEM values. 
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Following morphological analysis, we proceeded to compare and 
analyse any difference in both AluJ cassette inclusion and RNA editing levels 
among the three different conditions. Figure 6.2 shows the results obtained 
from the two PCR assays carried out. AluJ cassette inclusion levels remain 
similar between the three different conditions (Figure 6.2a), ranging between 
76.4 ± 3.3% to 89.9 ± 2.3%. The AluJ cassette inclusion levels measured in 
differentiated cells were similar to the levels observed in proliferating cells 
(70.9 ± 2.4%) (Figure 6.3b). Interestingly, although the levels of AluJ cassette 
inclusion were similar between these samples, a variation in RNA editing 
levels were observed (Figure 6.4b). Cells cultured in PDL with differentiation 
media showed RNA editing levels of 43.8 ± 5.7%. Cells cultured in PDL with 
proliferation media and replaced with differentiation media displayed 
significantly higher RNA editing levels (93.9 ± 6%), while cells cultured in non-
coated plates have shown RNA editing levels of 75.5 ± 12.3%. Differentiated 
cells cultured in PDL with proliferation media replaced with differentiation 
media as well as cells cultured in differentiation media both show a significant 
increase in RNA editing levels compared to proliferating cells (38.9 ± 1.9%) 
(Figure 6.4b). The high editing levels (at nearly 100%) observed in cells 
cultured in PDL with proliferation media replaced with differentiation media is 
noteworthy as these levels are reflective of a neuronal phenotype, as editing 
at the Q/R site in neurons virtually occur at 100% efficiency throughout life 
(Sasaki, Yamashita, Hideyama, & Kwak, 2014).  Since cells cultured in PDL 
with proliferation media replaced with differentiation media demonstrated the 
most neuronal-like phenotype (longest neurite projections and highest RNA 
editing levels), we proceeded to use these conditions in subsequent 
differentiation experiments. 
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a.
b.
Figure 6.3 Effect of differentiation conditions on AluJ insertion in SH-SY5Y cells. 
Figure shows a sample gel image of a) RT-PCR products from SH-SY5Y cells under varying 
differentiation conditions and b) a bar graph depicting AluJ cassette inclusion levels after 
differentiation. 
Gels  were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. Sample gel 
image shows the intensity of exon-skipped transcripts (127 bp, yellow arrow) against exon-
including transcripts (247 bp, red arrow).  
n=3.. Statistical comparisons were carried out using one-way ANOVA. All data points 
correspond to mean ± SEM values. 
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a.
b.
Figure 6.4 Effect of differentiation conditions on RNA editing in SH-SY5Y cells. 
Figure shows a sample gel image of a) BbvI digest products of differentiated SH-SY5Y cells 
in varying conditions and b) a bar graph depicting Q/R site editing percentages after 
differentiation. 
Gels in were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. Sample gel 
image shows the intensity of edited transcripts (323 bp, red arrow) against unedited transcripts 
(238 bp and 85 bp, yellow arrow).  
n=3, * = p≤0.05, ** = ≤0.01. Statistical comparisons were carried out using one-way ANOVA. 
All data points correspond to mean ± SEM values. 
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Once we determined the optimum conditions for cell differentiation, we 
then assessed morphological changes between RA-treated cells and non-RA-
treated cells, which act as undifferentiated controls. In the undifferentiated 
state, SH-SY5Y cells are morphologically characterised by neuroblast-like, 
non-polarised cell bodies with few, truncated projections (Kovalevich & 
Langford, 2013). Both RA-treated and non-RA-treated cells were seeded on 
PDL-coated plates at 60,000 cells per well. 350 µL of differentiation media was 
replaced at 2 day intervals for 7 days and morphological changes were 
visualised under a microscope. The neurite lengths of differentiated cells were 
compared to those measured in undifferentiated cells. Figure 6.5 shows the 
morphology of both differentiated and undifferentiated cells over the course of 
7 days. Identical cell morphology was observed in both cell populations at Day 
1 of differentiation, and the neurite projections were measured to be at similar 
lengths (Figure 6.6). By Day 3, a more distinct difference in morphology was 
observed in differentiated cells, reflected by the significant increase in neurite 
length compared to undifferentiated cells (Figure 6.6). Undifferentiated cells 
were also observed to possess a more rounded cell body compared to 
differentiated cells (Figure 6.5).  Differentiated cells continued to develop a 
more neuron-like phenotype, and the neurite projections continued to increase 
in length up to Day 7 (Figures 6.5 and 6.6). The mean neurite lengths of 
differentiated cells at Day 7 were measured to be at 198.9 ± 17 µM, whilst the 
mean neurite lengths of undifferentiated cells were significantly lower (93.2 ± 
4.4 µM) (Figure 6.6). Differentiated cells also proliferated at a much lower rate 
compared to undifferentiated cells (Figure 6.5). Control cells did not show any 
significant increase in mean neurite length from Day 1 to Day 7 (Figure 6.6) 
and continued to proliferate up to Day 7 (Figure 6.5). The bar graph in Figure 
6.4 shows how the mean length of neurite projections of differentiated cells 
are significantly higher compared to undifferentiated cells. 
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Conditions PDL  and retinoic acid PDL only
Day 1
Day 3
Day 5
Day 7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Comparison of cell morphology between differentiated and undifferentiated 
SH-SY5Y cells. 
Figure shows microscope images of SH-SY5Y cells cultured in RA-treated media (left panel) 
and non-RA-treated media (right panel) for 7 days. Neurite projections are indicated by yellow 
arrows. Scale bars represent 400 µm. 
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Figure 6.6 Comparison of mean neurite lengths between differentiated and 
undifferentiated SH-SY5Y cells.  
Figure shows the mean lengths of neurite projections from SH-SY5Y cultured in RA-treated 
media (black bars) and non-RA-treated media (grey bars) for 7 days.  
RA; retinoic acid. Neurite lengths were quantified using NeuronJ. For each condition, the 
neurite lengths of n>6 cells were measured. *** = p≤0.001, **** = p≤0.0001 . Statistical 
comparisons were carried out using student’s paired t-test. All data points correspond to mean 
± SEM values. 
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6.2.2 EFFECTS OF PMO 9 AND PMO 9A ON ALUJ CASSETTE 
INCLUSION AND RNA EDITING IN DIFFERNTIATED CELLS 
 
SH-SY5Y cells were cultured according to the conditions described in 
the previous section. 5 µM of PMOs 9 (AluJ+93+117) and 9A (AluJ+94+118) 
were used to transfect these cells and their effects were compared to two 
different control conditions: differentiated cells (cultured in RA-treated media) 
and undifferentiated cells (cultured in proliferation media). Cells were 
transfected at Day 6 of differentiation. RNA was when harvested at Day 7 of 
differentiation and exon skipping and RNA editing PCR assays were 
performed. Figure 6.7 shows the difference in AluJ cassette insertion between 
transfected and non-transfected cells. Both RA-treated and undifferentiated 
cells showed similar AluJ cassette inclusion levels (84.24 ± 0.5% and 77.78 ± 
1.6%, respectively). Transfection with both PMO 9 (AluJ+93+117) and 9A 
(AluJ+94+118) resulted in significant reduction of AluJ cassette inclusion when 
compared to both controls. PMO 9 (AluJ+93+117) lowered AluJ cassette 
inclusion levels to 32.93 ± 4.8%, while AluJ cassette inclusion was reduced to 
37.1 ± 1.2% in PMO 9A-transfected cells.  
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Figure 6.7 The effect of PMO 9 and PMO 9A on AuJ insertion in differentiated SH-
SY5Y cells.  
Figure shows a) a representative gel image of RT-PCR products of differentiated SH-SY5Y 
cells treated with 5 µM PMO 9 and PMO 9A and b) bar graph depicting AluJ cassette 
inclusion percentages in differentiated SH-SY5Y cells treated with 5 µM PMO 9 and PMO 
9A for 24 hours compared to RA-treated cells and undifferentiated cells.  
Gels were run in a 1.5% agarose gel in 1X TAE buffer against Hyperladder V and visualized 
under UV light using a GELDOC system. Images were quantified using ImageJ. “-ve” 
denotes negative control. Sample gel images show the intensity of exon-skipped transcripts 
(127 bp, yellow arrow) against exon-including transcripts (247 bp, red arrow).  
RA, retinoic acid. n=3-4, **** = p≤0.0001. Statistical comparisons were carried out using 
one-way ANOVA. All data points correspond to mean ± SEM values. 
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A BbvI RNA editing assay was then carried out to assess the RNA 
editing levels in the cells. The RNA editing percentages calculated in 
differentiated cells (both transfected with PMOs and non-transfected cells) 
were normalised to the levels measured in undifferentiated cells. Figure 6.8 
shows the RNA editing levels of these cells. PMO 9-transfected cells improved 
RNA editing levels up to 151.3 ± 6.1%, whilst transfection with PMO 9A 
(AluJ+94+118) increased RNA editing up to 133.2 ± 10.9%, which was 
expected as low AluJ cassette inclusion was observed (Figure 6.5). RA-
treated cells also showed higher levels of RNA editing (162.6 ± 10.9%), 
reflective of the results previously described in Section 6.2.1 (Figure 6.4b). All 
three conditions displayed a significant increase in RNA editing compared to 
undifferentiated cells (Figure 6.8b). However, since RA-treated cells displayed 
high baseline levels of RNA editing, statistical analysis revealed no significant 
difference in editing levels between PMO-transfected cells and RA-treated 
cells (p>0.05) (Figure 6.8b).  
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Figure 6.8 The effect of PMO 9 and PMO 9A on RNA editing in differentiated SH-
SY5Y cells. 
Figure shows a) a representative gel image of RT-PCR products of differentiated SH-
SY5Y cells treated with 5 µM PMO 9 and PMO 9A and b) bar graph depicting RNA editing 
percentages in differentiated SH-SY5Y cells treated with 5 µM PMO 9 and PMO 9A for 
24 hours compared to RA-treated cells and undifferentiated cells.  
Gels were run in a 2.5% agarose gel in 1X TAE buffer against Hyperladder V and 
visualized under UV light using a GELDOC system. Images were quantified using ImageJ. 
Sample gel images show the intensity of edited transcripts (323 bp, red arrow) against 
unedited transcripts (238 bp and 85 bp, yellow arrow).  
RA; retinoic acid. n=3-4, * = p≤0.05, ** = p≤0.01. Statistical comparisons were carried out 
using one-way ANOVA. All data points correspond to mean ± SEM values. 
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6.2.3 PIN1 AND WWP2 EXPRESSION IN DIFFERENTIATED SH-SY5Y 
CELLS 
 
Once the effects of PMOs on AluJ inclusion and RNA editing in 
differentiated cells were assessed, the mRNA levels of Pin1 and WWP2 were 
then evaluated in PMO 9- and PMO 9A-transfected cells. In addition to 
examining the regulation of Pin1 and WWP2 in PMO-transfected cells, we also 
sought to study the regulatory levels of Pin1 and WWP2 in differentiated SH-
SY5Y cells. The relative expression levels of both Pin1 and WWP2 were 
normalised to levels measured in undifferentiated cells, with β-actin used as a 
housekeeping reference gene. As the increase in RNA editing resulting from 
PMO treatment have consistently resulted in upregulation or downregulation 
of Pin1 and WWP2, respectively (previously discussed in Chapter 5), the same 
outcomes were expected in differentiated cells, which can be seen in Figure 
6.9. 
Transfection of differentiated SH-SY5Y cells with 5 µM PMO 9 
(AluJ+93+117) increased the level of Pin 1 mRNA (6.98 ± 0.8 fold-change vs 
cells only) (Figure 6.9a) while the mRNA levels of WWP2 were reduced (0.34 
± 0.05 fold-change vs cells only) (Figure 6.9b). The levels of Pin1 mRNA 
measured in PMO 9-transfected cells compared to RA-only treated cells did 
result in any significant change in expression (p>0.05) (Figure 6.9a). The same 
outcome was also observed in WWP2 mRNA levels of PMO 9-transfected and 
RA-treated cells (p>0.04) (Figure 6.9b).  PMO 9A-transfected cells also 
displayed comparable patterns in both Pin1 and WWP2 expression levels to 
PMO 9-transfected cells, where Pin1 expression increased (9.24 ± 2.4 fold-
change vs cells only) (Figure 6.9c), and a downregulation in WWP2 levels was 
detected (0.23 ± 0.02 fold-change vs cells only) (Figure 6.9d). No significant 
difference in both Pin1 and WWP2 mRNA levels were calculated between 
PMO 9A (AluJ+94+118) and RA-treated cells (Figures 6.9c and d).  
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Overall, differentiated SH-SY5Y cells (cultured in RA-treated media) 
also displayed the same patterns of Pin1 and WWP2 expression as PMO-
transfected cells. Pin1 mRNA expression was upregulated (6.66 ± 1.2 fold-
change vs cells only) (Figure 6.9a and c), whilst a reduction in WWP2 levels 
was observed (0.18 ± 0.02 fold-change vs cells only) (Figure 6.9b and d). The 
results procured here reflect the outcomes of previous findings – the regulation 
of Pin1 and WWP2 in undifferentiated cells, where similar mRNA expression 
levels were observed (reviewed in Chapter 5), and increased Pin1 and 
decreased WWP2 expression are consistent with the increased RNA editing 
levels observed in PMO-transfected and RA-treated cells (Figure 6.9).  
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Figure 6.9 Pin1 and WWP2 mRNA expression in differentiated SH-SY5Y cells. 
qRT-PCR analysis of mRNA isolated from differentiated SH-SY5Y cells transfected with  5 µM 
of PMOs 9 and 9A. Bar graphs a and b show expression levels of Pin1 and WWP2 in PMO 9-
transfected cells; and bar graphs c and d show expression levels of Pin1 and WWP2 in PMO 
9A-transfected cells. 
Expression of Pin1 and WWP2 was assessed using the LightCycler 480 (Roche) and reactions 
were performed using the LightCycler SYBR Green I Mastermix (Roche). The expression 
levels of β-actin were used as a reference gene. The gene expression levels were defined 
based on the threshold cycle (Ct), and relative expression levels were calculated using the 2-
DDCt method. Measurements were made from three separate transfections in triplicate. 
RA; retinoic acid. n=4, * = p≤0.05, ** = p≤0.01, *** = p≤0.001. Statistical comparisons were 
carried out using one-way ANOVA. All data points correspond to mean ± SEM values.  
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Additionally, we also compared the effects of both PMO 9 
(AluJ+93+117) and PMO 9A (AluJ+94+118) on the mRNA expression of Pin1 
and WWP2 in both proliferating and differentiated cells. In Chapter 5, we 
transfected proliferating SH-SY5Y cells with 5 µM of PMOs 9 and 9A and 
found increased levels in Pin1 mRNA expression (Figures 5.3a and c) whilst 
WWP2 expression were reduced (Figures 5.3b and d). The fold-change values 
of the genes compared to non-transfected proliferating cells are listed in Table 
6.1. In the case of both proliferating and differentiated cells, transfection with 
PMO 9 (AluJ+93+117) has resulted in upregulation of Pin1 expression (Figure 
6.8a). Furthermore, Pin1 expression is significantly higher in PMO 9-
transfected proliferating cells compared to PMO 9-transfected differentiating 
cells (Figure 6.10a). WWP2 mRNA levels also showed significant reduction in 
expression in both proliferating and differentiated cells compared with non-
transfected proliferating cells (Figure 6.10b). Both proliferating and 
differentiated cells transfected with PMO 9A (AluJ+94+118) showed significant 
increase in Pin1 expression compared to non-transfected proliferating cells 
(Figure 6.10c). Consistent with results seen in PMO 9-transfected cells, 
significant downregulation of WWP2 mRNA levels were observed in PMO 9A-
transfected cells (Figure 6.10d). Contrary to the results observed in Pin1 
mRNA levels of PMO 9-transfected cells, statistical analysis did not show any 
significant difference in WWP2 mRNA levels between proliferating and 
differentiated cells transfected with PMO9 and either Pin1 and WWP2 mRNA 
levels between proliferating and differentiated cells transfected with PMO9A 
(p>0.05) (Figures 6.10b, c, and d). 
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Figure 6.10 Comparison of Pin1 and WWP2 mRNA expression in proliferating and 
differentiated SH-SY5Y cells. 
qRT-PCR analysis of mRNA isolated from proliferating and differentiated SH-SY5Y cells 
transfected with  5 µM of PMOs 9 and 9A. ‘Cells only’ refers to non-transfected proliferating 
cells. Bar graphs a and b show expression levels of Pin1 and WWP2 in PMO 9-transfected 
cells; and bar graphs c and d show expression levels of Pin1 and WWP2 in PMO 9A-
transfected cells. 
Expression of Pin1 and WWP2 was assessed using the LightCycler 480 (Roche) and reactions 
were performed using the LightCycler SYBR Green I Mastermix (Roche). The expression 
levels of β-actin were used as a reference gene. The gene expression levels were defined 
based on the threshold cycle (Ct), and relative expression levels were calculated using the 2-
DDCt method. Measurements were made from three separate transfections in triplicate. 
RA; retinoic acid. n=4, * = p≤0.05, ** = p≤0.01, *** = p≤0.001, **** = p≤0.0)01. Statistical 
comparisons were carried out using one-way ANOVA. All data points correspond to mean ± 
SEM values.  
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Fold-change in expression 
PMO 
transfected 
Gene 
Proliferating 
cells 
Differentiated 
cells 
PMO 9 
Pin1 11.58 ± 3.7 6.98 ± 0.8 
WWP2 0.41 ± 0.08 0.34 ± 0.05 
PMO 9A 
Pin1 6.26 ± 0.7 9.24 ± 2.4 
WWP2 0.14 ± 0.04 0.23 ± 0.02 
 
Table 6.1 Fold-change values of Pin1 and WWP2 mRNA expression in both proliferating 
and differentiated cells. 
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6.3 DISCUSSION 
 
Although animal models more precisely imitate certain characteristics 
of a disease, there are some disadvantages to using them, such as time, cost 
and ethics. Many variables in a live animal can affect the study of different 
mechanisms. Cell culture models are advantageous in that they are easier to 
perform and repeat experiments, whilst also being time- and cost-saving. 
Thus, cell models are a good candidate for preliminary studies of the efficiency 
of various substances, more so when a more controlled setting is essential. In 
this chapter, we attempted to differentiate SH-SY5Y cells into a more 
neuronal-like cell model as differentiated cells possess both morphological 
and biochemical likenesses to human neurons. SH-SY5Y cells were cultured 
in RA-treated media in three different conditions: PDL-coated plates with 
differentiation media, PDL-coated plates with proliferation media replaced with 
differentiation media, and non-coated plates. When compared to 
undifferentiated cells, differentiated SH-SY5Y cells expressed longer, neurite-
like projections (Figures 6.3 and 6.4). Differentiated cells cultured in PDL with 
proliferation media replaced with differentiation media also demonstrated 
near-complete RNA editing (Figure 6.2b), a biochemical characteristic that is 
reflective of neurons, since near 100% editing at the Q/R site of neurons is 
essential for normal GluA2 receptor function (S Maas, Patt, Schrey, & Rich, 
2001). Differentiation of cells also promotes a reduction in proliferation rate 
(Figure 6.3), due to the withdrawing of cells from the cell cycle (Kovalevich & 
Langford, 2013). 
Whilst the effects of PMOs on AluJ cassette inclusion and RNA editing 
in proliferating SH-SY5Y cells has been established, it was still not known 
whether morphological or biochemical changes affects these two processes. 
RNA isolated from differentiated cells were analysed following transfection 
with PMOs 9 and 9A. The inclusion of the AluJ cassette in ADAR2 transcripts 
were measured in both PMO-transfected and RA-treated cells at Day 7 of cell 
differentiation. As expected, transfection with PMOs 9 and 9A resulted in the 
reduction of AluJ cassette expression in cells when compared to 
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undifferentiated cells and RA-treated cells (32.93 ± 4.8% and 37.1 ± 1.2%, 
respectively) (Figure 6.5). The levels of AluJ cassette inclusion following 
transfection with PMO 9 (AluJ+93+117) in differentiated cells (32.93 ± 4.8%) 
(Figure 6.5) are similar to those measured in undifferentiated cells (32.93 ± 
4.8%) (Figure 3.4). However, PMO 9A (AluJ+94+118) did not manage to 
decrease AluJ cassette levels in differentiated cells (37.1 ± 1.2%) as much as 
in undifferentiated cells at the same concentration (4.09 ± 2.3%) (Figure 3.5). 
In fact, whilst PMO 9A (AluJ+94+118) demonstrated to be most effective at 
exon skipping in undifferentiated cells (discussed is Section 3.3), the exon 
skipping efficacies of both PMO 9 (AluJ+93+117) and PMO 9A (AluJ+94+118) 
are similar in differentiated SH-SY5Y cells (Figure 6.5). It seems as if the 
morphological and biochemical changes in differentiated SH-SY5Y cells have 
prevented PMO 9A (AluJ+94+118) from binding as efficiently to the ADAR2 
transcript, although the reasoning behind this is uncertain. The endogenous 
AluJ cassette insertion levels in RA-treated cells were also compared to 
undifferentiated cells (Figure 6.5). The AluJ cassette inclusion levels in RA-
treated cells (84.24 ± 0.5%) did not significantly differ to AluJ cassette inclusion 
in undifferentiated cells (77.78 ± 1.6%) (p>0.05).  
The RNA editing levels in differentiated cells were then assessed 
following PMO transfection. Since we have previously hypothesised that 
promoting AluJ cassette inclusion can indirectly increase Q/R site editing, we 
observed the same results in PMO-transfected differentiated cells (Figure 6.6). 
Since PMO 9 (AluJ+93+117) showed greater exon skipping efficacy in 
differentiated cells, the RNA editing levels improved to 151.3 ± 6.1% compared 
to normalised controls. The RNA editing levels measured were slightly higher 
compared to those calculated in PMO 9A-transfected cells (133.2 ± 10.9%). 
Again, the results obtained here slightly differs to our observations in Chapter 
3, where PMO 9A (AluJ+94+118) resulted in higher increase in RNA editing 
levels compared to PMO 9 (AluJ+93+117). Considering that higher levels of 
AluJ cassette inclusion were known to result in reduced Q/R site RNA editing 
levels, it was therefore interesting to see that RNA editing levels in RA-treated 
cells (162.6 ± 10.9%) were higher than the levels quantified in undifferentiated 
cells. This further confirms that the high endogenous Q/R site editing levels in 
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differentiated SH-SY5Y cells is comparable to the high editing levels generally 
observed in neurons. 
Since RA-treated cells demonstrated high levels of RNA editing despite 
incorporating higher levels of the AluJ cassette when compared to PMO-
transfected cells, it was worth assessing whether Pin1 and WWP2 levels are 
regulated in differentiated cells. As discussed in Chapter 4, Pin1 acts a positive 
regulator for ADAR2 activity while WWP2 acts in a negative manner. 
Transfecting cells with PMOs 9 and 9A resulted in the upregulation in Pin1 
mRNA levels (Figures 6.7a and 6.7c), as expected. The levels of WWP2 
expression were reduced (Figures 6.7b and 6.7d), which additionally highlights 
the regulatory mechanism of both Pin1 and WWP2 expression with regards to 
Q/R site RNA editing. Investigation of Pin1 and WWP2 expression levels in 
RA-treated cells revealed the same expression patterns of the two genes 
previously observed in PMO-transfected cells, where we detected increased 
Pin1 and reduced WWP2 expression (Figures 6.7e and 6.7f). The 
expressional patterns of both Pin1 and WWP2 mRNA observed in RA-treated 
cells here are reflective of the high RNA editing levels that were measured in 
these cells (Figure 6.6), thus further confirming a possible regulatory 
mechanism in Pin1 and WWP2 expression during Q/R site editing.  
It is therefore interesting to discern the possible underlying reasons 
behind the high endogenous RNA editing levels seen in differentiated cells, 
despite the fact that the cells displayed higher AluJ cassette inclusion and 
were not transfected with PMOs. Alternative splicing of the AluJ cassette may 
perform a key function in regulating editing activity in vivo at specific nucleotide 
sites (Paupard, O’Connell, Gerber, & Zukin, 1999). The human analog of the 
AluJ cassette insertion in rats is an alternative splicing event rat in ADAR2 pre-
mRNA as a 30-nt insertion in their carboxy terminal catalytic domains, which 
yields isoforms that differ in their editing efficiency (Gerber et al., 1997; Lai, 
Chen, Carter, et al., 1997). Studies have demonstrated almost parallel 
temporal and spatial expression patterns of the two rat isoforms, though the 
expression of the 30-nt cassette-containing isoform appears more abundant 
(Filippini et al., 2018b; Paupard et al., 1999).  In fact, another study has shown 
that expression of the normal transcript of Adarb1 appears to be at constant 
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levels throughout mouse brain development (Wahlstedt et al., 2009). Taken 
together, the results obtained by Paupard et. al., Wahlstedt et. al. and Filippini 
et. al. corroborates with the expression levels of the two ADAR2 isoforms we 
see in RA-treated cells (Figure 6.5). These data indicate that both splicing 
isoforms are required for normal neuronal function (Filippini et al., 2018b).  
The editing levels measured in RA-treated cells (Figure 6.6) could be 
an indicator of a self-editing process of ADAR, whereby a new 3’ splice 
acceptor site is created (modifying adenosine-adenosine to adenosine-
inosine) in the intronic sequence of the ADAR2 mRNA (Li et al., 2015). Editing 
of ADAR2 pre-mRNA increases throughout rat brain development (Behm et 
al., 2017; Hang, Tohda, & Matsumoto, 2008); however, this editing activity 
does not correlate with ADAR expression levels, illustrating the presence of 
other regulatory mechanisms which regulate editing activity (Behm & Öhman, 
2016). A study performed by (Filippini et al., 2018b) demonstrated increased 
self-editing process during primary neuron maturation in rat CNS. The self-
editing process is additionally characterized by the parallel expression of 
ADAR2 isoforms containing 47-nt cassette, whereby inclusion of this cassette 
results in a truncated, less active isoform of the ADAR2 protein (Rueter et al., 
1999). ADAR2 self-editing has also been demonstrated to take place in pre-
mRNA during early development of primary neurons, followed by a gradual 
increase of editing levels during maturation (Behm et al., 2017; Hang et al., 
2008). The expression of the less active ADAR2 isoform seems to contradict 
the increased editing levels reported during development, but fine-tuning 
ADAR2 activity (from self-editing) is essential for appropriate neuronal 
development. The increase of the inactive ADAR2 isoform may represent an 
autoregulatory mechanism where ADAR2 can prevent its own overactivity to 
avoid unwarranted and inappropriate RNA editing for numerous ADAR2 
substrates throughout the CNS (Feng et al., 2006).  
We have previously showed in Chapter 5 how Pin1 and WWP2 levels 
are regulated by ADAR2 during Q/R site RNA editing, where improved RNA 
editing in SH-SY5Y cells was a result of transfection with PMOs 9 and 9A. 
Similar expression levels were obtained in differentiated SH-SY5Y cells 
(Figures 6.7a-d). The same expressional patterns of Pin1 and WWP2 were 
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also measured in RA-treated cells (Figures 6.7e and f). The increase in RNA 
editing levels in maturing primary neurons has been attributed to the 
accumulation of ADAR2 in the nucleus during neuronal development (Behm 
et al., 2017). Accumulation of ADAR2 in the nucleus is essential for its 
interaction with Pin1 (Marcucci et al., 2011). Western blot analysis has 
previously revealed that Pin1 expression in developing neurons is expressed 
at low levels 1-3 DIV, and expression increased up to 13 DIV during maturation 
(Behm et al., 2017). The high RNA editing levels in RA-treated cells (Figure 
6.6), which may also have been caused by the high expression levels of Pin1 
in the cells (Figure 6.7e), could be attributed to the increasing accumulation of 
Pin1 in the nucleus. Additionally, other substrates for ADAR2 also exist, such 
as importin-α4, which mediates the nuclear import of ADAR2 (Behm & Öhman, 
2016).  
Pin1 regulates many proteins and processes within the cell. However, 
Pin1 itself is regulated by phosphorylation, inhibiting its activity (T. H. Lee, 
Chen, et al., 2011). (Marcucci et al., 2011) hypothesised that Pin1 acts at the 
core of a regulatory network, where any defects in normal biological processes 
leads to a reduction in Pin1 activity. This can eventually result in reduced 
ADAR2 activity with an ensuing reduction in the Q/R site editing of GluA2 
transcripts, causing increased calcium permeability of AMPA receptors. This 
influx of calcium can ultimately induce excitotoxic neuronal death. Hence, 
100% editing at the Q/R site of the GluA2 subunit may be a regulatory measure 
that indicates healthy neuronal function (Marcucci et al., 2011).  
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6.4 CONCLUSION 
 
To conclude, the work in this chapter demonstrates that PMOs 9 
(AluJ+93+117) and 9A (AluJ+94+118) are able to be successfully transfected 
into a more neuronal-like cell model, thus inducing alternative splicing of the 
AluJ cassette. What is interesting of note here is how we have observed high 
endogenous RNA editing levels in differentiated cells, which have been 
previously studied by (Lai, Chen, Lee, et al., 1997), where a rise in GluA2 Q/R 
site editing become progressively increased during neuronal differentiation of 
NT2 cells. Since editing levels are already high in differentiated cells, it would 
be worth attempting RNAi-induced gene knockdown of ADAR2 or Pin1 in 
differentiated cells in order to disrupt Q/R site editing, allowing us to quantify 
the effects of PMO 9 (AluJ+93+117) and 9A on improving RNA editing in 
differentiated cells. This can be followed by eventually testing PMOs 9 
(AluJ+93+117) and 9A (AluJ+94+118) in neurons. 
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CHAPTER 7 DISCUSSION 
7.1 ADAR2 SPLICING AND RNA EDITING 
 
 ADAR2, the enzyme responsible for the editing at the Q/R site of the 
GluA2 subunit of AMPA receptors, can exist as multiple splice variants. The 
insertion of a 120 bp AluJ cassette results in an ADAR2 isoform with reduced 
catalytic activity. PMOs 9, 9A, and 9B were designed to manipulate splicing of 
ADAR2 in order to exclude the AluJ cassette from the final transcript, resulting 
in a more active isoform of ADAR2. The expression of the ADAR2 isoform that 
does not express the AluJ cassette resulted in increased RNA editing levels 
in SH-SY5Y cells, highlighting the importance of alternative splicing in cells for 
normal cell function, as well as the correlation between ADAR2 activity and 
the role it plays in RNA editing. 
 Aside from RNA editing, ADARs also play a role during several key 
steps of miRNA maturation (Tomaselli et al., 2013). The maturation steps of 
both pre-miRNA and miRNA can be disrupted by ADARs that can sequester 
or edit the RNAs with crucial effects (Tomaselli, Locatelli, & Gallo, 2014). 
Although ADARs are deaminase enzymes, they can also serve as RNA-
binding proteins due to the presence of RNA-binding domains. Hence, ADARs 
have been shown to bind to various transcripts without editing them (Klaue, 
Källman, Bonin, Nellen, & Öhman, 2003). Consequently, the binding of 
ADAR2 to pri-376a was shown to sufficiently inhibit its processing by Drosha, 
which is independent of ADAR2 editing activity (Heale et al., 2009). 
Additionally, the involvement of A-to-I editing in the heterochromatic silencing 
mechanism, where ADAR regulates gene silencing in Drosophila, has been 
reported (Savva et al., 2013). This data reveals additional roles carried out by 
ADAR enzymes and a global role for RNA editing in regulating gene 
expression (Savva et al., 2013). Considering that ADAR enzymes perform 
various roles, it is therefore expected that the many different cell pathways can 
be influenced by ADARs. ADAR activity is differentially regulated and 
spatiotemporally controlled (Tomaselli et al., 2014). Hence, aberrant RNA 
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editing profiles can be seen in different human diseases, such as neurological 
and neurodegenerative diseases (schizophrenia, depression, Alzheimer’s 
disease, ALS), epilepsy, systemic lupus erythematosus (SLE), and cancers 
(Tomaselli et al., 2014).  
 In the case of ALS, deficiency in RNA editing at GluA2 Q/R site causes 
AMPA receptors to be permeable to Ca2+, leading to exaggerated Ca2+ influx 
and death of motor neurons (Figure 7.1). ADAR2 protein is cleaved by a 
calcium-activated protease in vertebrate neuronal cells treated with excess 
glutamate, suggesting that glutamate excitotoxicity is partly mediated by the 
suppression of GluA2 Q/R site editing (Mahajan et al., 2011). The expression 
and editing state of GluA2 appears to act as a gatekeeper that can switch the 
phenotype of cells between two states, differing by their vulnerability to toxicity 
(Buckingham, Kwak, Jones, Blackshaw, & Sattelle, 2008). Hence, the 
question is, what is the adaptive advantage of a mechanism whereby an error 
in that mechanism can cause massive loss of motor neurons? Recent 
evidence has shown that this may be to allow regulation of ADAR2 RNA 
editing of glutamate receptor transcripts in response to neuronal excitation. 
GluA2 RNA editing modifies residues at surface interfaces and influences 
tetrameric receptor assembly (Greger & Esteban, 2007). Glutamate receptors 
that contain unedited Q/R site subunits can undergo intracellular membrane 
transport to the cell surface adjacent to synapses more effectively (Gallo, 
Vukic, Michalík, O’Connell, & Keegan, 2017). Q/R site subunits that have been 
edited aggregate in the endoplasmic reticulum and may be destroyed prior to 
arriving at the cell surface; giving rise to the possibility that the evolution of 
ADAR2 editing is to deter glutamate signalling by synaptic scaling in response 
to general neuronal excitation (Gallo et al., 2017). This is vital for neuronal 
synaptic plasticity response in both AMPA and kainate receptors (Evans, 
Gurung, Wilkinson, Stephens, & Henley, 2017). However, it is still unclear 
whether the effects of editing on membrane trafficking involves other receptor 
classes or edited proteins (Gallo et al., 2017).  
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Several antisense oligonucleotide therapies are under development for 
non-neurodegenerative disorders. Most notably, Eteplirsen, an exon-skipping 
ASO designed for the treatment of Duchenne muscular dystrophy (DMD), was 
granted accelerated approval by the US Food and Drug Administration (FDA) 
in September 2016 (K. R. Q. Lim et al., 2017). However, attaining sufficient 
levels of ASO distribution in the target organ and establishing high cellular 
uptake is a major issue (Evers et al., 2015). Neurodegenerative disorders are 
at an advantage here, as ASOs are readily taken up by neurons and glia once 
reaching the nervous system (Evers et al., 2015). The uptake is suggested to 
happen through nucleic acid channels, but little is still known about the exact 
cellular uptake mechanism (Evers et al., 2015). Vascular barriers in the 
nervous system prevents the ASOs from entering the periphery, hence no 
rapid excretion or breakdown by the kidney or liver will occur, allowing the ASO 
to reach clinically effective concentrations (Evers et al., 2015). The use of 
ASOs that interfere with pre-mRNA splicing has prominently been researched 
for spinal muscular atrophy (SMA), where the inclusion of exon 7 is increased 
by blocking the exonic splicing silencers (ESS) and intronic splicing silencers 
(ISS) to modulate the splicing of SMN2. ASOs have also been applied to 
correct the ratio of tau protein isoforms as a possible treatment for 
frontotemporal dementia (FTD) (Peacey, Rodriguez, Liu, & Wolfe, 2012). Tau 
ADAR2 
downregulation
Q/R site-unedited 
GluA2
Expression of 
calcium-
permeable AMPA 
receptors
Exaggerated 
calcium influx
TDP-43/nuclear 
pathology 
Death of motor 
neurons
Figure 7.1 Proposed cell death cascade of motor neurons in sporadic ALS by 
Yamashita et. al. (2017). 
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interacts with microtubules through its microtubule binding repeat domains 
encoded by exons 9 to 12. Tau isoforms with or without exon 10 (named the 
3R and 4R isoforms, respectively) is produced by alternative splicing of exon 
10 (Peacey et al., 2012). The ratio of 4R to 3R tau in healthy human brain is 
generally around 1. In FTD patients, however, the 4R to 3R ratio is shifted 
towards more exon 10-containing 4R, resulting in the formation of intracellular 
neurofibrillary tangles (Peacey et al., 2012). MAPT (microtubule associated 
protein tau) minigenes co-transfected with PNA ASOs targeting the 5’ splice 
site of exon 10 inhibited exon 10 inclusion, shifting the 4R to 3R ratio towards 
higher 3R tau level (Peacey et al., 2012). Considering that ASOs have been 
thoroughly researched and utilised to correct aberrant pre-mRNA splicing in 
other diseases, using ASOs for exon skipping to correct ADAR2 splicing to 
improve RNA editing has the potential for us in ALS therapy. Overall, we have 
shown that both PMO 9 (AluJ+93+117) and PMO 9A (AluJ+94+118) are both 
efficient and inducing exon skipping in SH-SY5Y cells, although at different 
degrees. Although only mild effects on RNA editing were observed in PMO-
transfected SH-SY5Y cells, this slight increase may be sufficient to safeguard 
motor neurons against excitotoxicity. This can be determined by studying the 
effects of glutamate overstimulation on cell viability in PMO-transfected cells. 
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7.2 PIN1 REGULATION DURING RNA EDITING 
 
Although our understanding of the amount and extent of RNA editing 
has increased rapidly, how the process is physiologically regulated is less well-
understood. It has been established that the same RNA transcript located in 
different regions of the brain is subjected to variable editing levels (Walkley & 
Li, 2017). Aside from ADAR editing enzymes themselves, only a small number 
of proteins that modulate RNA editing have been identified. Protein structural 
studies have revealed candidates for the alteration of ADAR protein function. 
The catalytic domain of ADAR2 comprises of inositol hexakiphosphate (IP6), 
an integral structure required for efficient editing activity (Macbeth et al., 2005). 
One curious postulation is that the formation of elevated IP6 from 
phospholipase C (PLC) following activation of 5-HT2c may increase nascent 
ADAR2 protein activity and account for some of the feedback onto 5-HT2c 
receptor editing (Schmauss, Zimnisky, Mehta, & Shapiro, 2010). 
Nevertheless, additional work is needed to establish whether levels of IP6 in 
neurons are rate-limiting for ADAR2 activity (Penn, Balik, & Greger, 2013). 
ADAR protein function and abundance have also been shown to be regulated 
by post-translational modifications such as SUMOylation, phosphorylation-
dependent propyl isomerisation, and ubiquitination (Penn et al., 2013). 
Moreover, it has been suggested that dynamic associations of ADARs with 
subcellular compartments are controlled as a way to sequester functional 
ADARs away from their nuclear targets. For example, editing site activity 
increases when ADAR2 is translocated to the nucleolus (Sansam et al., 2003). 
 One regulator that has been found to influence ADAR2 expression is 
CREB (cAMP-response element-binding protein), which can induce ADAR2 
expression in hippocampal CA1 neurons in rat brain following transient 
ischemic insults (Peng et al., 2006). More recent evidence revealed that JNK1 
(c-Jun Amino-Terminal Kinase 1) acts as a vital component in mediating 
glucose-responsive upregulation of ADAR2 expression in pancreatic b-cells, 
suggesting the functional relationship between the JNK1 pathway and the 
nutrient-sensing actions of ADAR2-mediated RNA editing in professional 
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secretory cells (Yang et al., 2012). Extensive profiling of A-to-I editing sites in 
human samples from the Genotype-Tissue Expression (GTEx) project recently 
identified AIMP2 (aminoacyl TRNA synthase complex interacting 
multifunctional protein 2) as a novel negative regulator of RNA editing, as its 
expression is negatively correlated with overall editing levels in thousands of 
samples (Tan et al., 2017). Further experiments and analyses in myoblasts 
suggests that AIMP2 partly functions by blocking ADAR1-mediated RNA 
editing, which was demonstrated to be essential for myoblast-to-myotube 
transition (Tan et al., 2017).  The identification of Pin1 and WWP2 as 
regulators of ADAR2 activity were revealed when Pin1-/- mouse embryonic 
fibroblasts show ADAR2 mislocalisation in the cytoplasm and reduced GluA2 
Q/R and R/G site editing, suggesting that Pin1 is required for the nuclear 
localisation and stability of ADAR2 (Marcucci et al., 2011). WWP2 was shown 
to negatively regulate ADAR2 activity by binding to ADAR2 and catalysing its 
ubiquitination and subsequent degradation (Marcucci et al., 2011). The 
involvement of these genes indicates that ADAR and other regulators can alter 
the editing efficiency observed at a given locus (Figure 7.2). 
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Figure 7.2 Trans regulation of A-to-I editing. 
Trans regulation can either enhance editing, such as with Pin1 phosphorylation of ADAR, or 
reduce editing, as happens with WWP2 (ADAR ubiquitination) or AIMP2 (decreases overall 
ADAR1 levels). Figure taken from Walkley and Li (2017). 
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Based on our findings, we have shown that Pin1 mRNA levels show 
significant increase in expression in both PMO 9- and PMO 9A-transfected 
cells when compared to non-transfected cells. Conversely, WWP2 mRNA 
levels show reduced expression in PMO 9- and PMO 9A-transfected cells. 
Similarly, when cells were transfected with PMO E1 (which was designed to 
disrupt Q/R site editing), WWP2 mRNA levels showed increased expression. 
The results we obtained corroborates the findings by (Marcucci et al., 2011), 
whereby the higher Pin1 mRNA levels were found to act as a positive regulator 
for ADAR2 activity, since PMO 9 (AluJ+93+117) and PMO 9A (AluJ+94+118) 
transfected cells showed improved Q/R site RNA editing levels compared to 
control cells. Further Pin1 and WWP2 mRNA experiments were also 
performed in differentiated SH-SY5Y cells. Once SH-SY5Y cells have reached 
the differentiated state, the cells possess more neuronal-like properties, such 
as near-complete Q/R site editing levels, as opposed to the RNA editing levels 
measured in proliferating cells. This was an interesting observation as both 
differentiated and proliferating cells displayed similar levels of AluJ cassette 
inclusion in the cells. The expression levels of Pin1 mRNA in differentiated 
cells were also similar to those measured in PMO-transfected cells, thus 
implying that the increase in Pin1 mRNA that we have observed in PMO-
transfected cells was, in fact, due to increased RNA editing, and not 
necessarily only caused by the expression of a more active ADAR2 isoform 
without the AluJ cassette.  
 Functionally, Pin1 plays a key role in various cellular processes, such 
as the cell cycle, cell signalling, transcription and splicing, DNA damage 
response, germ cell development and neuronal survival (Lu & Zhou, 2007). 
Pin1 also uses several mechanisms to regulate several targets and various 
steps of a cellular process to synergise and drive the cell in one direction (T. 
H. Lee, Pastorino, et al., 2011). Hence, the regulation of prolyl isomerisation 
catalysed by Pin1 may function as a timing mechanism, which enables the cell 
to turn phosphoprotein function on or off with great efficiency during dynamic 
cellular processes (T. H. Lee, Pastorino, et al., 2011). The deregulation of Pin1 
has an essential role in many pathological conditions, particularly premature 
ageing, cancer, and Alzheimer’s disease (T. H. Lee, Pastorino, et al., 2011). 
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Levels of soluble Pin1 are decreased in AD patient brains compared with age-
matched control brains (Lu et. al. 1999) and Pin1 expression is reduced in 
neurons that are vulnerable for tauopathy (Liou et al., 2003), suggesting a 
protective role played by Pin1 and that a reduction in Pin1 levels might account 
for neurodegeneration.  
 Seeing its involvement in cancer and AD, Pin1 can be a used as a 
diagnostic marker and therapeutic tool for these diseases. Overexpression of 
Pin1 in postnatal neurons effectively prevented neurodegeneration in AD 
mouse models. A possible approach to treat neurodegeneration and AD is by 
preventing Pin1 downregulation by the brain-specific transcription factor AP4, 
or increasing Pin1 function in disease-affected neurons by inhibiting the 
oxidation of Pin1. However, since the effects of Pin1-based therapies depend 
on the individual’s specific nature of neurodegeneration or neural 
biochemistry, further work is required to establish when and where targeting 
Pin1 would it a viable therapeutic target (Driver et al., 2015).  
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7.3 FUTURE WORK 
 
In this thesis, we have demonstrated that alternative splicing of ADAR2 
was successfully manipulated in SH-SY5Y cells, which endogenously express 
the GluA2 subunit. The effects of the PMOs were also studied in differentiated 
cells, which contain a more neuronal phenotype. Hence, it is worth testing the 
effects of the PMOs in primary neurons, as the ADAR2 splicing variants in rats 
have just been recently characterized (Filippini et al., 2018a) (Figure 7.3). 
However, this work would still require an optimization of a PMO transfection 
protocol for primary neurons, as they are notoriously difficult to transfect. The 
effects of PMOs on cell viability can also be studied by overstimulation of 
glutamate in PMO-transfected cells, and by visualizing the number of neurons 
expressing Ca2+-permeable AMPA receptors by cobalt uptake staining (Kuner, 
2005; Ludo Van Den Bosch et al., 2000) (Figure 7.3). 
Since we have characterized Pin1 mRNA levels in PMO-transfected 
cells, the same experiments can also be performed in human iPSCs during 
differentiation. It is also worth investigating whether there are other factors 
contributing to the increase in RNA editing during SH-SY5Y differentiation. 
Additionally, it would also be interesting to study the effects of elevated and 
disrupted editing on miRNA dysregulation (such as miR-132, miR-143 and 
miR-55), since the implication of miRNA dysregulation has not yet been fully 
elucidated in neurodegenerative disorders. Additionally, the effects of PMOs 
on other genes known to regulate ADAR2 activity (CREB and AIMP) can also 
be examined (Figure 7.3). We have shown that excluding the AluJ cassette 
from the final ADAR2 transcript can indirectly improve Q/R site editing. Future 
studies can determine if other editing sites can also be affected by expressing 
a more catalytically active ADAR2 isoform. Thus, the effects of PMOs on other 
Q/R editing sites can also be studied, such as the GluK1 and GluK2 subunits 
of kainate receptors (Figure 7.3), which can provide a better understanding of 
the impact of improved or reduced RNA editing in the genome.  
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PMOs targeting ADAR2 (PMO 9 and PMO 9A) and GluA2 (PMO E1) 
mRNA 
iPSCs, 
neurons
SH-SY5Y
GluA2, GluK1 and 
GluK2 subunits
AluJ expression and 
Q/R site editing levels
Cell viability
CREB, AIMP, 
Pin1, WWP2
miR-132, 
miR143, miR-55
Expression levels 
and localisation
Figure 7.3 Summary of proposed future work to be performed. 
a) PMOs can be further used in different cell lines (iPSCs, rat neurons) and can be used to 
study other Q/R editing sites (GluK1 and GluK2) to investigate AluJ cassette expression and 
Q/R site editing. Cells can be further tested for viability following glutamate overstimulation. 
b) The effects of PMO transfection in cells can be studied by measuring expression levels 
of CREB, AIMP and miRNAs. Additionally, the localization of CREB, AIMP, Pin1 and WWP2 
(whether localized in the nucleolus or cytoplasm) can be tested. 
a. 
b. 
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